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EXECUTIVE SUMMARY  
 
In Europe, one widely accepted standard is that public resources should be used in the most efficient 
and effective way, therefore governments needs to supervise the expenditures and evaluate the 
policy at the same time. This dissertation tries to guide the policy makers with an economic evaluation 
of the drug policy. It presents an economic evaluation of the Belgian drug policy with a public 
expenditure study on legal and illegal drugs, and a generalised cost-effectiveness analysis on alcohol. 
In addition, this dissertation contributes to European policy research with cross-country comparisons 
on public expenditures (on drug policy and substance abuse treatment in hospitals) and on cost-
effectiveness.  
The first study “Drugs in Figures III” measures the public expenditures (anno 2008) on illegal and legal 
drugs (tobacco, alcohol and psychoactive medication). The financial data are collected by the top-
down and bottom-up approach, followed by the procedure of data processing (drug specific data, a 
proration technique and unit expenditure). The study presents the percentage of government money 
for drugs (illegal drugs, alcohol and psychoactive medication) that is spent on the traditional four 
pillars of drug control: prevention (1.24%), treatment (76.5%), harm reduction (0.24%) and law 
enforcement (21.67%). Furthermore, the public expenditures on illegal drugs are examined over time 
and across countries, in order to provide insight into the dynamics of drug policy. However, this cross-
country comparison is encountered with difficulties because of conceptual and methodological.   
The second study concentrates on the public spending for illegal drug and alcohol treatment in 
hospitals for 21 EU member states. A uniform methodology is used with data drawn from the Eurostat 
database (anno 2010 data) to enable a valid cross-national comparison. The total public spending for 
hospital-based treatment of illegal drug and alcohol abuse in the 21 EU member states is presented. 
The results confirm that public expenditures for alcohol treatment exceed those for illegal drug 
treatment. Furthermore, this study also show a large variation in public spending on substance abuse 
treatment in hospitals across the EU member states. The variation between countries is explained by 
factors such as the hospital cost per day, the organization of substance abuse treatment, cultural and 
social norms regarding substance use, etc.  
The third study focuses on the generalised cost-effectiveness of alcohol interventions. Firstly, this 
study evaluates the cost-effectiveness of the Belgian alcohol policy (anno 2008). The WHO cost-
effectiveness modelling framework is used to measure the effect of alcohol interventions on the 
health of the Belgian population (expressed in disability adjusted life years, DALYs). The combination 
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of six alcohol interventions is investigated: random breath testing, mass media “drink driving” 
campaign, increased taxation, advertising ban, reduced hours of sale and brief intervention in primary 
care. Advertising ban appear to be the most cost-effective intervention to reduce alcohol burden in 
Belgium, a volumetric taxation and a reduction of opening hours complete the top three. Secondly, 
the cross-country comparison suggests that these legislative interventions are the most cost-effective 
strategies in multiple countries.  
In conclusion, the public expenditure study and the generalised cost-effectiveness analysis (GCEA) are 
important tools for the economic evaluation of a national drug policy. These economic evaluations aid 
policy makers with the reallocation of drug budgets, and they contribute to a more evidence-based 
drug policy. Moreover, the cross-country comparisons (on public expenditures and on cost-
effectiveness) should enable us to compare the drug policies of different countries. Hence, the 
challenge continues to find a way to overcome the methodological and conceptual problems in a 
cross-country comparison. 
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NEDERLANDSTALIGE SAMENVATTING  
 
In Europa, geldt het algemeen principe dat publieke uitgaven op de meest efficiënte en effectieve 
manier dienen te worden besteed, bijgevolg dienen deze uitgaven te worden gecontroleerd en 
geëvalueerd door overheden. Dit proefschrift tracht beleidsmakers hierbij te ondersteunen met een 
economische evaluatie van het drugsbeleid. Er wordt een economische evaluatie van het Belgische 
drugsbeleid gepresenteerd met een studie naar de overheidsuitgaven voor legale en illegale drugs, en 
een “generalised” kosteneffectiviteit analyse (GCEA) van alcoholinterventies.  Daarenboven, draagt dit 
proefschrift bij tot het Europees beleidsonderzoek met een cross-country studie van de 
overheidsuitgaven (enerzijds van het drugsbeleid, anderzijds van illegale drug en alcohol behandeling 
in ziekenhuizen) en de kosteneffectiviteit. 
De eerste studie “Drugs in Cijfers III” meet de overheidsuitgaven (anno 2008) voor het beleid inzake 
illegale en legale drugs (tabak, alcohol en psychoactieve medicatie). De financiële data werden 
verzameld aan de hand van de top-down en bottom-up aanpak, vervolgens werd de data verwerkt 
(drugspecifiek, verdeelsleutel of eenheidsuitgaven). De studie presenteert de verdeling van de 
druggerelateerd overheidsuitgaven (illegale drugs, alcohol en psychoactieve medicatie) over de vier 
traditionele pijlers van het drugsbeleid: preventie (1.24%), hulpverlening (76.5%), harm reduction 
(0.24%) en veiligheid (21.67%). Voor de overheidsuitgaven illegale drugs wordt eveneens een 
vergelijking over de tijd heen gemaakt, en een vergelijking met andere landenstudies. Deze cross-
country studie werd weliswaar bemoeilijkt door conceptuele en methodologische verschillen tussen 
de diverse landen. 
De tweede studie onderzoekt de overheidsuitgaven voor illegale drug en alcohol behandeling in 
ziekenhuizen voor 21 EU lidstaten. Een uniforme methodologie met data van de Eurostat database 
(anno 2010 data) werd toegepast om een valide landenvergelijking te bekomen. De totale 
overheidsuitgave voor hospitalisatie van illegale drugs en alcoholmisbruik wordt gepresenteerd voor 
21 EU lidstaten. De studie bevestigt de hogere overheidsuitgaven voor alcohol in vergelijking met 
illegale drugs, bovendien wordt een grote verscheidenheid tussen de verschillende lidstaten 
waargenomen. De variatie wordt onder meer verklaard door factoren zoals de ligdagprijs, de 
organisatie van drughulpverlening, culturele en sociale normen ten aanzien van alcohol- en 
druggebruik,... 
De derde studie focust zich op de kosteneffectiviteit van alcohol interventies. In eerste instantie, 
wordt de kosteneffectiviteit van het Belgisch alcoholbeleid (anno 2008) geëvalueerd. Het WHO “cost-
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effectiveness modelling framework” werd gehanteerd om het effect van alcoholinterventies op de 
gezondheid van de Belgische populatie te meten (uitgedrukt in “disability adjusted life years” DALY). 
De combinatie van zes interventies werd onderzocht: alcoholcontroles in het verkeer, media 
campagne rijden onder invloed, verhoogde accijnzen, advertentieverbod, beperking verkoopsuren en 
korte interventie door huisartsen. Het verbod op alcoholreclame wordt als meest kosteneffectieve 
maatregel beschouwd voor België, daarna volgen de interventies verhoogde accijnzen en een 
beperking van de openingsuren. In tweede instantie werd een landenvergelijking uitgevoerd, 
meerdere landen beschouwen de wetgevende interventies als meest kosteneffectieve strategie.  
Ter conclusie, de studie naar overheidsuitgaven en kosteneffectiviteit (GCEA) zijn belangrijke 
instrumenten voor een economische evaluatie van het nationaal drugsbeleid. Er wordt namelijk 
informatie verstrekt aan de beleidsmakers voor de reallocatie van het drugsbudget, op deze manier 
dragen de studies bij tot een evidence-based beleid. Daarnaast stellen de cross-country studies (naar 
overheidsuitgaven en kosteneffectiviteit) ons in de mogelijkheid om het drugsbeleid van diverse 
landen te analyseren en te vergelijken. Weliswaar bestaat de uitdaging erin om de methodologische 
en conceptuele problemen te overstijgen in een landenvergelijking. 
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INTRODUCTION  
 
Resource allocation is considered to be one of the three economic functions of the government 
(besides macroeconomic stabilization and income redistribution). This function expresses the idea that 
a government has to provide welfare to its citizens and should in some circumstances do this by 
providing goods and (more often) services that its citizens demand (Musgrave & Musgrave, 1989; 
Escolano et al., 2015). Hence, this point of view confronts the government with choices about how 
many means should go to which different tasks. The resources in the public sector are mostly 
generated through taxes, one widely accepted standard is that public resources should be used in the 
most efficient and effective way, consistent with other core values (such as transparency, 
accountability, lack of corruption, etc.) (Mandl, Dierx & Ilzkovitz, 2008). In health economics, the term 
allocative efficiency is used to describe this distribution of resources among different programmes to 
achieve the maximum possible socially desired outcome for the available resources (Hutubessy, 
Chisholm, Edejer & WHO-CHOICE, 2003). A number of related methods have been developed to guide 
decisions (on distribution) about public spending. The two main methods of economic evaluation that 
are typically promoted for governments are the cost-benefit and cost-effectiveness analysis (Godfrey, 
2006). Such studies are in keeping with the New Public Management movement’s emphasis on 
efficiency and accountability in governmental operations (Osborne & Gaebler, 1992; Behn, 2001; 
Pollitt, 2003). The tools and ideals of evaluation research have been relevant for a number of areas 
(e.g. health care, crime, etc.) to evaluate policy choices (Godfrey, 2006). This dissertation contributes 
to the economic evaluation of drug policy in EU member states with a particular focus on the Belgian 
drug policy, by studying the public spending and cost-effectiveness of drug policy. The term “drug 
policy” must be understood as policy activities regarding legal and illegal drugs. 
 
The economic evaluation of drug policy has been gaining momentum since the beginning of the 21th 
century. The EU drugs strategy (2013–2020) supports this evolution by stating that actions must be 
evidence-based and cost-effective (Council of the European Union, 2012). The European action plan to 
reduce the harmful use of alcohol 2012–2020 of WHO Europe also states that “countries that are most 
active in implementing evidence-based and cost–effective alcohol policies and programmes will profit 
from substantial gains in health and well-being, productivity and social development” (WHO, 2012, 
p5). Moreover, in view of the current economic crisis and the resulting austerity measures being 
implemented by governments across Europe, public expenditures have increasingly become a subject 
of discussion. This austerity has led to reductions in public spending in the categories of health, social 
protection and public order and safety, consequently this had an impact on the public financing of 
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drug-related initiatives (EMCDDA, 2014). This puts a new premium on measuring and valuing the 
“return on investment” of government expenditures for drug policy interventions (Maynard, 2004). 
Therefore, economic evaluation studies are necessary to provide important information to aid 
decisions about drug policies. 
 
The public expenditure studies, with an estimation of public spending on drug control and drug 
problems, are considered as an intermediate stage in economic evaluation.  These public expenditure 
studies are an important step for the economic evaluation of drug policy interventions (EMCDDA, 
2008; Vander Laenen, Vandam, De Ruyver & Lievens, 2008), since they could be used for three 
purposes: (1) evaluation of the drug policy expenditure mix, (2) comparison between public spending 
and policy pronouncements, and (3) to study the evolution of public expenditures on drugs over time. 
Firstly, it provides insight into how drug expenditures are composed and what the public authorities’ 
so-called “policy mix” is (Reuter, 2006; Vander Laenen et al., 2008). The drug phenomenon is 
multidimensional and entails that authorities from all levels of government (national, regional and 
local), all from their own policy domains and with their own competencies, contribute to the 
realisation of the drug policy. Therefore it is indispensable to list the expenditure of the competent 
authorities in the pursuance of their policy options. Secondly, in view of the growing demands for 
accountability and evidence-based policy, a public expenditure study could show whether the 
government’s stated priorities for drug policy are mirrored in their actual expenditures. Most 
countries of the EU implemented an integral and integrated drug policy, in which several policy levels 
and domains are involved (EMCDDA, 2008; Vandam, Colman, Vander Laenen & De Ruyver, 2010). In 
Belgium, the Federal Drug Policy Note of 2001 (Belgian Federal Government, 2001) and the Joint 
Statement of the Inter-ministerial Conference on Drugs in 2010 (Inter-ministerial Conference on 
Drugs, 2010) also pursuits an integrated and global drug policy. Moreover, these documents state that 
prevention gets the highest priority, followed by treatment for those people who come into problems 
by their drug use. A penal intervention should be considered to be an “ultimum remedium” or final 
remedy towards drug users, in fact repression should be directed towards trade/commerce in drugs 
and drugs production. These official policy pronouncements should be compared with the country’s 
drug budget in order to see whether spending matches the rhetorical priorities. Thirdly, a time 
analysis of the public expenditures may provide a sense of historical context and reveals changes in 
drug control strategies. The public expenditures of a country can be tracked over time alongside 
various outcomes. For example, the impact of drug policies and/or expenditures on problem 
indicators (e.g. prevalence of illegal drug use) could be measured. 
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It is clear that research into public expenditure is important to meet the requirements of an evidence-
based policy, nevertheless public expenditure studies do have their limitations too. External 
expenditures – defined as expenses incurred indirectly by society as a result of substance use – and 
private costs are excluded in a public expenditure analysis (Kopp & Fenoglio, 2002). Consequently, no 
information is available on the public and private financing mix of drug policy (and the private 
financing mechanisms such as the patient cost of hospitalisation). Only a social cost analysis can 
provide the total social cost of drugs in a given society, and this social cost study may provide policy 
recommendations to reallocate drug budgets in accordance with the (health) impact of the different 
types of drugs (McDonald, 2011).  
 
Other evaluation methods such as cost-benefit and cost-effectiveness analysis 1  hold a strong 
relationship with the public expenditure study, because they cannot be completed without the 
estimation of public spending on drug policy. In the economic evaluation studies, the public 
expenditures serve as the independent variable and outcomes (e.g., OD deaths) as the dependent 
variable. For example, the cost-effectiveness of alcohol prevention and treatment models has been 
assessed by a number of cost-effectiveness analysis (CEA) studies (e.g. Månsdotter, Rydberg, Wallin, 
Lindholm & Andréasson, 2007; Raistrick, Heather & Godfrey, 2006; Tobler & Stratton, 1997). These 
CEA studies compare the relative costs as the health gains of different interventions, therefore they 
are an important aid to public health decision-making. However these studies are not able to present 
a sectoral perspective; a sectoral CEA compares a range of interventions in order to find the optimal 
mix of interventions (Hutubessy et al., 2003). The Generalised Cost-Effectiveness Analysis (GCEA) is 
most useful to guide resource allocation decisions with an intervention mix that maximises health for 
a given set of resource constraints, since the costs and effectiveness of multiple interventions are 
compared (Edejer et al., 2003). The cost-effectiveness of a drug policy mix has been studied with this 
GCEA2. Using this GCEA it is possible to simulate the most cost-effective drug policy mix of a country 
and to evaluate the current drug policy. Firstly, GCEA studies measure which mix of government 
interventions is likely to produce the greatest effectiveness in terms of costs. To this end, the 
intervention strategies to reduce the burden of hazardous alcohol use or illegal drug use or tobacco 
use are evaluated by their comparative impact on population-level health. Secondly, using a GCEA, the 
interventions are evaluated with respect to a counterfactual of “doing nothing” (Murray, Evans, 
Acharyan & Baltussen, 2000) and this null scenario provides information for decision-makers on what 
could be achieved if they reallocated the expenditures for drug policy (Edejer et al., 2003). 
 
The primary focus of this dissertation is the economic evaluation of drug policy, we evaluate the public 
spending (on drug policy and substance abuse treatment in hospitals) and cost-effectiveness in 
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different European countries3. In addition, the Belgian drug policy serves as important case study for 
this economic evaluation, with a public expenditure study on drugs (in the first study of the 
dissertation) and a GCEA on alcohol interventions (in the third study of the dissertation). The Belgian 
setting is an interesting case from a public management point of view. European countries, including 
Belgium, are confronted with a high burden of disease due to legal and illegal drugs: a 9.2% of the 
disability adjusted life years (DALYs) – years of life lost due to either premature mortality or to 
disability – is caused by alcohol, 12.2% by tobacco and 1.8% by illegal drugs (Rehm, Taylor & Room, 
2006). Moreover, in the context of the social cost of the harmful use of alcohol, Belgium is even 
confronted with higher costs  (2.5% of GDP in 1999;  Degreef, Pacolet & Bouten, 2003) than the 
European average (1.3% of the GDP in 2003; Rehm, Shield, Rehm, Gmel & Frick, 2012). At first sight, 
these high costs could not be ascribed to the epidemiological situation, since the prevalence of 
problematic alcohol consumption and illegal drugs4 is similar to the European average (Gisle et al., 
2010). Other factors should be taken into account to explain the high social cost on alcohol. Therefore, 
an economic evaluation of the Belgian drug policy is recommended. This evaluation may indicate 
room for improvement in public spending on drug policy and may identify how the alcohol-
attributable burden could be avoided if cost-effective interventions were implemented. 
 
Some aspects of drug policy can be studied within a single country (e.g. prevention interventions in 
different secondary school classrooms); however, many important dimensions of policy operate at the 
national level, making cross-national comparisons of both policies and problem severity important. 
Three purposes are distinguished for undertaking a cross-country comparison in health policy: learning 
about national policies; learning why they take the forms they do; and learning lessons from these 
policy analyses (for the application in other countries) (Marmor, Freeman & Okma,  2005). There is a 
growing body of cross-country comparisons on health policy (Cacace, Ettelt, Mays & Nolte, 2013), and 
these comparative studies have also gained attention from drug policy analysts. Different approaches 
have been acknowledged to compare alcohol policies between countries: government spending, cost-
of-illness, consumption and patterns of use, burden of disease, composite harm indices, generalised 
cost-effectiveness analysis and alcohol policy index (Ritter, 2007). The public expenditure and GCEA 
approach are both distinguished as interesting tools to develop comparisons between countries 
(Ritter, 2007; Reuter, 2006; Kopp & Fenoglio, 2003). Therefore, both types of cross-country 
comparisons have been conducted in this dissertation. The first study of this dissertation conducted a 
cross-country comparison on public expenditures for drug policy; and the second study compared the 
public spending on hospital treatment for 21 EU member states5. A cross-country comparison on 
government spending allows us to calculate the proportion of a country’s gross domestic product that 
is spent on drug policy. Moreover, a comparison with other countries makes it possible to view the 
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different options in drug policy and explore the correlation between different drug policies and public 
expenditures. The third study of the dissertation investigates if GCEA studies could be used in a cross-
country comparison to compare the cost-effectiveness of alcohol policies in different countries. An 
analysis of different government intervention mixes may enhance the comparison of alcohol policies 
between countries. In fact, a cross-country comparison of the cost-effectiveness of alcohol 
interventions would enable to monitor alcohol interventions with benchmarking information and this 
may potentially improve the effectiveness and cost-effectiveness of alcohol policy (Ritter, 2007). 
Despite the potential of the public expenditure and GCEA study for a cross-country comparisons, it 
should be stated that cross-country comparisons are encountered with difficulties because of 
conceptual and methodological differences across countries (Ritter, 2007; Reuter, 2006). During this 
dissertation, the methodological issues for the public expenditure and GCEA in a cross-country 
comparison are discussed more in detail. 
 
Overall, the three studies in this dissertation contribute to the economic evaluation of drug policy. The 
first study “Drugs in Figures III“ is conducted to provide insight into the composition of the Belgian 
drug policy expenditures mix. This study measures the public expenditures (anno 2008) of Belgian 
drug policy (illegal drugs, alcohol, tobacco and psychoactive medication). The financial data are 
collected by the top-down and bottom-up approach, followed by the procedure of data processing 
(drug specific data, a proration technique and unit expenditure). The study presents the percentage of 
government money for drugs that is spent on the traditional four pillars of drug control: prevention, 
treatment, harm reduction and law enforcement (Reuter, 2006). These results show that drug policy 
expenditures are not necessarily in alignment with the priorities, strategic goals and objectives of the 
Belgian drug policy. Furthermore, a cross-country comparison was infeasible because of the 
conceptual and methodological differences in the national public expenditure studies.  
 
During the first study, it has become clear that a uniform methodology is necessary to estimate the 
public expenditures on legal and illegal drugs in different countries. Therefore, the second study 
searched for a uniform methodology across the EU member states in order to allow a valid cross-
national comparison. Based on the international database of Eurostat, consolidated data were 
retrieved to measure government spending for the hospital treatment of illegal drug and alcohol 
abuse in 21 EU member states. The public drug expenditures on hospitalisation are estimated by 
multiplying the average cost per hospital day by the number of hospital days for treating illegal drug or 
alcohol disorders. This study showed a large variation in public spending on substance abuse 
treatment in hospitals. This variation is explained by factors such as the hospital cost per day, the 
organization of substance abuse treatment, cultural and social norms regarding substance use, etc. 
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The results from the first and second study indicated that public expenditures for alcohol treatment 
exceed that for illegal drug treatment (even the treatment expenditures per-dependent user)6. In 
Belgium, at least 75 % of the treatment expenditures is for alcohol, therefore it might seem warranted 
to investigate if the Belgian alcohol policy could improve its cost-effectiveness. As third study, a GCEA 
have been conducted to measure which mix of government interventions are likely to produce the 
greatest cost-effectiveness. The study starts with the selection of interventions that reduce alcohol-
attributable harm and the effect of each intervention derives from the alcohol literature. Furthermore, 
Belgian data on mortality and prevalence of hazardous alcohol use are collected. The cost-
effectiveness of six alcohol was investigated for Belgium with the WHO cost-effectiveness modelling 
framework. The costs are assessed in Euros for the year 2008 and the intervention effects are 
expressed in disability adjusted life years (DALYs). The optimal intervention mix for alcohol control in 
Belgium is presented: the best combination in case of two policy options is increased taxation and 
advertising ban; and the brief intervention in primary care should be implemented as a third policy 
intervention. Furthermore, the cross-country comparison shows that legislative interventions 
(increased taxation, advertising ban and reduced opening hours), in comparison with other 
interventions such as brief intervention and random breath testing, are the most cost-effective 
strategies across countries. The results of this cross-country comparison with GCEA should be 
interpreted with caution, therefore the conceptual and methodological differences across studies are 
explained. 
  
The three studies are presented as three consecutive chapters in this dissertation. They are followed 
by a conclusion, policy recommendations and suggestions for future research. 
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ENDNOTE
                                                          
1
 The Cost-effectiveness analysis (CEA) is a form of economic analysis that determines the costs and outcomes 
(effects) of an activity (or similar alternative activities). The Cost-benefit analysis (CBA) is an analysis in which the 
economic and social costs and benefits of a policy/medical care are considered. For the allocation of funds in a 
CBA, the general rule is that the ratio of the marginal benefit to marginal cost should be equal to or greater than 
1 (Porta, 2008). 
2
 Most GCEA studies focus on alcohol (Chisholm, Rehm, Van Ommeren & Monteiro, 2004; Cobiac, Vos, Doran & 
Wallace, 2009; Holm, Veerman, Cobiac, Ekholm & Diderichsen, 2014; Lai, Habicht, Reinap, Chisholm & Baltussen, 
2007), nevertheless the GCEA studies of Lai et al. (2007) and Chisholm, Doran, Shibuya & Rehm (2006) measured 
the cost-effectiveness of tobacco and/or illegal drug interventions. 
3
 During the cross-country comparisons, we focus on European countries because of the health care systems. 
The proportion of public financing of health expenditures are somewhat comparable in the EU countries 
(governments in the EU-21 finance on average 73% of the health expenditures). This differs from countries such 
as the United States where less than 50% of health spending is publicly financed (Eurostat, 2013). 
4
 In a 2008 Belgian health survey 10.3% of the participants reported a problematic alcohol consumption. The 
same survey reported a 5% year prevalence for cannabis and 1.5% for other illegal drugs (e.g. cocaine, 
amphetamines, ecstasy, heroin, etc.)  (Gisle et al., 2010). (These prevalence rates remained stable between 2008 
and 2013; Gisle & Demarest, 2014) 
5
 This study used international databases to facilitate cross-country comparisons that could highlight the impact 
of substance abuse on public health budgets. The cross-country comparison is restricted to hospitals, since data 
were unavailable for other types of treatment providers. 
6
 However, the treatment expenditures per dependent user (minimum 780 euros per alcohol dependent and 
maximum 395 euros per illegal drug user) should be interpreted with caution, since the user estimates are not 
completely comparable. The National Health Interview Survey (IPH, 2010) reports data on alcohol in terms of 
weekly overconsumption (2008: weekly overconsumption for 7.9% of the population, aged 15 years and older) 
and the year prevalence is reported for illegal drugs (2008: year prevalence of 5.1% for cannabis and 1.5% for 
other drugs, aged 15 years to 64 years). 
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STUDY 1  
DRUGS IN FIGURES III: STUDY OF PUBLIC EXPENDITURES  
ON DRUG CONTROL AND DRUG PROBLEMS1 
 
ABSTRACT 
Background: There is growing interest in public expenditure studies with regard to drug policy. These 
studies have a potential role on multiple levels. They provide insight into how drug expenditures are 
composed and what the public authorities’ so-called ‘policy mix’ is. Moreover, in view of the growing 
demands for accountability and evidence-based policy, these studies show whether the government’s 
stated priorities for drug policy are mirrored in their actual expenditures. Finally, the potential role of 
public expenditures studies increases with a comparison over time and across countries. These 
comparisons may provide important insight into the dynamics of drug policy. The present study serves 
as both an important case study – in this case of Belgian public expenditures – and also as a model to 
explore the potential role(s) of public expenditure studies more generally.  
Methods: This paper measures the public expenditures (anno 2008) of Belgian drug policy. It advances 
beyond two previous studies (De Ruyver et al. 2004, 2007) in two distinct ways: by carrying out a new 
and more refined estimation of public expenditures on illegal drugs and by providing a first estimation 
of expenditures concerning legal drugs (tobacco, alcohol and psychoactive medication). Drugs in 
Figures III combines two methods of data-collection for the inventory of public expenditures. The top-
down approach starts from the resources made available by the different public authorities involved in 
drug policy. The bottom-up approach starts from activities taking place in the field and traces the 
money flow back to the public authorities’ funding. 
Results: The results of ‘Drugs in Figures III’ make two important contributions. Firstly, the study 
presents the percentage of government money for drugs that is spent on the traditional four pillars of 
drug control: prevention, treatment, harm reduction and law enforcement. Secondly, public 
expenditures on illegal drugs anno 2008, put in comparative perspective with the previous estimations 
of ‘Drugs in Figures II’, gives insight into the evolution of public expenditure on drugs over time. The 
potential third level being a cross-country comparison encounters more difficulties because of 
                                                          
1
 A version of this paper has been published as Lievens, D., Vander Laenen, F., Caulkins, J. & De Ruyver, B. (2012). 
Drugs in Figures III Study of Public Expenditures on Drug Control and Drug Problems. In Cools, M., De Ruyver, B., 
Easton, M., Pauwels, L., Ponsaers, P., Vande Walle, G., Vanderbeken, T., Vander Laenen, F., Verhage, A., 
Vermeulen, G., Vynckier, G. (Eds.), European Criminal Justice and Policy, Governance of Security Research Paper 
Series (pp 41-63). Antwerpen-Apeldoorn: Maklu. 
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conceptual and methodological differences in expenditure measurement across countries. The cross-
country comparison shows that a uniform methodology is necessary to estimate the public 
expenditures in different countries, studying expenditures for legal and illegal drugs. 
 
Key words: Public expenditure, drug policy, illegal and legal drugs, cross-country comparison 
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1. INTRODUCTION 
Public expenditure studies with regard to drug policy are gaining momentum. Since the beginning of 
the 21th century studies on public expenditure have been conducted in Australia, Belgium, 
Luxembourg, the Netherlands, and Sweden, among other countries (Origer, 2002; Postma, 2004; 
Rigter, 2006; Ramstedt, 2006; De Ruyver et al., 2004, 2007; Kopp & Fenoglio, 2003, 2006; Moore, 
2008; Mostardt, Flöter, Neumann, Wasem, & Pfeiffer-Gerschel, 2010). The United States of America 
has a long tradition of studying federal (as opposed to national1) public expenditures on illegal drug 
control with the Office of National Drug Control Policy (ONDCP) annual Budget Summary report 
(federal spending only; ONDCP, 1989-2011), augmented just for the years 1990-1991 with an attempt 
to measure state and local spending (ONDCP, 1993). The National Center on Addiction and Substance 
Abuse (CASA) released complementary studies of the total budget impact of legal and illegal drugs. 
They were called the ‘Shoveling up’ studies (CASA, 2001 & 2009) because they pointed out that more 
than 95% of the $467.7 billion annual total was spent mitigating the consequences of substance abuse 
rather than treating or preventing it.  Indeed, over 70% was spent just on healthcare for conditions to 
which untreated addiction contributes. These diverse public expenditure studies have one thing in 
common; they are all an important step for the economic evaluation of drug policy interventions 
(EMCDDA, 2008; Vander Laenen, Vandam, De Ruyver & Lievens, 2008). 
 
In this contribution, three important roles for public expenditure studies are discussed in the 
monitoring and economic evaluation of drug policy interventions. The first investigates the country’s 
drug budget in a single time period, and compare it to official policy pronouncements to see whether 
spending matches the rhetorical priorities. On a second level one may examine expenditures over time 
within one jurisdiction; this provides a sense of historical context and the changing face of drug 
control. These first two levels stress that a public expenditure study is of value for decision makers in 
their own country. Another way to get a sense of perspective on one’s own drug policy is to make 
comparisons with other countries. The third level considers the potential role of public expenditures 
studies in a cross-country comparison (Reuter, Ramstedt & Rigter, 2004). 
 
Understanding current public expenditures enables us to evaluate the commitments of governments 
in the drug policy field. A public expenditure study indicates the public resources dedicated to drug 
policy and shows whether the government’s stated priorities for that drug policy are mirrored in its 
budget. A drug budget provides insight into how the drug expenditures are composed or what the 
public authorities’ ‘policy mix’ is. Consequently, the prevailing balance between the various sectors of 
drug policy (prevention, treatment, harm reduction and law enforcement) becomes visible (Moore, 
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2005; Vander Laenen et al., 2008). Likewise, it is possible to examine the division of expenditures 
between legal and illegal drugs. 
 
The public is often interested not only in whether spending matches announced priorities, but also in 
whether both are aligned with what the scientific evidence suggests are the most cost-effective 
programmes.  For some types of programmes, cost-effectiveness can be studied at the micro level, 
e.g. by randomly assigning dependent users to different treatment programmes or classrooms to 
different prevention programmes.  However, other policies and programmes operate at the national 
level, which makes research designs more difficult, and sometimes not possible at all.  Hence, a 
complementary analytic approach is to see whether changes in distributions of funding are predictive 
of changes in problem outcomes.  
 
This can be done with time series methods for a single jurisdiction.  So, on a second level, the public 
expenditures of a country can be tracked over time alongside various outcomes.  This may allow for 
the measurement of the drug policies’ and/or the expenditures’ impact on problem indicators. 
However, if there is considerable stability over time in a country’s expenditures (the institutional 
framework of drug policy stays the same and the drug expenditures do not undergo significant 
changes), then a cross-country comparison could possibly provide more insight. 
 
That is, sometimes one can get more variation in the independent variables (budget, policy) by 
comparing different countries than by comparing one country at different points in time, and that 
variation can be used in several ways (MacCoun and Reuter, 2001). The variation may provide 
important insight into the dynamics of drug policy across nations. For example, it has been observed 
that enforcement dominates the budget in most public expenditure studies on illegal drugs.  There are 
various plausible explanations. The imbalance could stem from a political decision to invest more on 
law enforcement. Or law enforcement may simply involve more expensive activities. Or the cause 
could lie in the realities of drug markets (since the drug markets activity has an effect on the public 
sector effort to enforce prohibitions, and this may determine the enforcement expenditures) (Reuter, 
2006).  
 
Secondly, a cross-country comparison could enable individual nations to assess whether better 
performance could be expected (Reuter, 2006). A country having high treatment expenditures per 
problematic user, in comparison with other countries, could indicate the use of inefficient treatment 
programmes or a (mental) health care system with limited cost-effectiveness.  
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Thirdly, a comparison with other countries makes it possible to view the different options in drug 
policy and explore the correlation between different drug policies and public expenditures. A cross-
sectional study involves the observation of a set of public expenditures from different countries at a 
single point in time. A panel study, on the other hand, uses variation over time and across countries in 
drug policy spending. Such methods may predict the impact of a change in drug policy on the public 
expenditures for prevention, treatment, enforcement or harm reduction (Lievens & Caulkins, 2010). 
For example, the Netherlands are known for tolerant drug policy, and from this point of view, one 
would expect less expenditures for enforcement in comparison with other countries. However, Rigter 
(2006) shows that 76% of the drug budget is spent on enforcement in the Netherlands. The 
unexpectedly large investment in enforcement by the Dutch government has several explanations. 
The public and political view has generally been ‘antidrug’ despite making a partial exception for 
cannabis; also, the country is a hub of international drug trading routes, just as it is a hub of 
international trade of all sorts (Rigter, 2006). This case shows us that there is not necessarily a 
correlation between a tolerant drug policy and lower enforcement expenditures. 
 
In order to explore the potential role(s) of a public expenditure study described above, we will use the 
results of a study (‘Drugs in Figures III’) of the public expenditures of the Belgian drug policy for the 
year 20082. To this end, the main questions addressed are: a) What is the composition of the Belgian 
drug policy mix? b) Which evolutions took place in the field of Belgian public drug expenditures (2004 
versus 2008)? and c) What does the cross-country comparison tell about the dynamics of drug policy 
across nations? Finally, the answers to these questions are used to conclude if a public expenditure 
study can fulfil its potential role. 
 
The chapter has been organized in the following way. The first part deals with the methodology used 
in the ‘Drugs in Figures III’ study3; it describes the approach used to identify, measure and classify 
public expenditures. The next section outlines the results; the estimate of Belgian public drug 
expenditures will be presented and compared over time and across countries. Finally, the implications 
of these findings are discussed by referring to the three important roles of a public expenditure study. 
 
2. METHOD 
An analysis of public drug expenditure studies in Europe (Vander Laenen et al., 2008) indicates that 
conceptual and methodological frameworks vary across these studies. With regard to the conceptual 
field, there is no global definition that determines the scope of public drug expenditures. This 
enhances the risk of wrongly including spending that should not appear in the budget, and wrongly 
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excluding spending that should appear (Walsh, 2004). From this point of view it is important to define 
which areas of expenditure lie within or beyond the scope of a public expenditure study. Secondly, the 
methods for estimating government drug policy expenditures vary from study to study. Different 
methodological steps and choices are possible and have their effect on the figures. A comparison over 
time or across countries asks for a single and clear methodology used in a uniform manner to avoid 
‘measurement error’ (Murphy, Davis, Liston, Thaler & Webb, 2000). Therefore, it is worthwhile to 
describe in some detail the concepts used in the study, as well as the approach taken to data 
collection and data processing. 
 
2.1. Conceptual framework  
This third Drugs in Figures study uses the same definition for public expenditure as the two previous 
studies: “the composition of the drug budget as an estimation of public authorities’ expenditures on 
the drug policy” (De Ruyver et al., 2007, p.31). The drug budget of the public authorities is analysed at 
each level of competency (national, regional, provincial and local) for the different policy domains 
(prevention, treatment, harm reduction and law enforcement).  
 
This study focuses on the direct nature of the public expenditure: “investments or budget lines of 
public authorities for actions expressly and directly aimed at implementing drug policy” (Vander 
Laenen et al., 2008, p. 26). This differs from, for instance, the CASA studies mentioned above which 
also included other types of spending (e.g., healthcare provided to treat sequelae of untreated drug 
use). Consequently, external expenditures related to the consequences of drug use are not included in 
the public expenditure analysis. Examples of excluded expenditures are policing expenditures for 
property and violent crimes resulting from drug use or expenditures for treatment of lung cancer due 
to smoking. Furthermore, the definition of public expenditure already indicates that private 
expenditures are excluded. This means that the spending of individuals and private organizations4 is 
not measured. A corollary merits stating explicitly.  Under this conceptual framework, the total social 
cost is not measured; the public expenditure is one element of the social cost of the drug problem, but 
it is not the entirety of social costs. 
 
2.2. Methodological framework 
This study attempts to refine the methodology of ‘Drugs in figures I and II’ (De Ruyver et al., 2004, 
2007) in order to carry out a new estimation of public expenditures (anno 2008) on illegal drugs and a 
first estimation for legal drugs (tobacco, alcohol and psychoactive medication5). The methodology 
consists of three phases: data collection, data processing and data classification.  
STUDY 1 
17 
 
Data collection: top-down and check on top-down 
In order to collect data, both a top-down and bottom-up approach are applied. The “top-down 
approach” is a method that starts from the resources made available by the different public 
authorities involved in drug policy. First, the public authorities are identified (De Ruyver et al., 2004, 
2007). Afterwards, the public authorities’ drug budgets are collected and analysed. This top-down 
approach starts with an analysis of the budget lines of the public administrations. The bottom-up 
approach is an approach that starts from the activities in the field and traces the money flow back to 
the public authorities funding.  
In the study, 98.45% of the identified expenditures comes through the top-down approach. Top-down 
data, that come from official accounting documents such as national budgets, may be more valid for 
the study, since these data are audited by the Court of Audit and therefore are partially protected 
from political pressure. Uncertainty arises about the data available from the bottom-up approach, 
although their impact on the results (1.55%) is limited. These public expenditures come from 
organizations that depend on the government for most of their funding.  
 
Data processing: Drug specific Proration technique & Unit expenditure  
The rough financial data are collected during the first phase, followed by the procedure of data 
processing. In line with the previous Drugs in Figures studies, three methods are distinguished: drug 
specific data, a proration technique, and unit expenditure. In the study, 75.85% of the identified 
expenditures is processed by the unit expenditure calculations, 15.48% by proration technique and 
8.67% is drug specific. These methods have several advantages, but also a couple disadvantages that 
are listed below. 
 
For the drug specific methodology, no further calculations are necessary, because the expenditures 
are exclusively used for drug policy. The other methods are used for drug programmes that are 
embedded within broader budget categories. This means that a process must be followed to ascribe a 
portion of that broader budget category to the drug programme. Typical approaches are the proration 
technique or unit expenditure calculations (Van Malderen, Vander Laenen & De Ruyver, 2009). The 
proration technique is for example used for estimating the expenditure on enforcement by police, 
judicial authorities and customs. The expenditures of the local police are calculated by multiplying the 
total local police budget by the fraction of all offences that are offences concerning violations of drug 
laws. In some cases the methodology of unit expenditure is preferred, because it simplifies the 
calculation6. For example, the public drug expenditures on hospitalisation are estimated by multiplying 
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the average expenditure for hospitalisation per day by the average number of days that drug users are 
hospitalised.  
 
The main disadvantage of the proration method is that it can lead to distorted figures, because this 
methodology assumes that, for example in the case of law enforcement, all criminal activity has the 
same unit cost. However, a number of studies (e.g. Aos, 2006; Carey, 2005) have documented the 
common sense notion that the cost per arrest varies widely across offence types.  In Washington State 
the average cost of an arrest varies from 31,648 dollars for murder to 5,370 dollars for drug offenses 
(Aos, 2006). The difference in the cost of arrest by offense is not taken into account in the proration 
method and consequently the amount of drug expenditures could be exaggerated. They are likewise 
exaggerated to the extent that the police do things other than arrest criminals; presumably some 
portion of policing expenditures are better thought of as allocated to traffic control, order 
maintenance, and emergency response, not to arresting people, and so do belong in the aggregate 
pool that is prorated by the relative number of arrests by crime type.  The results should also be taken 
with caution since for the underlying aggregate expenditure data were provided by interested 
institutions/actors, leading to a possible contestation of the reliability of those data. Finally these 
examples show that the drug budget is a fragile construction. The results of the public expenditure 
studies can only be estimations, and the quality of the studies is only as good as the quality and 
timeliness of the available data (Vander Laenen et al., 2008). 
 
Classification 
The classification of public expenditure allows expenditures to be classified according to their goal, 
and this allows an insight into the ‘policy mix’ of the drug policy. The classification system of Reuter 
(2004) is applied: prevention, treatment, harm reduction and enforcement. In the studies of Ramstedt 
(2006), Rigter (2006) and Moore (2008) the four conventional categories have also been used. The 
addition of a fifth category “other” in this study is required because some of the expenditures could 
not be assigned to one of the four pillars of drug policy. The following expenditures are added, 
amongst others, to the category “other”: European School Survey Project on Alcohol and Other Drugs 
and contribution to Pompidou Group7. 
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3. RESULTS 
 
3.1. One time period: comparison across sectors and to policy pronouncements     
Numeric results  
In 2008, Belgian public authorities spent between 655,473,287 Euros and 1,294,698,299 Euros on 
drug policy (for illegal drug, alcohol, psychoactive medication and tobacco), with a best estimate8 of 
975,085,793 Euros. A comparison across sectors is made for illegal drugs, alcohol and psychoactive 
medication in table 19 and the comparison across sector for tobacco policy is presented separately in 
table 2. 
Table 1: Estimated drug policy expenditures (illegal drugs, alcohol and psychoactive medication), Belgium, 2008 
(rounded million Euros). 
Category Low estimate High estimate Baseline 
Baseline 
fraction of total 
expenditures (%) 
Prevention 12 12 12 1.24 
Treatment 438 1036 737 76.5 
Harm reduction 2.3 2.3 2.3 0.24 
Enforcement 188 229 209 21.67 
Other 3.4 3.4 3.4 0.35 
Total 644 1283 964 100 
 
Table 1 illustrates that treatment accounts for 76.5% of the total drug policy expenditures, and 
enforcement expenditures represent about one-fifth (21.67%). Prevention (1,24%), harm reduction 
(0.24%) and other policy activities (0.35%) are minor components of spending. For the category 
treatment there is a very wide range between the low and high estimate, because the expenditures 
for the hospitalisation sector depend on the inclusion or exclusion of hospitalisation costs for 
secondary diagnoses of substance abuse/dependence. Further analysis shows that at least three-
quaters10 of the treatment expenditures is for alcohol. If the expenditures for illegal drugs are analysed 
separately11, the policy mix changes to: 49.14% treatment, 45.09% enforcement, 3.85% prevention, 
0.79% harm reduction and 1.14% other.  Conversely, for alcohol, the domination of treatment 
spending is that much greater. 
 
With regard to illegal drugs, the underlying idea of the Belgian federal drug policy note of 200112 was 
that prevention should be the highest priority, followed by treatment, with repression as a final resort. 
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Contrary to those stated policy intentions, the most substantial expenditures relate to treatment, 
followed by enforcement and then prevention and harm reduction.  
 
Table 2 presents the expenditures for the tobacco policy and shows that enforcement is the largest 
expenditure (68.88%), treatment with 18.74% is second in rank and prevention accounts for 11.54%. 
 
Table 2: Estimated tobacco policy expenditures, Belgium, 2008 (rounded million Euros). 
Category
13
 Expenditures 
Fraction of total 
expenditures (%) 
Prevention 1.3 11.54 
Treatment 2.2 18.74 
Enforcement 7.9 68.88 
Other 0.1 0.85 
Total 11.5 100 
 
At first, it seems a remarkable result that enforcement dominates the budgetary pie of tobacco policy. 
Part of the explanation is that tobacco policy is not entirely laisser-faire; tobacco smoking is prohibited 
in workplaces, public spaces, restaurants,... and the management of that prohibition (or regulation) 
requires financial means. However, the larger explanation is that tobacco enforcement’s relative share 
is so large primarily because treatment spending is so small.  The treatment expenditures are rather 
limited because the reimbursement of tobacco dependence treatment is restricted to patients who 
are pregnant14. Furthermore, hospitalisation costs for tobacco are not included because spending on 
treatment for consequences of drug use (such as lung cancer in the case of tobacco) is viewed as an 
external expenditure and so is excluded from the study.  
 
Since 2004, the Belgian tobacco policy officially tries to transcend the legal framework and a 
predominant repressive approach by focusing on prevention and on treatment of dependence 
(Federal plan tobacco control, 2004). The expenditures tell another story, however, since the biggest 
investments are still made to ensure compliance and to enforce the laws prohibiting the sale and 
distribution of tobacco products to minors, smoking bans, tobacco advertising, etc. 
 
Interpretation 
In an ideal world the drug budget should support the announced policy, and at a superficial level one 
might expect the highest priorities to receive the largest budget allocations. But these examples show 
that Belgian drug policy in practice fails to align programme resources with its announced priorities, 
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strategic goals and objectives. Carnevale (2008) draws attention to the fact that the administration 
must ensure a match between the goals of the drug control strategy and the budget passed to 
support it. He even goes one step further by claiming that there should be a consistency between 
funding and the effectiveness of interventions. The consensus in the academic literature is that 
“treatment works”, and many studies conclude that treatment produces social benefits that exceed its 
programmatic costs (Gerstein et al., 1994; Rajkumar and French, 1997; Cartwright, 2000; Harwood et 
al., 2002; Belenko et al., 2005). For example, the study of Caulkins et al. (1999) indicates that 
treatment is more cost-effective than school-based prevention at reducing cocaine consumption. 
Another study found that the treatment of heavy (cocaine) users is more cost-effective than supply-
control programmes (Rydell, Caulkins & Everingham, 1996). These studies assessed cost-effectiveness 
at the margin; that is, they addressed how the next million dollars might best be spent.  So strictly 
speaking they do not directly inform what the optimal allocation shares are. However, they suggest 
that from an effectiveness point of view, an optimal drug policy should spend more on treatment 
rather than enforcement, as compared to the status quo. Within this framework, the Belgian drug 
policy in 2008, with high expenditures for treatment, follows science rather than policy. However, this 
is a statement that needs to be handled with care, because a good match between funding and 
effective programmes is complex in different ways, which we will discuss in detail in the discussion 
section of the chapter.  
 
3.2. Comparison over time 
Numeric results  
The expenditures of 2008 are being compared to the ones of 2004, derived from ‘Drugs in figures II’ 
(De Ruyver et al., 2007). The latter study, with a research scope limited to illegal drugs, found that 
over 50% of the public expenditures dealing with illegal drugs went to enforcement, approximately 
40% to the treatment sector (harm reduction included), and the share of prevention amounted to just 
under 4%. It is difficult to make a comparison with the 2004 estimate, because of differences in 
research scope and methods of performing the calculations. Therefore, a new calculation is made for 
the year 2008 using the same proration techniques as in 2004. This provides a consistent comparison 
across years, allowing for direct comparisons between past and future budgets produced with the 
same methods. The public expenditures for illegal drugs are calculated by the previous method and 
are presented in table 3. 
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Table 3: Estimated drug policy expenditures (illegal drugs), Belgium, 2004 versus 2008 
Category 
Expenditures of 2004 expressed in 2008 
monetary units
15
 
Expenditures of 2008 
Prevention 12,294,733 3.72 % 11,412,257 2.91 % 
Treatment 130,909,594 39.58 % 133,557,858 34.05 % 
Harm reduction min. 340,628
16
 0.10 % 2,329,752 0.59 % 
Enforcement 186,038,337 56.24 % 243,000,490 61.96 % 
Other 1,190,329 0.36 % 1,890,813 0.48 % 
Total 330,773,622 100 % 392,191,170 100 % 
 
Between 2004 and 2008, the government expenditures for drug policy have increased quite 
substantially by more than 61 million Euros (18.57%), with 92.75% of this increase going to supply 
reduction programmes. Only small changes in expenditures are noticed for demand reduction. The 
main reason for the increase in treatment is rising hospital costs per day; for example, the average 
daily cost in psychiatric hospitals goes from 178.76 Euros to 242.04 Euros, while the number of drug 
dependence diagnoses declines.  
 
In table 4 the expenditures for supply reduction are analysed for each level of the criminal justice 
system.  
Table 4: Expenditures enforcement (illegal drugs), Belgium, 2004 versus 2008 
Category Expenditures 2004
17
 Expenditures 2008 
Detection 152,318,468 81.87 % 168,989,940 69.54 % 
Prosecution  3,832,648 2.06 % 6,799,870 2.80 % 
Sentencing 3,883,307 2.09 % 6,229,902 2.56 % 
Sentence execution 21,836,579 11.74 % 57,430,379
18
 23.63 % 
Indefinable level of 
the criminal justice 
system 
4,167,335 2.24 % 3,550,399 1.46 % 
Total 186,038,337 100 % 243,000,490 100 % 
 
Increasing expenditures are observed for each level of the criminal justice system. Two factors have 
influenced this evolution. First, the general budget on each level has increased more than one would 
expect on the basis of inflation. Secondly, an upward trend in the number of recorded drug crimes is 
noticed: on the level of detection the number rises from 4.27% in 2004  to 4.53% in 2008, for 
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prosecution from 4.05% to 5.7% and for sentencing from 2.29% to 2.99%. Similar increases19 are 
revealed for two subcategories of the level of the sentence execution: the houses of justice and 
penitentiary. 
 
Interpretation 
The Belgian comparison over time shows changes in the drug budget, especially in the field of 
enforcement. This could indicate that drug policy has influenced the public expenditures. This is 
probably not the case since the Belgian federal drug policy note of 2001 remained applicable during 
the years 2004-2008, and no important changes were made in the national drug policy. A sequence of 
small decisions on several levels is responsible for the decreasing prevention expenditures and 
increasing treatment and enforcement expenditures20. For example, the police reports on the offence 
‘illegal drug possession’ and ‘import/export illegal drugs’ increased between 2004 and 2008. It is 
possible that the focus on drug tourism has enhanced the enforcement expenditures (Vander Laenen, 
De Ruyver, Christiaens & Lievens, 2011). Another explanation could be an increase in the fight against 
public (illegal) drugs nuisance (Ward, 2011). Finally, there may have been no change in enforcement 
policy per se, but an increase in arrests because of an increase in the level of the underlying criminal 
activity.   
 
Secondly, the Belgian public expenditure study of 2004 warned that prevention is underfinanced. The 
2004 study was used as an argument by the prevention sector to ask the government for more 
funding, a request that was not granted, as the 2008 study shows. The comparison over time shows 
that resources for prevention programmes not only did not grow; they actually decline, while 
resources for enforcement increase (by 29.01%). It seems that it was not possible or desirable for 
Belgium to change the (historical) drug policy mix and enlarge the pillar prevention over this period of 
four years. It is much simpler for a government to maintain the historical resource allocation than to 
carry out changes to the resource allocation mix (McDonald, 2011). Furthermore, the drug 
expenditures are always after-the-fact calculations based on decisions made by those competent 
public authorities and therefore they use data collected from budgets and/or accounting statement. 
The results of a public expenditure study may be useful for guiding future decisions, but it is not a 
decision forcing instrument (Reuter, 2006). 
 
3.3. Cross-country comparison 
A comparison with other public expenditure studies is difficult, because of the differences in the 
applied conceptual framework. For example, the studies of Sweden and the Netherlands take into 
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account a fraction of the reactive expenditures (spending related to the consequences of drug use, 
Moore, 2008). In table 5, 6 and 7 a cross-country comparison is provided21, but the estimates for 
Sweden, the Netherlands and Luxembourg are reorganized to match the conceptual framework of 
‘direct’ expenditures. The conceptual differences are eliminated by excluding amongst others the 
expenditures for HIV/AIDS treatment to patients infected via IDU and drug related crimes. However, 
differences remain with regard to methodology and social welfare systems. 
 
First, a comparison of the results of the global public expenditures for seven countries will be 
presented. Second, the drug expenditure mixes of four countries are studied.  
 
3.3.1. Global public expenditures  
Numeric results 
In the first part of this cross-country comparison, the following indicators are examined: proportion of 
gross domestic product (GDP) and the expenditures per capita. Belgium’s public expenditure on drug 
policy (illegal drugs) for the year 2008 amounted to 296 million Euros. On the 1st of January 2008, 
Belgium’s population stood at 10,666,866 inhabitants and Belgium’s GDP was 344.7 billion Euros. This 
means that public expenditure on drug policy represented 27.78 Euros per inhabitant or 0.09 % of the 
GDP.  
 
Table 5: Cross-country comparison (illegal drugs)
22 
Country Year 
Expenditure 
(million Euros) 
Proportion of 
GDP(%) 
Per capita 
(Euros) 
The Netherlands 
(Rigter, 2006) 
2003 1721
23
 0.36 106.07 
Germany 
(Mostardt, 2010) 
2006 5144 - 6024 0.22 - 0.26 62.45 - 73.13 
Sweden 
(Ramstedt, 2006) 
2002 502
24
 0.19 56.25 
Australia
25
 
(Moore, 2008) 
2002 - 2003 770 0.17 39.20 
Luxembourg 
(Origer, 2002 & 2010
26
) 
1999 
2009 
22
27
 
38
28
 
0.11 
0.1 
51.54 
77 
Belgium 2008 296 0.09 27.78 
France 
(Kopp & Fenoglio, 2006) 
2003 907 0.06 15.04 
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The absolute amount of public expenditures in a country might be caused by the size and wealth of 
this country, e.g., because wages of police and treatment workers might tend to be higher in more 
affluent countries. So drug-related expenditure as a proportion of GDP is also relevant, because it 
takes into account that a richer country might invest more in drug control for a given size problem 
(Reuter, 2006). An analysis of this indicator and the expenditure per capita, tells us that the 
Netherlands, Germany and Sweden invest the largest share of GDP in drug policy, whereas France and 
Belgium are located at the bottom. Australian drug expenditures are situated between these 
extremes. It is difficult to draw conclusions for Luxembourg, since the proportion for public 
expenditures on illegal drugs of the GDP is rather low, although the expenditures per capita lean more 
towards Sweden and Germany.  
 
As mentioned, we cannot compare U.S. expenditures directly, because the most comparable figures 
pertain only to federal spending.  However, we can work the calculation in reverse. The average 
proportion of GDP across the seven countries in the table is about 0.175%.  If the U.S. spent 0.175% of 
its $14.5 trillion GDP on drug control, that would be about $25 billion per year.  That is considerably 
more than the federal government spends, but less than twice as much. So if state and local spending 
on drug control exceeds federal spending, as was the case back in 1990 and 1991 (ONDCP, 1993), the 
last time direct estimates were made, then the U.S. spends a larger proportion of its GDP on drug 
control than the average of the countries in the table.  On the other hand, spending at a rate that 
matched the highest country in the table, the Netherlands at 0.36% of GDP, would require that the 
U.S. spend over $50 billion per year on drug control, which is on the high side of guesses typical made 
about U.S. national spending.   
 
Interpretation 
It is clear that the public expenditure in Belgium and France is far from the level of expenditure in the 
Netherlands and (less) than half of the expenditures in Sweden and Germany. A possible explanation 
lies in the history of the countries’ drug policy.  
 
Both Belgium and France developed a drug policy at a later stage than countries such as the 
Netherlands and Sweden. Apart from the adoption of the international drug laws and regulations and 
accompanying expenditures for law enforcement, in Belgium and France, subsidies in the field of 
prevention or treatment remained scare. Only after societal and political changes at the beginning of 
the 1990s, did the Belgian government start to develop a drug policy; its first drug policy note was 
written in the year 2001 (De Ruyver, Vander Laenen & Eelen, 2011). A similar story occurs in France. 
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The French government waited until 1999 to develop a triennial plan that defines priorities for action, 
objectives and specific measures (Collin, 2001).  
 
The countries with high drug-related public expenditures have a longer history in drug policy. For 
example, Sweden transformed to a clear law-enforcement approach already at the end of the 1960s 
(Lenke & Olsson, 1996). The Dutch drug policy, regarded as liberal and tolerant, has its foundations in 
the early involvement of the Netherlands in the legal trade of coca and opium. Since 1960s the 
Netherlands viewed drug addiction as a social problem and they amended radically the Opium Act in 
1976 (Chatwin, 2003). Germany’s drug policy has a long standing history, and it is also progressive in 
comparison with other countries (Schroth, Helfer & Gonshorek, 2011). Furthermore, Australia has 
formed a framework of drug policy, with the principle of harm minimisation, since 1985 (Green, 2002). 
The development of an Australian drug policy can be situated in time between the Netherlands, 
Sweden and Germany on the one hand and Belgium and France on the other hand. This might explain 
why Australia has an average drug expenditure in comparison with the other countries. 
 
This correlation between level of expenditure and longevity of formal national policy could be purely 
coincidence.  It could also readily be a spurious correlation stemming from an omitted third variable, 
to use social science parlance; that is, countries with worse drug problems may both launch their 
formal policy sooner and spend more, on average.  However, the correlation does also raise the 
provocative policy that formalizing a policy creates a bureaucratic tendency to grow budgets over 
time.  So that even if the official policy adopts a lenient tone, the very existence of that formal policy 
may stimulate greater expenditures over time, perhaps including expenditures on enforcement.  To be 
clear, no such causal inference can be supported by this simple cross-sectional comparison.  But it is 
an interesting hypothesis that might merit empirical investigation in further work.   
 
Stepping back from such generalities, one can at least say in conclusion, the combination of the cross-
country comparison results and the drug policy history provides support for the following conjecture: 
the late development of the Belgian drug policy may have delayed growth in the financial investments 
in drug policy.  
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3.3.2. Drug expenditure mixes 
Numeric results 
A second way to conduct a cross-country comparison is by studying the drug expenditure mixes of 
different countries. As mentioned, the Belgian policy mix for illegal drugs consists of 49.14% 
treatment, 45.09% enforcement, 3.85% prevention, 0.79% harm reduction and 1.14% other. The level 
of spending per pillar is taken into account in Table 6 and 7. For the comparison, the countries that 
used the same policy categories (prevention, treatment, law enforcement and harm reduction) are 
included. The drug expenditure mixes of the four countries are presented in two separate tables. The 
policy mixes of the Netherlands and Australia are presented separately because it is not correct, from 
a methodological point of view, to compare them with the figures of Belgium or Sweden.   
Table 6: Cross-country comparison (illegal drugs)
 
for Sweden and Belgium
30
 
 
Table 7: Cross-country comparison (illegal drugs)
 
for the Netherlands and Australia 
 
First of all, harm reduction and prevention are the smallest sectors in each country, with the exception 
of prevention in Australia. Australia’s spending on prevention appears to be higher than their 
expenditure on treatment or other countries’ spending on prevention because its figures include 
school-based drug prevention programmes32. Those expenditures are not taken into account in the 
Belgian and Swedish study, due to lack of information about the proportion of drug prevention in 
school time. Furthermore, the Dutch expenditures for harm reduction are bigger than for prevention. 
This seems plausible because the Netherlands have consistently practiced a policy of harm reduction 
to drug problems (Chatwin, 2003). 
 
Secondly, tables 6 and 7 also tell that the majority of spending is on enforcement, except for in 
Belgium. It has been assumed that supply control interventions absorb the great bulk of drug control 
Country Year Prevention Treatment 
Harm 
reduction 
Enforcement Other 
Sweden
29
 2002 1.6 % 35.5 % 0.2 % 62.7 % / 
Belgium 2008 3.9 % 49.1 % 0.8 % 45.1 % 1.1 % 
Country Year Prevention Treatment 
Harm 
reduction 
Enforcement Other 
The Netherlands
31
 2003 2.4 % 20.2 % 4.3 % 68.8 % 4.2 % 
Australia 2002 -2003 23 % 17 % 3 % 55 % 1 % 
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spending in punitive countries as the United States (Caulkins, 2009), but these results show that they 
also do in countries often associated with less hawkish policies, including the Netherlands and 
Australia. Belgium strikes the eye because of the slightly bigger amount of treatment expenditures in 
comparison with the enforcement expenditures. This is due in part to methodological differences and 
to differences in the health care systems in the countries. For example, the Dutch study used a 
methodology that probably underestimated the drug-related costs in hospitals33. Consequently the 
expenditures for general health care are much lower in the Dutch study (general health care counts 
for 2.56% of the total treatment sector, in comparison with the Belgian proportion of 55.53%). 
Furthermore, the Swedish number of hospital days for a drug-related diagnosis is also less than in 
Belgium (Sweden: 60,900 and Belgium: 146,813).  
 
Interpretation  
It is hard to draw any conclusions in a cross-country comparison, given the uncertainties about the 
methodology. For example, the Dutch and German studies indicated high expenditures for the 
enforcement sector. Rigter (2006) found that 76% (adapted estimation in table 7: 68.8%) of the 
expenditures belong to this sector. The German study of Mostardt (2010) estimated that police, courts 
and prisons spend a minimum of 3.3 billion Euros (65.4%) and a maximum of 4.2 billion Euros (70%) on 
drug enforcement. This might indicate that countries with high expenditures for drug policy have, in 
comparison, a bigger sector enforcement. On the other hand, the proration techniques to calculate 
drug-related expenditures in the enforcement pillar vary in the studies. In the Belgian study, the 
proportion of police reports for ‘illegal drugs’ (1%) is applied on the general police budget. The Dutch 
study used the share (13%) of Opium Act offences in the total number of cases leading to detention 
verdicts in courts. A test is conducted where this Dutch proration technique is applied for Belgium. The 
Belgian share of drug offences in the total number of cases leading to imprisonment is 15.29 %. If this 
share is applied to the police budget, than the Belgian policy mix changes to: 79.18% enforcement, 
18.64% treatment, 1.46% prevention, 0.30% harm reduction and 0.43% others. It is clear that different 
proration techniques can distort the cross-country comparison and it possibly explains the larger 
sector enforcement for the Netherlands. 
Secondly, the different welfare security systems further complicate a comparison of countries’ public 
expenditures. There are big differences between the welfare states, and this becomes clear in the 
various social expenditures (Cantillion, 2009). Social expenditures’ proportion of GDP is for example 
much lower for Australia (16% in 2007) than for Belgium (27.3% in 2007). From this point of view, it is 
plausible that the Australian treatment expenditures are lower than the expenditures in the other 
countries in the cross-country comparison34. 
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4. DISCUSSION 
The ultimate goal of a public expenditure study is to improve drug policy. A preliminary clear view on 
the public expenditures is necessary to assist policy makers in setting priorities (Moore, 2008), 
because an appropriate drug policy should rely on the assessment of drug related public expenditure 
(EMCDDA, 2008). This paper investigated if a public expenditure study can fulfil the potential role of 
informing the decision makers on three levels. The results of ‘Drugs in Figures III’ show that the study 
passes for the first two levels. Firstly, the study provides insight into how the drug expenditures are 
composed and what the public authorities so-called ‘policy mix’ is. The study shows whether the 
government’s stated priorities for that drug policy are mirrored in their expenditures. Secondly, the 
study gives insight into the evolution of public expenditures on drugs over time.  
 
On a first level, the composition of a country’s drug policy expenditures mix becomes clear during a 
comparison across sectors. From this comparison it is surprising to find that public expenditures on 
prevention are a fraction of the amount spent on treatment. This is particularly true for the prevention 
of tobacco and alcohol: only 9.52 % of the amount spent on prevention is spent for the prevention of 
tobacco and alcohol. Since further analysis shows that at least 75.59%35 of the treatment expenditures 
is for alcohol, it might seem warranted to invest more in prevention, both from a cost-effectiveness 
point of view as well as from a social cost point of view. (The pattern of spending should consider the 
drug types that are the source of most harm to society, McDonald, 2011.) It seems that decision 
makers need the drug policy expenditures mix to monitor the balance of resource allocation, namely 
equality in the quantum of funds allocated to the various drugs and implementation sectors 
(McDonald, 2011).  
 
The comparison of drug policy expenditures to policy pronouncements brings up that there is no 
match between government’s spending and policy declarations in the Belgian case. The Belgian drug 
policy developed in a bottom up manner: it proceeds from the work field. Consequently, the public 
expenditures are more dependent on activities and initiatives in the field, and less dependent on the 
federal drug policy. This being said, the budget proportions should not necessarily match with 
priorities. There are several reasons why, even in an ideal world, central priorities may not be 
associated with the largest budget outlays. For one, the priorities may be pursued through a policy or 
a mandate, not a programme with a specific budget line. This is clearly the case in Belgian drug policy 
since only 8.69% of public expenditure on drugs is drug specific and thus retraceable as such in the 
budget lines. Another reason is that political statements of priority often represent directions of 
change, not absolute levels. So when a new administration makes a particular programme its priority, 
that may mean large percentage increases in spending on that programme, not that the programme’s 
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level of funding will suddenly become the largest. In fact, the historical resource allocation formulae 
will not be fundamentally changed by putting into place a (new) policy drug note (McDonald, 2011).  
 
The second level, a comparison over time, sketches the evolutions in the field of public drug 
expenditures. There was no significant change in the Belgian drug policy that could explain the rising 
expenditures for the pillars enforcement and treatment (to a limited extent). There is no need to 
automatically link a change in drug budget to a change in policy. A closer study of general trends in the 
public expenditures can reveal different kind of explanations. The treatment expenditures in Drugs in 
Figures III are raised because the treatment of all patients has become more expensive in hospitals, 
namely the hospital costs per day spent in hospital rose substantially over the four years between the 
two studies. In contrast, the growth in enforcement spending is caused by a deliberate policy option to 
increase enforcement activity with regard to the possession and import/export of illegal drugs.  
 
As for the third potential role of public expenditure studies, a cross-country comparison should make 
it possible to view the different options in drug policy and to explore correlations between different 
drug policies and public expenditures. If not, the cross-country comparison can only be of limited 
value for decision makers. From the results section it has become clear that it is very difficult to draw 
conclusions on a cross-country level because the question always remains if variations in expenditures 
can be attributed to methodological differences. We illustrated that indeed small changes in proration 
technique can easily generate other results, and this makes public expenditure studies fragile (Vander 
Laenen et al., 2008). From this point of view, a cross-country comparison should be avoided until 
there is a uniform methodology to estimate the public expenditures in different countries. In this 
respect, the initiative of the EMCDDA to develop a common EU-wide methodology for public 
expenditure studies warrants applause (EMCDDA, 2008). However, even if an identical methodology is 
used, (historical) differences in social security systems and institutional factors will still make it difficult 
to compare public expenditure study results across countries. For example, the reality of private 
investments in drug policy complicates comparisons across place and space. If one country has a 
tradition of larger private involvement/donations while another leaves most of its investment to 
government, a cross-country comparison becomes hazardous. Such differences can be the accidental 
consequences of differences not directly related to drug policy.  For example, in countries with large 
private and parochial school systems, government expenditures on school-based prevention may be 
substantially less than societal investments in school-based prevention programmes.  Indeed, a public 
expenditure study is limited to the estimation of public expenditures on drug policy actions; neither 
private expenditures nor external expenditures are included. Therefore only a social cost study can 
provide the total social cost of drugs in a given society.  Alternately, one could define a new type of 
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study, one that tracked public and private proactive expenditures but which did not include the other 
social costs (e.g., reactive spending, monetized value of morbidity and mortality, etc.). 
 
In conclusion, a public expenditure study can play an important role on two levels: a comparison 
across sectors and over time. The public expenditure study can be an instrument for guiding the drug 
policy toward a balanced resource allocation. Moreover, the public expenditure studies can fulfil an 
important role by serving as the first step for economic evaluation of drug policy interventions, where 
a cost analysis and social cost study are the next steps. The ultimate goal of public expenditure studies 
is to derive important information for policy makers and to improve policy making. However, caution 
must be applied when using the results of a public expenditure study alone for policy (decision 
making) purposes. 
 
Firstly, a full policy evaluation can only be completed by combining information about public 
expenditures with a range of other types of information/studies. This means basing it upon 
epidemiological data about new trends in drug use and groups of (problem) drug users, on data about 
reached target groups (in prevention, early intervention and treatment) and on evaluation and 
effectiveness studies. A public expenditure study identifies facts that are worth looking into more 
deeply, but only further research can detect for example a lack of performance. Ideally, this leads to 
an evidence-based policy, where the financial resources are assigned to the implementation and 
evaluation of evidence-based prevention, regulatory, treatment, and harm-reduction interventions 
(Wood et al., 2010).  
 
Secondly, through a public expenditure study the resource allocation to and balance in the various 
drugs and implementation sectors became clear. The EU Strategy 2005-2012, states that “The present 
integrated, multidisciplinary and balanced approach of combining demand and supply reduction will 
remain the basis of the Union’s approach to the drugs problem in the future” (Council of the EU, 2004, 
p. 5). It is not clear how demand and supply reduction will be ‘combined’ to reach this balance. In 
general, what is an ‘appropriate’ or desired balance in resource allocation will depend on the criteria 
deemed to be essential in (drug) policy decision making. For example, it could mean that the resources 
need to be allocated in accordance with the relative burden that a type of drugs imposes on society. 
To others, it means allocating the public expenditures to cost-effectiveness programmes (McDonald, 
2011). There are thus multiple meanings of the word balanced, and it is interpreted differently by 
academics and politicians. The drug budget is most of the time allocated from the departments of law 
enforcement and health (Ritter, 2010). The public expenditure studies show that policymakers choose 
for law enforcement, although research indicates that the cost-effectiveness of treatment and harm 
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reduction is substantially higher than in the criminal justice sector (Boyum & Reuter, 2005). De Beck et 
al. (2009) confirm that governments are still investing in drug policies and practices that are not 
supported in the scientific literature, and even conflict with evidence-based results (Reuter, 2001; 
MacCoun & Reuter, 2008). Politicians follow the historical allocation and want to comply with the 
prevailing standards. Academics on the other hand, embrace cost effectiveness as an important 
principle for drug policy. Although a tension exists between the scientific and political worlds, both 
parties have one thing in common: they  want to reduce drug-related harm. This brings us back to the 
importance of a social cost study. Based on a social cost study, the drug budgets could be contrasted 
with the (health) impacts of the various classes of drugs, which would allow for reallocation of drug 
budgets (Mc Donald, 2011). For example, an Australian study indicated that the social cost for tobacco 
is three times higher than for illegal drugs (Collins & Lapsley, 2008). The international overview of 
Single et al. (2003) indicated that the government drug budget on average represented only 5 % of the 
social costs of drug use.  
 
In this paper different manners are explained where the public expenditure study could play an 
important role for drug policy. Public expenditure studies can provide a valuable basis for an 
assessment about the public spending on drug policy and they can contribute to a more objective 
discussion (Mostardt et al., 2010). These kinds of studies can be applied to other criminological policy 
domains (Van Malderen et al., 2009). The demand for estimations of governmental costs in response 
to crime is likely to increase in the future (Bowles, 2009). The credit crisis of 2008 puts pressure on the 
criminal justice budgets and this may enhance the interest in public expenditure studies and economic 
analysis in general. After all, good supervision on the level of public spending will decrease at least the 
financial burden of crime on society. 
 
STUDY 1 
33 
 
5. REFERENCES 
Aos, S. (2006). Evidence-Based Public Policy Options to Reduce future Prison Construction, Criminal 
Justice Costs, and Crime Rates. Olympia: Washington State Institute for Public Policy. 
 
Belenko, S. & Peugh, J. (2005). Estimating drug treatment needs among state prison inmates. Drug and 
Alcohol Dependence, 77, 269-281. 
  
Boyum, D. & Reuter P. (2005). An analytic assessment of U.S. drug policy. Washington DC: AEI Press. 
 
Bowles, R. (2009). The Costs of Crime: introduction. European Journal on criminal policy and research, 
15 (4), 307-308.  
 
Cantillion, B. (2009).  The Paradox of the Social Investment State: Why did poverty not decline? 
(berichten D/2009/6104/03). Centrum voor sociaal beleid Universiteit Antwerpen. 
 
Carey, S., Crumpton, D., Finigan, M., & Waller, M. (2005). California Drug Courts: A Methodology for 
Determining Costs and Benefits: PHASE II: Testing the Methodology. Portland: NPC Research. 
 
Carnevale, J. (2008). Back to Basics: Principles of an Effective National Drug Policy. Policy Brief: Fixing 
national  drug control policy. Gaithersburg, MD: Carnevale Associates. 
 
Cartwright, W.S. (2000). Cost-benefit analysis of drug treatment services: Review of the literature. 
Journal of Mental Health Policy and Economics,  3, 11–26. 
 
CASA (2001). Shoveling up: The Impact of Substance Abuse on State Budgets. New York: Columbia 
University. 
 
CASA (2009). Shoveling up II: The Impact of Substance Abuse on Federal, State and Local Budgets. New 
York: Columbia University. 
 
Caulkins, J. (2009). Illicit substance abuse and addiction. In Weimer, D. & Vining, A. (eds.), Investing in 
the disadvantaged: assessing the benefits and costs of social policies (pp. 83-102). Washington DC: 
Georgetown University Press.  
 
Caulkins, J., Rydell, P., Everingham, S., Chiesa, J. & Bushway S. (1999). An Ounce of Prevention, a Pound 
of Uncertainty: The Cost-Effectiveness of School-Based Drug Prevention Program MR-923-RWJ. Santa 
Monica, CA: RAND. 
 
Chatwin, C. (2003). Drug policy developments within the European Union. British Journal of 
Criminology, 43, 567-582. 
 
Collin, C. (2001). National Drug Policy: France. Available at: 
http://www.parl.gc.ca/Content/SEN/Committee/371/ille/library/france-e.htm [Accessed 23 
September 2011]. 
 
STUDY 1 
34 
 
Collins, D. & Lapsley, H. (2008). The costs of tobacco, alcohol and illicit drug abuse to Australian society 
in 2004/05. National Drug Strategy Monograph Series No. 64. 
 
Council of the EU (2004). EU Drugs Strategy (2005-2012). Available at: 
http://www.encod.org/info/IMG/pdf/EU_Drugs_Strategy_2005-2012-2.pdf [Accessed 19 October 
2011]. 
 
DeBeck, K., Wood, E., Montaner, J., & Kerr, T. (2009). Canada's new federal 'National Anti-Drug 
Strategy': An informal audit of reported funding allocation. International Journal of drug Policy, 20(2), 
188-191.  
 
Demotte, R. (2004). Federal plan tobacco control (Federaal Plan ter bestrijding van het tabaksgebruik). 
 
De Ruyver, B., Casselman, J. & Pelc, I. (2004). Drug policy in figures. Study of the actors involved, cost 
price calculation and population reached. Ghent: Academia Press. 
 
De Ruyver, B., Pelc, I., De Graeve, D., Bucquoye, A., Nicaise, P. & Cornelis, L. (2007). Drug policy in 
Figures II. Follow-up research into the actors, public spending and reached target groups. Ghent: 
Academia Press. 
 
De Ruyver, B., Vander Laenen, F.  & Eelen, S. ( 2011). Country report Belgium. Pompidou Group - 
Integrated Policy Expert Group. 
 
European Monitoring Centre for Drugs and Drug Addiction (2008). Towards a better understanding of 
drug-related public expenditure in Europe (Selected issue). Lisbon: Office for Official Publications of the 
European Communities. 
 
Gerstein, D.R., Harwood, H., Fountain, D., Suter, N., & Malloy, K. (1994). Evaluating recovery services: 
The California Drug and Alcohol Treatment Assessment (CALDATA). Washington, DC: National Opinion 
Research Center. 
 
Green, C. (2002). Minimising the Harm of Illicit Drug Use: Drug Policies in Australia (Research brief No 
2002/06). Queensland Parliamentary Library. 
 
Harwood, H.J., Malhotra, D., Villarivera, C., Liu, C., Chong, U., & Gilani, J. (2002). Cost Effectiveness and 
cost benefit analysis of substance abuse treatment: A literature review. Rockville, MD: Substance 
Abuse and Mental Health Services Administration. Center for Substance Abuse Treatment. 
 
Kopp, P. & Fenoglio, P. (2003). Public spending on drugs in the European Union during the 1990s. 
Lisbon: EMCDDA. 
 
Kopp, P. & Fenoglio, P. (2006). Le coût social des drogues en 2003. Les dépenses publiques dans le 
cadre de la lutte contre les drogues. Paris : OFDT. 
 
STUDY 1 
35 
 
Lamkaddem, B. & Roelands, M. (eds.) (2010). Belgian National report on drugs. Brussels: OD Public 
Health and Surveillance, Scientific Institute of Public Health. 
Lenke, L. & Olsson, B. (1996). Sweden: zero tolerance wins the argument? In Dorn, N., Jepsen, J. & 
Savona, E. (eds), European Drug Policies and Enforcement (pp. 106-118). Houndsmill: MacMillan. 
 
Lievens, D. & Caulkins, J. (2010). Studies on public drug expenditure: the potential role, limitations and 
relationship to actual drug policy. Unpublished paper 
 
MacCoun, R.J. & Reuter, P. (2001). Drug war heresies: Learning from other vices, times, and places. 
New York: Cambridge University Press. 
 
MacCoun, R.J. & Reuter, P. (2008). The implicit rules of evidence-based drug policy: A U.S. perspective. 
International Journal of Drug Policy, 19, 231-232. 
 
McDonald, D. (2011). Australian governments’ spending on preventing and responding to drug abuse 
should target the main sources of drug-related harm and the most cost-effective interventions. Drug 
and alcohol review, 30, 96-100. 
 
Moore, T. J. (2005). Monograph No. 01: What is Australia’s “drug budget”? The policy mix of illicit 
drug-related government spending in Australia. Fitzroy: Turning Point Alcohol and Drug Centre. 
 
Moore, T. (2008). The Size and Mix of Government Spending on Illicit Drug Policy in Australia. Drug 
and Alcohol Review, 27, 404-413. 
 
Mostardt, S., Flöter, S., Neumann, A., Wasem, J. & Pfeiffer-Gerschel, T. (2010). Public Expenditure 
Caused by the Consumption of Illicit Drugs in Germany. Gesundheitswesen Bundesverband Der Arzte 
Des Offentlichen Gesundheitsdienstes Germany, 72(12), 886-894. 
 
Murphy, P., Davis, L., Liston, T., Thaler, D. & Webb, K. (2000). Improving Anti-Drug Budgeting. Santa 
Monica, California: RAND. 
 
Office of National Drug Control Policy (1989-2011). National drug control strategy: FY 1989-2011 
Budget summary. Washington, DC: The White House. 
 
Office of National Drug Control Policy (1993).  State and local spending on drug control activities: 
Report from the national survey of state and local governments. Washington, DC: The White House. 
 
Origer, A. (2002). Le coût économique direct de la politique et des interventions publiques en matière 
d’usage illicite de drogues au Grand-Duché de Luxembourg. Séries de recherche n°4. Luxembourg: 
Point focal OEDT Luxembourg – CRP-Santé. 
 
Origer, A. (2010). The 2010 national drug report “Grand Duchy of Luxembourg”. Available at: 
http://www.sante.public.lu/publications/rester-bonne-sante/drogues-illicites-dependances/etat-
phenomene-drogue-gdl-rapport-annuel-relis/etat-phenomene-drogue-gdl-rapport-annuel-relis-2010-
fr-en.pdf [Accessed 5 September 2011]. 
STUDY 1 
36 
 
 
Postma, M.J. (2004). Public expenditure on drugs in the European Union 2000-2004. Lisbon: EMCDDA. 
 
Rajkumar, A.S. & French, M.T. (1997). Drug use, crime costs, and the economic benefits of treatment. 
Journal of Quantitative Criminology, 13, 291-323. 
 
Ramstedt, M. (2006). What drug policies cost. Estimating drug policy expenditures in Sweden, 2002: 
work in progress. Addiction, 101, 330-338. 
 
Reuter, P. (2001). Why does research have so little impact on American drug policy?, Addiction, 96, 
373-376. 
 
Reuter, P., Ramstedt, M. & Rigter, H. (2004). Developing a Framework for Estimating Government Drug 
Policy Expenditures. Lisbon: EMCDDA. 
 
Reuter, P. (2006). What drug policies cost. Estimating government drug policy expenditures. Addiction, 
101, 315-322. 
 
Rigter, H. (2006). What Drug Policies Cost. Drug Policy Spending in the Netherlands in 2003. Addiction, 
101, 323-329. 
 
Ritter, A. (2010). Conceptualising ‘balance’ in national drug policy. Drug and Alcohol review, 29, 349-
351. 
 
Rydell, P., Caulkins, J. & Everingham, S. (1996). Enforcement or Treatment? Modeling the Relative 
Efficacy of Alternatives for Controlling Cocaine. Operations Research, 44, No. 5, 687-695. 
 
Schroth, S., Helfer, J. & Gonshorek, D. (2011). Germany. In Kleiman, M. & Hawdon, J. (eds.), 
Encyclopedia of drug policy (pp. 313-315). Thousand Oaks: Sage publications. 
 
Single, E., Collins, D., Easton, B., Harwood, H., Lapsley, H., Kopp, P., et al. (2003). International 
Guidelines for Estimating the Economic Costs of Substances Abuse. Geneva: World Health 
Organization. 
 
Vander Laenen, F., Vandam, L., De Ruyver, B. & Lievens, D. (2008). Studies on public drug expenditure 
in Europe: possibilities and limitations. Bulletin on Narcotics, LX, 23-39. 
 
Vander Laenen, F., De Ruyver, B., Christiaens, J. & Lievens, D. (2011). Drugs in Cijfers III. Ghent: 
Academia Press. 
 
Van Malderen, S., Vander Laenen, F. & De Ruyver, B. (2009). The study of expenditure on drugs, a 
useful evaluation tool for policy. In Cools, M., De Kimpe, S., De Ruyver, B., Easton, M., Pauwels, L., 
Ponsaers, P., Vander Beken, T., Vander Laenen, F., Vande Walle, G., Vermeulen, G. (eds.), Gofs 
Research Paper Series, Contemporary Issues in the Empirical Study of Crime (pp. 49-78). Antwerpen: 
Maklu. 
STUDY 1 
37 
 
 
Walsh, J. (2004). Fuzzy math: why the White House drug policy budget does not add up. FAS Drug 
Policy Analysis Bulletin, 10, 1 -6. 
 
Ward, J. (2011). Policing Public drugs nuisance through the anti-social behavior legislation: questions 
and contradictions. European Journal on Criminal Policy and Research, 17, 323-341. 
 
Wood, E., Werb. D., Kazatchkine, M., Kerr, T., Hankins, C., Gorna, R., Nutt, D., Jarlais, DD., Barre-
Sinoussi, F. & Montaner, J. (2010). Vienna Declaration: a call for evidence-based drug policies. The 
Lancet, 376, 310-312. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
STUDY 1 
38 
 
6. ENDNOTES
                                                          
1
 A study on national public expenditures would estimate local, state and federal spending.  
2
 At the time of the study, data from the justice department and hospitalisation was only available for the year 
2008. 
3
 In 2004, the Belgian research “Drug policy in Figures, A study into the actors involved, public expenditure and 
target groups reached” (Drugs in Figures I) has been published (De Ruyver et al., 2004). In 2007 a new estimation 
of public expenditures on illegal drugs has been carried out: Drugs in figures II (De Ruyver et al. 2007). The 
methodology in the present study ‘Drugs in figures III’ is refined and extended to carry out a new estimation of 
public expenditures (anno 2008) on illegal drugs and a first estimation for legal drugs (tobacco, alcohol and 
psychoactive medication). 
4
 Such as the expenditure of drug users and expenditure of charity funds. Other examples include drug testing 
and EAP programmes paid for by private employers and, in countries such as the United States that have large 
private health insurance markets, drug and alcohol treatment and smoking cessation paid for by private health 
insurance.   
5
 The expenditures for a policy with regard to potential misuse and dependence of alcohol and psychoactive 
medication. 
6
 The proportion of drugs is taken into account for a repartition key and therefore the quantity of ‘drugs’ is 
divided by the total amount. For an unit expenditure less data are required because only the quantity ‘drugs’ (for 
example, number of hospitalisation days drugs) is necessary to estimate the drug related public expenditure. 
7
 European School Survey Project on Alcohol and Other Drugs (ESPAD) is a collaborative effort of research teams 
in more than forty European countries, the overall aim is to repeatedly collect comparable data on substance 
use in Europe among 15–16 year old students 
The Pompidou Group is an inter-governmental body formed within the Council of Europe, their mission is to 
contribute to the development of multidisciplinary, innovative, effective and evidence-based drug policies in the 
Member States. 
8
 A great deal of the expenditures are measured with unit expenditure or proration technique and this must be 
regarded as approximations as they are built mainly on various assumptions. Therefore intervals are presented: 
a low end estimate and a high-end estimate augment the baseline or best point estimates (which is the average 
between low and high estimate). 
9
 The expenditures are not presented separate for each type of drugs, because the sector of alcohol is entangled 
with illegal drugs. For instance, treatment activities focus on both type of drugs and this makes it impossible to 
measure the exact amount of expenditures for alcohol or illegal drugs.  
10
 Minimum 557 million of the treatment expenditures is specifically labeled for alcohol treatment (for example 
treatment of alcohol abuse in hospitals, the project ‘alcohol and pregnancy’,…). 
11
 There is a probably an overestimation of illegal drug expenditures for the sector prevention and treatment, 
because a large amount of the expenditures is used for interventions that do not distinguish between alcohol en 
illicit drugs. 
12
 The federal drug policy note resulted in a Joint Declaration of the Inter-ministerial Conference on Drugs in 
January 2010. 
13
 No category harm reduction for tobacco is included, because no public expenditures are identified in this 
domain for the year 2008 (Vander Laenen et al. 2011). 
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14
 Since September 2009, the reimbursement of tobacco dependence is extended to each patient that wants to 
quit smoking. Consequently, the public expenditure for tobacco will raise in the year 2010 with 3.4 million Euros.  
15
 The expenditures mentioned in the 2004 study are expressed in terms of their real value in 2008. Inflation is 
taken in account (general index= 111.32 base 2004, year 2008)  
16
  In the Drugs in Figures III study, the Flemish expenditure for syringe exchange programmes are no longer 
listed as prevention; it is considered as the minimum amount for harm reduction.  
17
 Inflation is taken in account (general index= 111.32 base 2004, year 2008) 
18
 The methodology of Drugs in Figures II could not be used for the penitentiary, because the necessary 
information for the proration technique was not available. The minimal estimation of Drugs in Figures III is 
therefore taken into account. 
19
 The proportion of new mandates ‘drugs’ in houses of Justice increased from 13.12% to 17.20%.  
The population in the penitentiary for a drug offence increased with 9,78% (minimum estimate) and with 15.45% 
in the case of drug offences in combination with other offences(maximum estimate).    
20
 The dependence rates of drug use did not change in Belgium during the period 2004-2008 (Lamkaddem & 
Roelands, 2010).  
21
 A comparison with US studies is not possible, because the studies are limited to federal expenditures (ONDCP, 
1989-2011) or because the expenditures for illegal drugs could not be extracted from the total expenditures for 
substance use (CASA, 2009). 
22
 If the public expenditure per capita or the proportion of GDP is not mentioned in the study, then authors’ 
calculations are made with the statistics (population or GDP of the country) of OECD (Organisation for Economic 
Co-operation and Development). Retrieved October 10, 2011, from OECD.StatExtracts: 
http://stats.oecd.org/Index.aspx?DataSetCode=SOCX_AGG. 
23
 Original expenditures: 2,185 million Euros. Expenditures for drug related crime (462 million Euros) and 
treatment of people with infectious diseases arising from drug use (2.8 million Euros) are subtracted (appendix). 
24
 Original expenditures: 737 million Euros. Expenditures for drug related crime (235 million Euros) are 
subtracted (appendix).  
25
 The proactive government expenditures of Australia are taken into account. The amount of 1,875 million $ 
reactive expenditures is excluded. 
26
 An update of the study Origer (2002) is conducted for the year 2009. Information available in the 2010 
national drug report “Grand Duchy of Luxembourg” from Origer (2010).  
27
 The original expenditures were 23 million Euros. Expenditures for HIV/AIDS treatment provided to patients 
infected via intravenous drug use (1.3 million Euros) are subtracted.  
28
 The cost for HIV/AIDS treatment provided to patients infected via intravenous drug use cannot be subtracted, 
because the precise amount is not reported. The total expenditure of 38 million Euros is consequently an 
overestimation. 
29
 The expenditures for drug-related crimes are excluded for the cross-country comparison with Belgium. The 
original division of the drug  policy expenditures in the Swedish study is 24 % treatment, 75 % enforcement, 1 % 
prevention and 0.1 % harm reduction (Ramstedt, 2006). 
30
 Germany, France and Luxembourg are excluded from this comparison because they used other classification 
systems. Proportions for the Netherlands and Sweden were calculated without the reactive expenditures. 
31
 Original division: 13 % treatment, 75 % enforcement, 2 % prevention and 10 % harm reduction (Rigter, 2006). 
STUDY 1 
40 
 
                                                                                                                                                                                     
32
 In the study of Moore (2008) is 1% of governments’ education expenditures marked as illicit drug prevention. 
33
 The total direct addiction treatment costs in general health care were calculated by taking one-third of the 
expenditures of addiction care centers into account (Rigter, 2006). The Belgian study multiplied the daily cost 
with the days spent in a hospital for a drug-related diagnosis (Vander Laenen et al., 2011). 
34
 In 2007, the total public social expenditure as a percentage of GDP is 20.1% for the Netherlands and 27.3% for 
Sweden. Retrieved October 10, 2011, from OECD: http://stats.oecd.org/Index.aspx?DataSetCode=SOCX_AGG. 
35
 Minimum 557 million of the treatment expenditures is specifically labeled for alcohol treatment (for example 
treatment of alcohol abuse in hospitals, the project ‘alcohol and pregnancy’,…). 
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STUDY 2  
PUBLIC SPENDING FOR ILLEGAL DRUG AND ALCOHOL TREATMENT IN HOSPITALS:  
AN EU CROSS-COUNTRY COMPARISON2 
 
ABSTRACT 
Background: In view of the current economic crisis and the resulting austerity measures being 
implemented by governments across Europe, public expenditure for substance abuse treatment has 
increasingly become a subject of discussion. An EU cross-country comparison would allow an 
estimation of the total amount of public resources spent on substance abuse treatment, compare 
various substance abuse treatment funding options, and evaluate the division of expenditures 
between alcohol and illegal drugs. The purpose of this study is to estimate the public spending of EU 
countries for alcohol and illegal drug abuse treatment in hospitals. 
Methods: Our study uses a uniform methodology in order to enable valid cross-national comparisons. 
Our data are drawn from the Eurostat database, which provides anno 2010 data on government 
spending for the treatment of illegal drug and alcohol abuse in 21 EU member states. The cross-
country comparison is restricted to hospitals, since data were unavailable for other types of treatment 
providers. The systematic registration of in- and outpatient data is essential to monitoring public 
expenditures on substance abuse treatment using international databases. 
Results: Total public spending for hospital-based treatment of illegal drug and alcohol abuse in the 21 
EU member states studied is estimated to be 7.6 billion euros. Per capita expenditures for treatment 
of illegal drug abuse vary, ranging from 0.1 euros in Romania to 13 euros in Sweden. For alcohol 
abuse, that figure varied from 0.9 euros in Bulgaria to 24 euros in Austria. These results confirm other 
studies indicating that public expenditures for alcohol treatment exceed that for illegal drug 
treatment.  
Conclusions: Multiple factors may influence the number of hospital days for alcohol or illegal 
substance abuse treatment, and expenditures fluctuate accordingly. In this respect, we found a strong 
correlation between gross domestic product (GDP) per capita and public expenditures per hospital 
day. The prevalence of problematic (illegal or legal) drug use in a country did not correlate significantly 
with the number of hospital days. Other factors must be included in the analysis of public 
                                                          
2
 A version of this paper has been published as Lievens, D., Vander Laenen, F. & Christiaens, J. (2014). Public 
spending for illegal drug and alcohol treatment in hospitals: an EU cross-country comparison. Substance Abuse 
Treatment, Prevention, and Policy, 9, 26. 
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expenditures for the treatment of substance abuse, such as the drug policy in a given country and the 
social norms regarding alcohol consumption.  
 
Key words: drugs, alcohol, substance abuse, public health, hospital-based treatment, Europe, public 
expenditure 
 
 
 
 
 
 
 
 
 
 
 
 
 
STUDY 2 
43 
 
1. INTRODUCTION 
Illegal drugs and especially alcohol have a significant health impact on human life in Europe. The 
burden of diseases resulting from alcohol and illegal drugs is enormous; together they account for 
11% of disability adjusted life years (DALY’s1) lost in Europe (Rehm, Taylor & Room, 2006). The 
European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) indicated that at least 1.2 
million individuals received some kind of treatment for illegal drug use in the EU and its candidate 
countries (EMCDDA, 2013a). In addition, Rehm, Shield, Rehm, Gmel & Frick (2012) estimated that 
approximately 1.1 million people with an alcohol use disorder in the EU are in treatment2. A 
considerable share of substance abuse treatment is provided in hospitals. EU countries reported more 
than 161,000 hospital discharges for mental and behavioral disorders due to illegal drug use, and 
another 707,000 due to alcohol use in 2010 (Eurostat, 2013a). From the sheer number of people in 
treatment, it is clear that substance abuse treatment has an economic impact. 
 
Rising health care costs have increased pressure on providers, insurers, and policymakers to monitor 
the costs of all health care services (Bray & Zarkin, 2006). Moreover, public expenditures for substance 
abuse treatment are increasingly a subject of discussion in view of the economic crisis and of austerity. 
The cuts in government spending across Europe may affect substance abuse treatment; therefore, it is 
crucial that policymakers understand the economic value of substance abuse treatment services 
(EMCDDA, 2011; Collins et al., 2010). This economic evaluation of substance abuse treatment is 
gaining momentum (Bray & Zarkin, 2006), and the EU drugs strategy (2013-2020) supports this 
evolution by stating that actions must be evidence-based and cost-effective (Council of the European 
Union, 2012). This puts a new premium on measuring and valuing the ‘return on investment’ of 
government expenditures for drug and alcohol abuse interventions (Maynard, 2004). This type of 
evaluation method is clearly linked to public expenditure studies, because it cannot be completed 
without the estimation of public spending on substance abuse treatment. Some aspects of drug and 
alcohol policy can be studied within a single country; for example, secondary school classrooms can be 
randomly assigned to receive one prevention curriculum or another, with effects on self-reported 
substance use assessed at follow-up. However, many important dimensions of policy operate at the 
national level, making cross-national comparisons of both policies and problem severity important.   
 
Unfortunately, making valid cross-national comparisons can be surprisingly difficult because of 
differences in definitions, data, and organizational structures across countries. Creating a foundation 
for cross-national comparisons has been a multi-decade endeavor undertaken by many researchers, 
notably those at the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA, 2008). This 
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study contributes to that effort by estimating public expenditures on hospital-based treatment in a 
consistent manner for 21 EU member states.  
The current study is unique in that few cross-national comparisons of substance abuse treatment 
costs have been conducted. A previous attempt to calculate the total European cost of illegal drug 
treatment services (published in a EMCDDA selected issue in 2011), suffered from limited data 
(EMCDDA, 2011). Rehm et al. (2012) estimated the social cost to the EU countries for the treatment 
and prevention of harmful alcohol use and alcohol dependence to be 6.3 billion euros (2010). 
However, they did not report on the cost for specific types of services such as outpatient treatment 
and inpatient treatment. As a result, the cost for hospital treatment is unknown. Neither is it possible 
to prorate the estimate of Rehm et al. (2012) since the cost per episode of treatment tends to be 
higher in inpatient settings (EMCDDA, 2011). Our study aims to remedy this by estimating hospital-
based treatment expenditures.  
 
The study is conducted within the framework of policy evaluation and therefore focuses on public 
spending. Public expenditures are the direct instrument of public policy and they dominate in the 
financing of substance abuse treatment. Within the EU, health care is mainly financed by 
governmental funding because the public resources in the health care system are supported through 
general taxation and/or insurance-based systems (Pestieau, 2006).  
 
Total public expenditures related to illegal drugs and alcohol (including but not limited to substance 
abuse treatment) have been estimated in social cost studies and public expenditure studies. Such 
studies have been conducted in Australia, the United States, Canada and some EU countries such as 
Belgium, Luxembourg, the Netherlands and Sweden (CASA, 2001, 2009; Garcia-Altés et al., 2002; 
Origer, 2002; Fenoglio, Parel & Kopp, 2003; De Ruyver, Casselman & Pelc, 2004; Rigter, 2006; 
Ramstedt, 2006; Kopp & Fenoglio, 2006; De Ruyver et al., 2007; Moore, 2008; Mostardt et al., 2010; 
Vander Laenen et al., 2011).  While many of these studies follow a common set of general principles, 
they differ in particulars and so cannot support cross-national comparisons.    
 
Some cross-country studies of costs or public expenditures in the field of alcohol and/or illegal drugs 
have been conducted in Europe, including for treatment spending (Kopp & Fenoglio, 2003; Postma, 
2004; Andlin-Sobocki & Rehm, 2005; Anderson & Baumberg, 2006; EMCDDA, 2011; Gustavsson et al. 
2011; Lievens et al., 2012;). However, while each of these studies are valuable, they suffer from one or 
more methodological problems. Kopp & Fenoglio (2003) and the EMCDDA (2011) were confronted 
with incomplete or imprecise data provided by the EU member states. Other studies merely compiled 
STUDY 2 
45 
 
data from different national studies and so were confronted with data of varying quality (Andlin-
Sobocki & Rehm, 2005; Anderson & Baumberg, 2006; Gustavsson et al., 2011). Lievens et al. (2012) 
even concluded that a truly valid cross-country comparison may be infeasible because of the 
conceptual and methodological differences in the national public expenditure studies. 
 
Nevertheless, having an EU cross-country comparison of the public expenditures for substance abuse 
treatment would be valuable for several reasons (Ritter, 2007; EMCDDA, 2008; Lievens et al., 2012). It 
would allow one to estimate the total amount of public resources spent on substance use treatment. 
Moreover, it would allow comparison of  substance abuse treatment funding in different countries. 
Country profiles providing information on treatment organization and its budgetary impact could be 
compiled and used as a first step in a full economic evaluation to find the most cost-effective way of 
organizing substance abuse treatment (Maynard, 2004). Finally, an EU cross-country comparison 
would enable examination of the division of expenditures between alcohol and illegal drugs, allowing 
for recommendations on resource allocations (McDonald, 2011). 
 
The remainder of this paper is organized as follows: first, public expenditures (including social security 
funds) for illegal drug and alcohol treatment in hospitals are presented and compared across EU 
countries. This will provide insight into the dynamics of substance abuse treatment organization 
across countries. Second, an estimate of the total EU spending on hospital substance abuse treatment 
is given. The public expenditures for illegal drug treatment are compared to expenditures for alcohol 
treatment. Finally, we discuss the factors that may influence the number of hospital days and the 
expenditures that come with it. 
 
2. METHODS  
Particular care was taken to ensure a uniform methodology across the EU member states studied in 
order to allow a valid cross-national comparison. Databases of international organizations were 
analysed to identify health care expenditures for alcohol and illegal drug treatment3. The online 
databases of the following organizations were consulted: Organization for Economic Co-operation and 
Development (OECD); the European Commission; the World Health Organization (WHO); the United 
Nations (UN); European Monitoring Centre for Drugs and Drug Addiction (EMCDDA); European 
Medicines Agency (EMA); and European Centre for Disease Prevention and Control (ECDC). One would 
expect that these databases provide data on expenditures for various types of substance abuse 
treatment services. In the United States, both inpatient and outpatient cost of service groups include 
costs associated with mental health diagnosis, labs, and surgery services covered by Medicaid (Collins, 
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Cooper, Horn, Stohr, Walsh, Bostaph et al., 2010). However, an analysis of the EU databases makes 
clear that Eurostat is the only database that provides consistent and comparable data for treatment 
provided in hospitals. Information for other types of treatment providers, such as nursing and 
specialised residential care facilities and providers of ambulatory health care are not consistently 
available. In view of this limitation, the current study focuses on hospital treatment.  
 
The Eurostat database is used to measure public spending on illegal drug and alcohol treatment in 
hospitals. This database provides financial data (public health budgets for each type of treatment 
provider) with the System of Health Accounts4 and data on hospital activities (hospital days by 
diagnosis).  
The financial data are collected by the System of Health Accounts (published by Eurostat, OECD and 
WHO), which systematically describes the financial flows related to health care (OECD, Eurostat & 
WHO, 2011). For most EU countries, the public health budgets for each type of treatment provider are 
published on the Eurostat website (Eurostat, 2013b), although there were no data available for six EU 
member states (Greece, Estonia, Ireland, Italy, Malta and the United Kingdom). In the System of 
Health Accounts, public health expenditures are identified as those labeled ‘the general government’, 
which includes the central, state and local government and social insurance funds. Hospital 
expenditures include the expenditures for general hospitals, for mental health and substance abuse 
hospitals, and for other specialty hospitals5 (e.g. hospitals for infectious diseases, rehabilitative and 
preventive services). 
Eurostat also publishes hospital activities by diagnosis (Eurostat, 2013c) for each country; aggregated 
data are provided for total hospital discharges and total hospital days. In theory, these hospital 
statistics cover the activities for general, mental health and specialty hospitals (E. Cayotte, personal 
communication, August 19, 2013), although six countries are not able to report the hospital days for 
all hospital types. Consultation of the Eurostat and WHO country metadata indicates that data are 
missing for Belgium, Denmark, France, Luxembourg, the Netherlands and Spain. Therefore, the results 
for the latter countries will be presented separately.  
Based on the data in the Eurostat database, government spending on illegal drug and alcohol 
treatment in hospitals was identified using the following formula:  
average cost per hospital day  x  hospital days for treating illegal drug or alcohol disorders 
 
This method has some limitations. The first limitation is that the average cost per hospital day is 
calculated by dividing the public health expenditure of hospitals by the total hospital days for treating 
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all causes of diseases. This methodology assumes that all diagnoses have the same unit cost of 
treatment, despite the common-sense notion that the cost per hospital day varies across diagnosis. 
Furthermore, the hospital expenditures figure used to calculate the average cost per hospital day 
includes inpatient, emergency and outpatient services. The Eurostat database makes no distinction 
between types of treatment service. Consequently, the expenditures for outpatient and emergency 
services are attributed to inpatient activities and this leads to an overestimation of the average cost 
per hospital day. The second limitation is that the formula is based on the number of hospital days, 
but ‘hospital nights’ might be a more suitable term since hospital days are delineated as days in which 
a person admitted as an inpatient stays overnight in a hospital (Eurostat, 2013d). Thus, the measure 
excludes outpatient treatment and treatment of patients who were not admitted (e.g. those treated in 
the emergency room without admission).  Nevertheless, economic cost studies frequently use hospital 
days to estimate the hospitals costs for treating substance abuse (Rice, Kelman & Miller, 1991; Fox, 
Merrill, Chang & Califano, 1995; Single et al., 1998; Rice, 1999; De Ruyver et al., 2004, 2007; Jacobs et 
al., 2008; Vander Laenen et al., 2011). Hospital days are used as a measure because it is assumed to 
capture the prevalence of recorded substance abuse and they take into account the time spent for 
treatment. In the Eurostat database, hospital days with the primary diagnosis of mental and 
behavioral disorders due to psychoactive substance use or alcohol use (ICD10 codes6 F10-F19) are 
included. In the case of multiple diagnoses, the most severe and resource-intensive of these diagnoses 
is recorded as the primary diagnosis. Consequently, the public spending for substance abuse is 
underestimated because the patients with a non-substance-abuse-related primary diagnosis and a 
substance abuse disorder as secondary diagnosis are not taken into account. An overestimation is also 
possible for patients with a primary diagnosis of substance abuse and a secondary diagnosis (e.g. liver 
disease) that caused an extended stay in the hospital. 
 
This cross-country comparison is conducted for 21 of the 27 EU member states7 with data anno 2010. 
The public expenditures for illegal drug and alcohol treatment in hospitals are reported per capita, as a 
share of gross domestic product (GDP) and total. In order to explain these results, the individual 
components of the formula (public expenditure per hospital day, hospital days for illegal drug or 
alcohol treatment, and the proportion of hospital days attributable to drug treatment) and prevalence 
rates are presented. Additionally, the total amount of public spending for the EU for illegal drug and 
alcohol treatment in hospitals is estimated. This estimation is restricted to 21 EU member states. An 
extrapolation to the EU-278 is not possible given the lack of data on health expenditures9 for six EU 
member states (Greece, Estonia, Ireland, Italy, Malta and the United Kingdom).  
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3. RESULTS 
3.1. Public spending for illegal drug treatment in hospitals 
Numeric results 
Public expenditures for hospital treatment are presented in two tables. Table 1 presents the countries 
that register the illegal drug treatment hospitals days and expenditures for all types of hospitals 
(general, mental health and specialty hospitals). The countries in table 2 only provide data for general 
(2 countries) and specialty (4 countries) hospitals.  
Table 1: Hospital days and expenditures for illegal drug treatment (general, mental health and specialty hospitals), 
for 15 EU countries, 2010 
Country
*
 
Public 
expenditure per 
hospital day 
(euros) 
Hospital days 
for illegal drug 
treatment per 
1,000 capita
 
 
Proportion of 
hospital days 
attributable to 
illegal drug 
treatment (%) 
Illegal drug 
treatment 
expenditure by 
hospitals 
(million euros)
 
Illegal drug 
treatment 
expenditure by 
hospitals, per 
capita (euros) 
Illegal drug 
treatment 
expenditure by 
hospitals, as 
percentage of 
GDP 
Sweden 1532 9 0.88% 123 13.2 0.035% 
Austria
†
 507 15 0.62% 65 7.8 0.023% 
Germany 391 16 0.72% 523 6.4 0.021% 
Slovenia 432 7 0.59% 6 3.2 0.018% 
Finland
†
 428 6 0.28% 14 2.5 0.008% 
Slovakia 165 11 0.75% 9 1.7 0.014% 
Poland 167 9 0.70% 55 1.4 0.015% 
Czech Republic 211 17 0.79% 37 3.5 0.025% 
Portugal
 1045 0.6
‡
 0.11% 6 0.6 0.004% 
Hungary
 
121 5 0.28% 6 0.6 0.006% 
Latvia
† 140 3 0.24% 0.8 0.4 0.005% 
Bulgaria 69 3 0.19% 2 0.2 0.004% 
Lithuania 113 1 0.06% 0.4 0.1 0.001% 
Romania 81 1 0.07% 2 0.1 0.002% 
Cyprus
† 936 0.01
‡
 0.002% 0.006 0.01 0.00003% 
Mean
10 (SD) 423 (429) 7 (6) 0.42% (0.31%) 57 (133) 2.8 (3.7) 0.012% (0.01%) 
 
* 
The European countries are not classified in regions, because no global classification system is available for 
illegal drugs (contrary to studies on alcohol, which distinguish geographical areas by drinking traditions and 
patterns; WHO, 2013). Drug-related research (e.g., Montanari et al., 2013; Barrio et al., 2013) uses different 
types of classification according to the investigated type of drugs. Nevertheless, the conclusions for multiple 
countries are described by the UN geographical regions: Eastern Europe, Northern Europe, Southern Europe 
and Western Europe.  
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†
Contrary to the other countries, the live-born infants (Z38) of Austria, Cyprus, Latvia and Finland are not 
included in the total hospital days, and this could lead to an overestimation of the hospital expenditures. 
‡
The data for Cyprus cover only public sector hospitals. Portugal covers all public inpatient institutions and only 
two private hospitals. Consequently,  the hospital days for illegal drug treatment are underestimated, and this 
may affect the proportion of hospital days attributable to illegal drug treatment. Therefore, the hospital days 
and public expenditures for illegal drug treatment in Cyprus and Portugal will not be further analysed.  
 
Table 1 shows that on average the hospital expenditure for illegal drug treatment in the EU-15 is 2.8 
euros per capita and 0.01% of GDP. Table 1 also shows important differences between EU countries. 
Sweden invests the most in hospital-based illegal drug treatment (per capita 13 euros and 0.035% of 
GDP), primarily because its costs per hospital day appear to be extremely high. Austria (per capita 8 
euros and 0.023% of GDP) and Germany (per capita 6 euros and 0.021% of GDP) complete the top 
three, combining fairly high hospital expenditures (per capita)11 with high rates of hospital-based 
treatment for illegal drugs. A number of Northern and Eastern European countries (Bulgaria, Hungary, 
Romania, Lithuania and Latvia) reported hospital expenditures lower than 1 euro per capita and 0.01% 
of GDP. The cost per hospital day of these countries is less than one-third of the average in Sweden, 
Austria, and Germany, and this is combined with rates of hospital-based treatment per capita that are 
less than one-sixth in size.   
 
Interpretation 
The hospital expenditures for illegal drug treatment are calculated on the basis of public health 
expenditures and hospital days.  
 
First, the average public expenditure per hospital day across the 15 EU countries is 423 euros per day. 
Countries in Western and Southern Europe (except Germany) spend more than this average, with 
Sweden reporting the highest expenditure (1532 euros). Countries in Eastern Europe reported much 
less public funding in hospitals. The lower expenditures of Eastern European countries are mainly due 
to the lower economic power in terms of GDP (Shield et al., 2012) and the lower proportion of public 
financing of health expenditures (Chawla, 2007). 
Second, the number of hospital days for illegal drug treatment per 1,000 capita range from 1 to 17 
days. Austria (15), Germany (16) and the Czech Republic (17) registered the highest number of 
hospital days, whereas Lithuania (1) and Romania (1) registered the least number of hospital days. 
When comparing hospitals days for illegal drug treatment to the total number of hospital days, 
Sweden (0.88%), Slovakia (0.75%), Germany (0.72%) and the Czech Republic (0.79%) have the largest 
proportion of hospital days for illegal drug treatment. This may indicate that the latter countries 
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organize drug treatment mainly inside hospitals and/or that they are confronted with a high number 
of problem drug users.  
 
To discover whether differences in the prevalence of problem drug users can explain the observed 
(differences in) hospital days, figure 112 plots the number of hospital days used for drug treatment 
versus the number of problem illegal drug users (12 months prevalence), both expressed in per capita 
terms using data from the statistical bulletin of the EMCDDA (2013).   
 
Figure 1: Prevalence of problem drug use (2007-2011
*
) versus hospital days for 8 EU countries
 
  
* 
The prevalence for problem drug users aged 15-64. Depending on the availability of data, prevalence estimates 
are presented for the years 2007, 08, 09, 10 or 11. 
† 
The EMCDDA did not provide prevalence rates for Slovenia, Finland, Portugal, Hungary, Lithuania and Romania. 
 
Pearson’s correlation coefficient was used to analyse the linear association between hospital days and 
the prevalence of problem drug use, however no positive correlation is observed (r= -0.468, p= 0.243). 
This implies that the high number of hospital days in Sweden, Slovakia, Austria and Germany cannot 
be explained by these country’s prevalence rates of problem drug use. However, figure 1 gives an 
indication of how drug treatment is organized in the 8 EU member states. On the one hand, Germany, 
Austria, Slovakia, Poland and the Czech Republic have a high number of hospital days in comparison 
with the prevalence of problem drug use. In these countries, problem drug users treated in a hospital 
stayed three-to-four days on average. On the other hand, Latvia and Bulgaria report less than one 
hospital day per problem drug user despite their having a high prevalence of problem drug use. It 
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seems that most problem drug use treatment in these countries is organized outside hospitals. An 
alternative explanation could be that these countries provide less treatment altogether.  
 
As discussed above, France and Denmark only provide data for general hospitals. Belgium, 
Luxembourg, the Netherlands and Spain have information for specialty hospitals and general hospitals, 
but not for mental health hospitals. Therefore, the expenditure estimates for the countries in table 2 
are obviously underestimated. Nonetheless, table 2 shows that on average the hospital expenditure 
for illegal drug treatment in the EU-4 is 9.6 euros per capita and 0.015% of GDP. Luxembourg has the 
highest share of hospital days (2.50%) and of expenditures (34 euros per capita) attributable to illegal 
drugs in the EU. This could be explained by its relatively high public expenditures for hospital care and 
prevalence of problem drug use (6.2 per 1.000 capita) (EMCDDA, 2013b).  
 
Table 2: Hospital days and expenditures for illegal drug treatment (general and specialty hospitals), 
for 6 EU countries, 2010 
Country 
Public 
expenditure per 
hospital day 
(euros) 
Hospital days 
for illegal drugs 
per 1,000 capita
 
Proportion of 
hospital days 
attributable to 
illegal drug 
treatment (%) 
Illegal drug 
treatment 
expenditure by 
hospitals 
(million euros)
 
Illegal drug 
treatment 
expenditure by 
hospitals, per 
capita (euros) 
Illegal drug 
treatment 
expenditure by 
hospitals, as 
percentage of 
GDP 
 General hospitals  
France 1036 0.4 0.04% 29 0.4 0.001% 
Denmark
* 
2125 0.2 0.02% 2 0.4 0.001% 
Mean (SD) 1580 (770) 0.3 (0.2) 0.03% (0.02%) 15 (19) 0.4 (0.06) 
0.001% 
(0.0004%) 
 General and Specialty hospitals (no mental health or substance abuse hospitals)  
Luxembourg
† 1079 32 2.50% 17 34 0.044% 
Spain
† 1131 2 0.27% 97 2.1 0.009% 
Belgium 579 2 0.16% 12 1.1 0.003% 
Netherlands 1620 0.5
d
 0.07% 12 0.7 0.002% 
Mean (SD) 1102 (426) 9 (15) 0.75% (1.17%) 35 (42) 9.6 (16.6) 0.015% (0.02%) 
  
*
 Denmark and Belgium have only data with hospitals days available for 2009. 
† 
Contrary to the other countries, the live-born infants (Z38) of Luxembourg and Spain are not included in the 
total hospital days, and this could lead to an overestimation of the hospital expenditures. 
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3.2. Public spending for alcohol treatment in hospitals 
Numeric results 
Results for public expenditures for alcohol treatment in hospitals are also presented in two separate 
tables (table 3 and table 4) depending on whether data were available for the different types of 
hospitals. The countries are divided into four geographical areas based on the WHO classification 
concerning drinking traditions and patterns (WHO, 2013). However, it is difficult to draw conclusions 
on a regional level due to missing data for 12 EU member states  (Belgium, Denmark, Estonia, France, 
Greece, Ireland, Italy, Luxembourg, Malta, Netherlands, Spain and the United Kingdom). 
 
Table 3: Hospital days and expenditures for alcohol treatment (general, mental health and specialty hospitals),  
for 15 EU countries, 2010 
Country 
Public 
expenditure per 
hospital day 
(euros) 
Hospital days 
for alcohol 
treatment per 
1,000 capita
 
Proportion of 
hospital days 
attributable to 
alcohol 
treatment (%) 
Alcohol 
treatment 
expenditure by 
hospitals 
(million euros)
 
Alcohol 
treatment 
expenditure by 
hospitals, per 
capita (euros) 
Alcohol 
treatment 
expenditure by 
hospitals, as 
percentage of 
GDP 
Central-western and western country group  
(Belgium, France, Ireland, Luxembourg, Netherlands and UK missing) 
Austria
*
 507 47 1.88% 198 23.7 0.069% 
Germany 391 49 2.16% 1578 19.3 0.063% 
Mean (SD) 
Central-
western and 
western 
country group 
449 (82) 48 (2) 2.02% (0.2%) 888 (976) 21.5 (3.1) 
0.066% 
(0.004%) 
Central-eastern and eastern country group  
(Estonia missing) 
Slovenia 432 34 2.69% 30 14.5 0.084% 
Slovakia 165 58 4.11% 51 9.5 0.078% 
Poland 167 51 4.15% 325 8.5 0.092% 
Hungary 121 31 1.76% 38 3.8 0.039% 
Latvia
* 
140 19 1.68% 6 2.7 0.033% 
Czech Republic 211 53 2.54% 118 11.3 0.079% 
Lithuania 113 19 1.08% 7 2.2 0.026% 
Romania 81 13 0.73% 22 1.0 0.018% 
Bulgaria 69 13 0.87% 7 0.9 0.019% 
Mean (SD) 
central-eastern 
and eastern 
country group 
166 (109) 32 (18) 2.18% (1.30%) 67 (103) 6.0 (5.0) 
0.052% 
(0.030%) 
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Nordic countries  
(Denmark missing) 
Sweden 1532 11 1.10% 155 16.6 0.044% 
Finland
*
 428 25 1.19% 57 10.7 0.032% 
Mean (SD) 
nordic 
countries 
980 (780) 18 (10) 1.14% (0.06%) 106 (69) 13.6 (4.1) 
0.038% 
(0.009%) 
Southern Europe  
(Greece, Italy, Malta and Spain missing) 
Portugal 1045 3
†
 0.49% 29 2.7 0.017% 
Cyprus
* 
936 0.03
†
 0.01% 0.1 0.1 0.001% 
Mean (SD) 
southern 
Europe 
990 (78) 1.3 (1.8) 0.25% (0.35%) 14 (20) 1.4 (1.8) 
0.009% 
(0.011%) 
Mean (SD)  
EU-15 
423 (429) 28 (19) 1.76% (1.21%) 175 (399) 8.5 (7.4) 
0.046% 
(0.029%) 
 
* 
The live-born infants (Z38) of Austria, Cyprus, Latvia and Finland are not included in the total hospital days, and 
this could lead to an overestimation of the hospital expenditures. 
† 
The data of Cyprus covers only public sector hospitals. Portugal covers all public inpatient institutions and only 
two private hospitals. Consequently, the hospital days for alcohol treatment are underestimated, and this may 
also affect the proportion of hospital days attributable to alcohol treatment. The results of Southern Europe 
will not be analysed due to this missing data. 
 
 
Table 3 shows that on average the hospital expenditure for alcohol treatment in the EU-15 is 8.5 euros 
per capita and 0.046% of GDP. We see important differences between EU countries. The Central-
Western and Western country group have the highest expenditures in terms of GDP (average of 
0.066%) and per capita with 24 euros for Austria and 19 euros for Germany. This contrasts with many 
members of the Central-Eastern country group that reported an average hospital alcohol treatment 
spending of 6 euros per capita (0.052% of GDP). The Nordic country group reported spending of 14 
euros per capita but the lowest expenditures in terms of GDP (0.038%). 
 
Interpretation  
In this section we explain hospital expenditures for alcohol treatment using the financial investment in 
public health and hospital use.  
 
The first conclusion is that the public expenditures per hospital day vary extensively ranging from 69 
euros in Bulgaria to 1532 euros in Sweden. The average in Eastern European countries of 166 euros is 
much lower than the average of the 15 countries studied (423 euros). Consequently, countries with a 
similar proportion of hospital days attributable to alcohol treatment (e.g. Sweden and Lithuania) could 
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have a different outcome in terms of alcohol treatment expenditure per capita. As is the case for 
expenditures on illegal drug treatment, the lower expenditures of Eastern European countries could be 
explained by the mix of public and private funding of health care(Chawla, 2007) and differences in 
terms of GDP (Shield et al., 2012). 
The second conclusion is that Slovakia, Poland and the Czech Republic reported the highest number of 
hospital days for alcohol treatment, with more than 50 hospital days per 1,000 capita, a rate that 
translates to alcohol treatment accounting for more than 4% of hospital days in Slovakia and Poland. 
The Central-Western and Western country group reported on average 48 hospital days per capita 
(2.02% of hospital days for alcohol treatment). In the Nordic countries, the number of hospital days for 
alcohol treatment is limited to 1.14%. As is the case for illicit drugs, the hospital days are investigated 
by looking at a country’s substance abuse treatment organization and the prevalence rates. Rehm et 
al. (2012) provide an overview of 12‐month prevalence rates for alcohol dependence per European 
country. In figure 2, these prevalence rates are compared with the hospital days for alcohol.  
 
Figure 2: Prevalence of alcohol dependence (1999-2009
*
) versus hospital days for 13 EU countries 
 
* 
The prevalence of men and women aged 18-64. Depending on the availability of data, prevalence estimates are 
presented for varying years. 
 
As was the case for illegal drugs, no significant Pearson correlation (r= 0.003 , p= 0.991) was found 
between hospital days and the prevalence of alcohol dependence. The majority of European countries 
(8) have a prevalence of alcohol dependence between 4% and 6%. An exceptional case is Hungary, 
which has the highest prevalence rate of alcohol dependence with 10.85%, although the Hungarian 
number of hospital days for alcohol treatment lies below the average of the 13 countries studied (32.5 
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days). It is likely that Hungary, and Sweden and Bulgaria as well, organize alcohol treatment mostly 
outside of hospitals because for an estimated average of three-to-five persons with alcohol 
dependence (Rehm et al., 2012) only one hospital day is recorded in these countries. By contrast, 
Germany, Slovakia, Poland and the Czech Republic reported more than one hospital day of treatment 
per person with alcohol dependence.  
 
Table 4 provides an overview of the six countries that provided data limited to general (and specialty) 
hospitals. As was the case for table 2, the expenditures in hospitals in the countries in table 4 are 
underestimated. Despite the lack of data from mental health hospitals, on average the hospital 
expenditure for alcohol treatment in the EU-4 is 23 euros per capita and 0.035% of GDP. Luxembourg 
has the highest hospital expenditure (82 euros per capita and 0.1 % of GDP) for alcohol treatment in 
the EU, and the share of hospital days (5.94%) attributable to alcohol is high in comparison with the 
other EU countries (1.81%). At first sight, this could not be explained by the prevalence of people with 
alcohol dependence (which is relatively low; 3.4%) (Rehm et al., 2012).  
 
Table 4: Hospital days and expenditures for alcohol treatment (general and specialty hospitals),  
for 6 EU countries, 2010 
Country 
Public 
expenditure per 
hospital day 
(euros) 
Hospital days 
for alcohol 
treatment per 
1,000 capita
 
Proportion of 
hospital days 
attributable to 
alcohol 
treatment (%) 
Alcohol 
treatment 
expenditure by 
hospitals 
(million euros)
 
Alcohol 
treatment 
expenditure by 
hospitals, per 
capita (euros) 
Alcohol 
treatment 
expenditure by 
hospitals, as 
percentage of 
GDP 
 General hospitals 
Denmark
* 
 2125 3 0.40% 39 7.1 0.017% 
France 1036 5 0.52% 331 5.1 0.017% 
Mean (SD) 1580 (770) 4 (1) 0.46% (0.08%) 185 (206) 6.1 (1.4) 
0.017% 
(0.0003%) 
 General and Specialty hospitals (no mental health or substance abuse hospitals) 
Luxembourg
† 1079 76 5.94% 41 81.9 0.105% 
Belgium 579 9 0.72% 53 4.9 0.015% 
Spain
† 1131 3 0.38% 143 3.1 0.014% 
Netherlands 1620 1 0.19% 34 2.1 0.006% 
Mean (SD) 1102(426) 22 (36) 1.81% (2.76%) 68 (51) 23 (39.3) 
0.035% 
(0.047%) 
*
 Denmark and Belgium have only data with hospitals days available for 2009. 
†
 The live-born infants (Z38) of Luxembourg and Spain are not included in the total hospital days, and this could 
lead to an overestimation of the hospital expenditures. 
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3.3. Comparing public spending in the EU-21 for illegal drug and alcohol treatment in hospitals 
Public spending in the EU-21 for illegal drug and alcohol treatment in hospitals is presented in table 5. 
The public spending of six EU member states (Belgium, Denmark, France, Luxembourg, the 
Netherlands and Spain) with data limited to general and/or specialised hospitals is extrapolated to all 
types of hospitals. To do this, we pro-rated total hospital expenditures of the six EU countries in 
proportion to the number of patient days associated with substance abuse treatment. Table 1 and 313 
provide the proportion of hospital days attributable to illegal drug and alcohol treatment. The 
weighted average of the 15 EU countries, based on population, is 0.56% for illegal drugs and 2.18% for 
alcohol.  
 
Table 5: Public expenditures for illegal drug and alcohol treatment in hospitals for 21 EU countries
*
, 2010 
 Public expenditures 
(million euros) 
Public expenditures 
per capita (euros) 
Public expenditures  
in % of GDP 
Illegal drug treatment 1,703 4.7 0.020% 
Alcohol treatment 5,930 16.5 0.069% 
Total 7,633 21.2 0.089% 
* 
Source for population and GDP of EU countries:
 
Eurostat (2013e, 2013f) 
 
Table 5 shows that the total EU-21 spending for illegal drug and alcohol treatment in hospitals is 
estimated to be 7,633 million euros or 21 euros per inhabitant; the share of GDP is 0.089%. The 
hospital expenditures for alcohol treatment are three times higher than the expenditures for illegal 
drug treatment, due to the higher number of hospitalization days for alcohol treatment (table 1 and 3 
report 28 hospital days for alcohol treatment per 1,000 capita as compared to 7 days for illicit drug 
treatment).  
 
4. DISCUSSION 
This cross-country comparison provides insight into the public spending of governments in the EU on 
substance abuse treatment in hospitals. A uniform methodology based on international databases is 
used to provide consolidated data on the public expenditures for drug and alcohol treatment in 
hospitals. The total public spending on hospital-based substance abuse treatment is estimated to be 
7.6 billion euros in the 21 EU countries. Three-quarters (77.7%) of these public expenditures are used 
for alcohol treatment, while the remaining quarter (22.3%) is used for illegal drug treatment. That 
public spending for alcohol treatment exceeds spending for illegal drug treatment is consistent with 
previous studies (e.g. Fenoglio, Parel & Kopp, 2003; Collins & Lapsley, 2002; Single et al., 1998). As 
expected, the estimate of 5.9 billion euros in public expenditures for alcohol treatment in hospitals is 
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lower than the estimate of Rehm et al. (2012). They estimated a European cost, including private 
expenditures, of 6.3 billion euros for alcohol treatment and prevention. It is difficult to compare these 
studies and draw conclusions given the lack of data for all EU member states. This points to the 
importance of an international database with complete data for all EU countries. In the United States, 
data collection on the nominal costs of billed services attached to each individual client under, e.g., 
Medicaid is standardized across the fifty states. That is not the case in Europe (Collins et al., 2010). 
 
This study also showed a large variation in public spending on substance abuse treatment in hospitals 
across the 15 EU member states that did provide comparable data. These results are discussed by 
looking at the explaining factors, the policy implications and limitations of the study. 
 
Explaining factors  
The public spending on hospitalized substance abuse treatment can be explained by a variation in 
three factors: 1) the hospital cost per day, 2) the organization of substance abuse treatment and 3) 
the prevalence of problem illegal drug use and alcohol dependence.  We elaborate on each in turn.   
 
The hospital cost per day is influenced by the structure of health care expenditures. The health 
expenditures in Central‐East and Eastern Europe are much lower than in the other EU countries, 
because these countries have lower GDP per capita (Shield et al., 2012). There is a strong (Pearson) 
correlation between GDP per capita and the public expenditures per hospital day (r= 0.638, p=0.002). 
Next, the mix of public and private health financing may help explain differences in public spending on 
health care (see additional file 1). Most Eastern European countries are characterized by a limited 
share of public financing: 56% in Bulgaria, 64% in Hungary and 68% in Slovakia (one exception is 83% 
in the Czech Republic) (Eurostat, 2013g). The economic crisis affected the public-private financing mix 
for countries such as Bulgaria and Slovakia, since they reported a substantial increase of the private 
contribution and a corresponding decrease in public expenditure in 2010 (EMCDDA, 2014a). It is very 
likely that Denmark, Sweden and the Netherlands reported the highest public expenditures per 
hospital day partly because their proportion of public financing is high: the Netherlands 86%, Denmark 
85% and Sweden 82%. Moreover, in Eastern Europe it appears that informal patient payments 
continue to exist despite reforms within the health care sector (Lewis, 2004; Stepurko, Pavlova, Gryga 
& Groot, 2010). Private health insurance and out-of-pocket expenditures have a negative impact on 
the accessibility to health care, and this is linked to the high share of private financing (Thomson, 
Foubister & Mossialos, 2009). Limited accessibility may lead to an additional limitation of the number 
of hospital days.   
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Moreover, public hospital expenditures are influenced by the source of financing, i.e. general taxation 
or insurance-based systems. Countries with predominantly insurance-based systems (e.g. Belgium, 
France, the Netherlands, Germany and Luxembourg) have higher health care expenditures, because 
the insurance-based system is characterized by a lower degree of control over expenditures (Pestieau, 
2006).  
 
The number of hospital days directly influences public spending for alcohol and drug treatment. These 
hospital days are in turn influenced by the organization of substance abuse treatment in a country 
(Montanari et al., 2011). The Western European countries Austria and Germany reported a high 
number of hospital days per capita attributable to alcohol and illegal drug treatment. The Eastern 
European countries Poland and Slovakia also reported high hospital days, especially for alcohol 
treatment. This high number of hospital admissions/days suggests that these countries organize drug 
treatment mainly inside hospitals, while countries with a low number of hospital days may have more 
of a tradition of establishing specialised treatment outside hospitals. However, an alternative 
explanation is that the latter countries have shorter hospital stays. In fact, a couple of countries with a 
low number of alcohol hospital days reported a shorter average in-patient length of stay for alcohol 
treatment (e.g. Romania: 11.3 days, Lithuania: 8.3 days and Sweden: 4.7 days) than Austria (17.6 days) 
and Germany (13.3 days). The same conclusion can be drawn for illegal drug treatment, except for 
Bulgaria which reported longer stays for alcohol (27.6 days) and illegal drug treatment (18 days) 
(Eurostat, 2013h). Furthermore, the profile and the preferences of substance abusers may also 
influence the organization of drug treatment. Substance abusers have a personal preference for a 
specific type of treatment service that is based on indicators such as flexibility, accessibility, proximity 
of treatment service, etc. (Vanderplasschen, De Bourdeaudhuij & Van Oost, 2002; Appel & Oldak, 
2007). Moreover, clients may prefer outpatient treatment because it entails fewer out-of-pocket 
expenses. Outpatient treatment allows female clients to continue caring for their children (Khan et al., 
2013).  
 
In addition to the hospital cost per day and the organization of substance abuse treatment, we 
investigated whether the prevalence of illegal drug and alcohol problems in a country can explain the 
number of hospital days and the expenditures that come with it. One might expect that the more a 
country is confronted with substance abusers, the higher the hospital occupation for these problems 
will be. In fact, this is the presumption of economic-cost studies using hospital days to estimate the 
hospitals costs for treating substance abuse. However, we found no positive correlation between 
these two variables. For example, Latvia and Bulgaria reported a high prevalence of problem drug use 
in combination with a low number of hospital days. In this respect, the way a country’s drug treatment 
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is organized influences the relation between prevalence of substance abuse and number of hospital 
days. Furthermore, the prevalence rates could be affected by cultural factors and social norms 
regarding substance use. Rehm, Shield, Gmel, Rhem & Frick (2012) argue that alcohol is highly 
culturally embedded in Southern-European countries, therefore people in the region are more likely 
to deny alcohol dependence and this may result in lower admissions to hospitals. This shows that 
monitoring (trends in) the prevalence of problem drug users will not suffice to monitor the (trends) in 
public expenditure on substance use treatment. 
 
It should be noted that the expenditures on alcohol and illicit drug treatment cannot be explained 
solely by looking at the combination of the prevalence of problem illegal drug use and alcohol 
dependence, the hospital cost per day and the organization of substance abuse treatment in a 
country. Other factors such as a country’s cultural and social norms regarding substance use, its illicit 
drug or alcohol policy or the labor costs could play a role as well (EMCDDA, 2011). We identified an 
impact of these factors for the two outliers of this EU cross-country comparison. First, Sweden was the 
outlier in public spending for illegal drug treatment. Its public expenditure of 13 euros per capita can 
be explained by the high cost of hospitalization and the high proportion of hospital days attributable 
to illegal drug treatment (see table 1). Sweden’s drug policy may be an additional explanatory factor 
since Sweden prioritizes a drug free society and abstinence-driven treatments (Hallam, 2010). This 
approach may also be more expensive than other drug treatment policies. Cost-benefit analyses need 
to be consulted to determine which drug treatment investments bring about (financial) gains. Second, 
Luxemburg spends the most in Europe per capita on hospital expenditure for both alcohol and illegal 
drug treatment. The prevalence of problem illegal drug use (6.2 per 1.000 capita) (EMCCDA,2013b) 
and the high proportion of drug clients entering inpatient centers (79%) (EMCDDA, 2014b) influences 
the number of hospital days for illicit drugs. For alcohol, the share of hospital days could not be 
explained by the prevalence of people with alcohol dependence. We speculate that the high 
expenditures for Luxembourg could be ascribed to the smaller scale of drug treatment organization 
that imposes more costs on the health care budget. These examples demonstrate that multivariate 
research is necessary to determine which factors affect public spending on substance abuse 
treatment.  
 
Policy implications  
This study measured how much European governments spend treating illicit drug and alcohol 
problems in hospitals. Governments play an important role in financing health care, since  
governments in the EU-21 finance on average 73% of the health expenditures (see additional file 1). 
This differs from the United States where less than 50% of health spending is publicly financed. We 
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would like to highlight the importance of measuring direct treatment costs in political and policy 
decision-making. The comparability of results across countries provides information for policymakers 
and public administration (EMCDDA, 2008). The impact of substance abuse treatment in hospitals on a 
country’s budget is presented, and these data can be used to illustrate the budgetary consequences of 
different drug policies. The cost information in this study also provides a valuable basis for assessing 
total public spending on substance abuse treatment, not just hospital-based spending. It can also 
contribute to the evaluation of substance abuse interventions (French & Martin, 1996; 
Thavorncharoensap et al., 2009), since the public expenditure studies provide an important 
component for economic evaluation studies: the public expenditures serve as the independent 
variable and outcomes (e.g., OD deaths) as the dependent variable. Moreover, these economic 
evaluation studies can be used to conduct more complete economic evaluations of substance abuse 
treatment in EU countries. For example, country profiles could be developed compiling information on 
treatment organization and budgetary impact. Ideally, these efforts lead to an evidence-based policy 
where financial resources are assigned to cost-effective substance abuse treatment (Wood et al., 
2010). However, it remains to be seen if governments will be willing and able to make these 
investments in exchange for benefits in the long-term (i.e. cost savings and reduced human suffering).  
For example, Rehm et al. (2012) estimated that less than 10% of people with alcohol dependence in 
the EU receive treatment14. A 10% increase in health care coverage for hospital-based alcohol 
treatment in Europe would bring about an estimated 593-million-euro increase in hospitals’ public 
expenditure.  
 
Study limitations and recommendations 
This study uses data from the Eurostat database to measure how much European governments spend 
on treating illegal drug and alcohol problems in hospitals. International databases facilitate cross-
country comparisons that could highlight the impact of substance abuse on public health budgets 
(Degenhardt et al., 2008). Our cross-country comparison is restricted to hospitals since data were 
unavailable for other types of treatment providers. It is not clear which proportion of the drug and 
alcohol clients receive hospital treatment. The Treatment Demand Indicator (TDI15) used in the EU, 
cannot determine the proportion of substance use clients treated in hospitals since it only 
distinguishes between the  proportion of illegal drug clients in inpatient16 and outpatient centers. The 
TDI shows that the proportion of reported clients entering inpatient centers for drug-related problems 
varies to a large extent by country (from 2% in France to 79% in Luxembourg) (EMCDDA, 2014b)17. 
Notwithstanding the limitations of the current analysis, the impact of hospital expenditures for drug 
and alcohol treatment on the public budget should not be underestimated. Multiple studies (e.g. 
Costello, Copeland, Cowell & Keeler, 2007; EMCDDA, 2011; NCCMH, 2011) show that the unit cost for 
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hospital treatment is much higher than for outpatient treatment services. For example, inpatient 
detoxification in England is provided at a cost of 200 euros per patient per day and outpatient 
detoxification is provided at a cost of 8 euros per patient per day (Gossop & Strang, 2000). Moreover, 
Andlin-Sobocki, Jönsson, Wittchen and Olesen (2005) indicate that the cost for hospital care due to 
brain disorders in Europe (including alcohol and illicit drug use disorders) dominates total treatment 
cost. Public expenditure studies indicate that a large share of the public expenditures for substance 
abuse treatment is attributable to care in hospitals. For example, in Belgium the share of hospital 
treatment for alcohol and illegal drug use amounts to as much as 90.66% of the total public spending 
for substance abuse treatment (Vander Laenen et al., 2011). On the other hand, a Swedish study, with 
a research scope limited to illegal drugs, found a much lower share of hospital treatment. Ramstedt 
(2006) reported that hospital expenditures made up only 16% of the total illegal drug abuse health 
spending. In other words, insight into the expenditures on substance abuse treatment via hospital 
expenditures is complex, since it varies with the investigated substance and with several other factors 
discussed above. 
 
The analysis of international data for cross-country comparison purposes illustrated that, despite the 
great potential of these data(bases), much information is still lacking today. Ideally, these databases 
should provide hospital charges categorized according to diagnosis-related groups, as is the case with 
the Medicaid database in the United States (Collins et al., 2010). However, the Eurostat database is 
limited to public health care expenditures by provider (e.g. ambulatory health care, nursing and 
residential care facilities). In order to estimate the drug- and alcohol-related percentages of these 
budgets, the health care activities by diagnosis are required for outpatient and inpatient treatment 
services (apart from hospital-based treatments). Further research is necessary to develop variables in 
international databases that provide data for outpatient treatment sessions for substance abuse, 
inpatient days for substance abuse, consultations for substitution treatment, drug treatment 
counseling in prisons, etc. This data would allow researchers to compare public expenditures for 
different types of treatment regimes. Additionally these data could be used for more in-depth 
economic evaluations, i.e. whether specific treatment modalities are more cost-effective than others 
(Andlin-Sobocki, 2004; Babor et al., 2010). 
 
In our study in particular, we were confronted with the significant limitations of the Eurostat database. 
In the Eurostat database, hospital days are limited to primary diagnosis and health expenditures are 
not subdivided by inpatient, emergency or outpatient service. Next, the Eurostat data are sometimes 
incomplete because countries are not always able to provide data for all types of hospitals (general, 
mental health and specialty hospitals). A number of EU countries (Belgium, Denmark, France, 
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Luxembourg, the Netherlands and Spain) could not report data for mental health hospitals. 
Furthermore, the external causes of morbidity (the ICD-10 codes V00-Y84), such as accidents, 
intentional self-harm and assault (WHO, 2010) are not included in the total hospital days, resulting in a 
higher proportion of hospital days attributable to drugs/alcohol. This in turn leads to an 
overestimation of hospital expenditures for alcohol and illicit drug treatment in hospitals. Finally, 
Eurostat collects health care data via various public and private information sources in EU countries. 
These data reflect the country-specific way of organizing and reporting health care, and this may 
diminish comparability across countries (Eurostat, 2013i). In this respect, the health expenditures 
collected by the System of Health Accounts (SHA) differs from the general government expenditures 
by COFOG (Classification of the Functions of Government) function18. The SHA/COFOG differences 
highlight the uncertainty of estimates due to differences in information sources. 
 
With these limitations in mind, we recommend expanding the Eurostat data collection of hospital 
discharges with secondary diagnoses. Furthermore, the data coverage of the Eurostat database should 
be improved to obtain more reliable results for the EU member states since the consistency of 
reporting is indispensable for international benchmarking of budget expenditures across countries 
(Prieto, 2010). 
 
5. CONCLUSION 
This study highlighted the need for cross-country comparison of the public expenditures for substance 
abuse treatment. Despite limitations, this study presents the public spending for illegal drug and 
alcohol treatment in hospitals of 21 EU member states. The study corroborates other studies that 
found that public expenditures for alcohol treatment exceed public expenditures for illegal drug 
treatment. Multiple factors may influence the number of hospital days and the expenditures that 
come with it. In this respect, we found a strong correlation between GDP per capita and the public 
expenditures per hospital day. Other factors should be included in the future analysis of public 
expenditures for substance abuse treatment, such as the drug policy in a given country (in this study, 
we especially discussed the case of Sweden) and the social norms regarding alcohol consumption (in 
this study, we especially discussed various Eastern European countries).  
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6. APPENDIX 
Appendix 1– Percentage of health expenditures financed by the general government 
Table 6: General government share of total current health expenditure for 21 EU countries, 2010* 
 
Country Public spending (%) 
Austria 77.09 
Belgium 75.09 
Bulgaria 56.21 
Cyprus 42.12 
Czech Republic 83.33 
Denmark 84.56 
Finland 74.39 
France 77.46 
Germany 77.22 
Hungary 64.28 
Latvia 59.65 
Lithuania 71.48 
Luxembourg 82.42 
Netherlands 86.09 
Poland 71.68 
Portugal 67.38 
Romania 79.92 
Slovenia 73.09 
Slovakia 67.82 
Sweden 81.51 
Spain 73.87 
Mean (SD) 72.70 (10.57) 
 
*Data for 2010, except for Bulgaria (2008), Cyprus (2008), Latvia (2009) and Luxembourg (2008). 
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8. ENDNOTES
                                                          
1
 DALY is a metric to determine the burden of disease. Therefore, it takes into account the years of potential life 
lost (YLL) due to premature mortality and the years of productive life lost (YLD) due to disability. 
2
 The number of people with an alcohol use disorder in treatment is estimated by taking into account the 
prevalence of 11.9 million people with alcohol dependence and the treatment coverage (in- and outpatient) with 
a minimum of 8.7% and maximum of 10.2% (Rehm et al., 2012). 
3
 The analysis of international databases was part of a larger study on public expenditure on drug treatment that 
the authors conducted for the EMCDDA in 2013 (the reference will be updated after review). 
4
 Eurostat also reports “general government expenditure by function (COFOG)”. However the COFOG database 
can only provide data for 19 EU member states (instead of 21 EU member states with the SHA database), since 
there are no data for Belgium, Spain, Romania and Slovakia. Furthermore, this database does not make a 
distinction between expenditures for general hospitals, mental health and substance abuse hospitals and 
specialty hospitals (other than mental health and substance abuse hospitals). Consequently, it would not be 
possible to estimate hospital expenditures for general and specialty hospitals in Denmark, France, Luxembourg 
and Netherlands. 
5
 The specialty hospitals consists of acute care hospitals; emergency centers; orthopedic hospitals or specialty 
sanatoriums primarily engaged in providing medical post-acute care, rehabilitative and preventive services; 
traditional medicine hospitals; and special hospitals for infectious disease (tuberculosis hospitals, hospitals for 
tropical diseases). 
6
 The International Classification of Diseases (ICD) is the international coding system of diseases and other health 
problems. This standard diagnostic tool is used for epidemiology, health management and clinical purposes. 
7
 The European Union reached its current size of 28 member countries with the accession of Croatia on 1 July 
2013. Since the analysis is based on 2010 data, Croatia is not included in this study. 
8
 The authors also tested an extrapolation by regression. However, the regression with hospitals days for 
substance abuse treatment regressed on GDP per capita and prevalence of problem substance use was not 
significant (P>0.05). 
9
 The health expenditures are indispensable to estimate the cost per hospitalization day. An extrapolation of the 
health expenditures by population would neglect the strong correlation between GDP and hospital expenditures.  
10
 All means in tables 1 to 4 are calculated with the simple average method. 
11
 Sweden (1507 euros), Austria (1259 euros), Finland (904 euros) and Germany (893 euros) have the highest 
hospital expenditures per capita. 
12
 Figure 1 and 2 give an impression of the relationship between prevalence and hospital days for substance 
abuse. This comparison should be interpreted with caution, since hospital days are limited to primary diagnosis 
of mental and behavioral disorders due to psychoactive substance use or alcohol use. 
13
 The data of 15 EU member states are used for extrapolation, because these countries provided data to 
estimate the public expenditures for all hospital types. 
14
 Wittchen et al. (2011) state that only 25% of persons with mental disorders receive professional mental health 
treatment. 
15
 The TDI is a monitoring tool developed by the EMCDDA to gain insight into the characteristics, risk behaviors 
and drug use patterns of people with illegal drug problems. To this end, data are collected on the number and 
profile of clients entering drug treatment during each calendar year. This tool is being used by 30 countries (28 
EU member states, plus Norway and Turkey) who send their national data to the EMCDDA.
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16
 The inpatient centers include therapeutic communities, private clinics, units in a hospital and centers that 
offer residential facilities. 
17
 This proportion should be interpreted with caution since the data coverage of TDI ranges from 14% to 100% of 
existing inpatient units in the registering countries. 
1818
 The COFOG is restricted to government administrative sources and focuses on the classification of 
transactions in government-funded health care (Eurostat, 2011). The COFOG hospital services expenditures 
(code GF0703) of 13 EU member states are compared to the SHA hospital expenditures (code HP1). The COFOG 
expenditures deviate from the expenditures reported on by the SHA: a difference of less than 10% in health 
expenditures is retrieved for 6 EU member states (Bulgaria, Czech Republic, Germany, Cyprus, Lithuania and 
Slovenia) and more than 10% for 7 EU member states (Latvia, Austria, Poland, Finland, Hungary, Portugal and 
Sweden). For Portugal, the hospital expenditure measured by COFOG (749 million euros) is only 12.8% of the 
expenditure collected by SHA (5,843 million euros). 
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STUDY 3  
THE GENERALISED COST-EFFECTIVENESS ANALYSIS OF ALCOHOL INTERVENTIONS:  
A COMPARATIVE MEASURE?   
THE BELGIAN ALCOHOL POLICY AS A STARTING POINT FOR A CROSS-COUNTRY COMPARISON 
 
ABSTRACT 
Background: Since the start of the 2000s, Generalised Cost-Effectiveness Analysis (GCEA) studies have 
been conducted to simulate the cost-effectiveness of an alcohol policy mix, and to evaluate the 
current alcohol policy of a country. It is hypothesised that GCEA could also be a useful tool to compare 
the cost-effectiveness of alcohol policies in different countries. The purpose of this study is to 
investigate if these GCEA studies could be used in a cross-country comparison. A Belgian GCEA on 
alcohol interventions is conducted in order to explore the possibility for a cross-country comparison 
with other GCEA studies from Australia, Estonia and Denmark.  
Methods: Firstly, the cost-effectiveness of six alcohol interventions (random breath testing, mass 
media “drink driving” campaign, increased taxation, advertising ban, reduced hours of sale and brief 
intervention in primary care) was investigated for Belgium with the WHO cost-effectiveness modelling 
framework. Secondly, a cross-country comparison of GCEA studies on alcohol was conducted. The 
Belgian and Estonian cost-effectiveness ratios were discussed more in detail since both studies used 
the WHO framework. 
Results: The combination of the six alcohol interventions in Belgium could annually save up to 18,000 
DALYs and the implementation of these interventions would cost approximately 40.3 million euros per 
year. Advertising ban (35 euros per DALY averted) and increased taxation (172 euros per DALY 
averted) appear to be the most cost-effective interventions to reduce hazardous alcohol use. In fact, 
the cross-country comparison suggests that the legislative interventions (increased taxation and 
advertising ban) are the most cost-effective strategies in Australia, Belgium, Estonia and Denmark. 
Furthermore, Estonia generates better cost-effectiveness ratios than Belgium, especially for random 
breath testing, since the prevalence of hazardous drinking and alcohol-related traffic accidents is 
higher in the Estonian population.  
Conclusion: A cross-country comparison of GCEA studies is confronted with conceptual and 
methodological differences across studies. The GCEA studies should use a uniform methodology, such 
as the WHO framework, in order to facilitate comparisons on the cost-effectiveness of different 
alcohol policies. During the contextualisation process of a GCEA study, however, uniformity of the 
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methodology may still be endangered by the input of parameters (such as the intervention effects, the 
cost calculation of the interventions, etc.).  
 
Key words: cost-effectiveness, alcohol, interventions, Belgium, cross-country comparison 
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1. INTRODUCTION 
The WHO (2009) estimated that alcohol is responsible for 69 million disability adjusted life years 
(DALYs1) and alcohol is ranked as the third risk factor for burden of disease in the world (Lim et al., 
2012). The economic impact of alcohol is as damaging to the nations as its health effects (Burke, 
1988). In Europe, the social cost attached to alcohol was estimated at 1.3% of the GDP: 125 billion 
euros  in 2003 (Anderson & Baumberg, 2006), and 156 billion euros in 2010 (Rehm, Shield, Rehm, 
Gmel & Frick, 2012). More particularly, Belgian data confirm an even higher impact of alcohol on 
society. A Belgian social cost study on alcohol found a social cost proportion of 2.5% of GDP in 1999, 
equivalent to 6 billion euros (Degreef, Pacolet & Bouten, 2003). Moreover, a more recent study on the 
public expenditures for drug control and drug problems in Belgium indicated that spending on alcohol 
is much higher in comparison to the spending for illegal drugs, psychoactive medication and tobacco. 
Alcohol accounts for 64.8% of drug-control spending and an even greater share (75.4%) of drug 
treatment spending (Vander Laenen, De Ruyver, Christiaens & Lievens, 2011). 
 
It is clear that this burden of alcohol poses several challenges for public management. Moreover, the 
governmental budgets for alcohol policy are limited due to the current economic crisis and the 
resulting austerity. Health economic evaluations may provide valuable information for policy makers, 
in order to allocate the public resources for alcohol policy in the most efficient and effective way. 
These studies are in keeping with the New Public Management (NPM) movement’s emphasis on policy 
evaluation in governmental operations. This NPM provides a universal economic model of governance 
and organization with a focus on efficiency and effectiveness (Osborne & Gaebler, 1992; Behn, 2001; 
Pollitt, 2003). Moreover, NPM has encouraged economic evaluation research, these tools and ideals of 
evaluation studies are as relevant to alcohol policy as they are to other government functions such as 
health care, education and police. For example, the cost-effectiveness of alcohol prevention and 
treatment models has been assessed by a number of cost-effectiveness analysis (CEA) studies (e.g. 
Tobler & Stratton, 1997; Raistrick, Heather & Godfrey, 2006; Månsdotter, Rydberg, Wallin, Lindholm & 
Andréasson, 2007). In addition, the cost-effectiveness of an alcohol policy mix has been studied with 
the Generalised Cost-Effectiveness Analysis (GCEA). Using this GCEA it is possible to simulate the most 
cost-effective alcohol policy mix of a country and to evaluate the current alcohol policy. Firstly, GCEA 
studies measure which mix of government interventions is likely to produce the greatest effectiveness 
in terms of costs and health outcome. Therefore, the intervention strategies to reduce the burden of 
hazardous alcohol use are evaluated by their comparative impact on population-level health. 
Secondly, the interventions are evaluated with respect to a counterfactual of “doing nothing” (Murray, 
Evans, Acharyan & Baltussen, 2000) and this null scenario provides information for decision-makers on 
what could be achieved if they reallocated the expenditures for alcohol policy (Edejer et al., 2003). The 
STUDY 3 
76 
 
first GCEA for alcohol was carried out at the level of WHO regions by Chisholm, Rehm, Van Ommeren 
& Monteiro  (2004). Furthermore, three generalised cost-effectiveness studies (Cobiac, Vos, Doran & 
Wallace, 2009; Holm, Veerman, Cobiac, Ekholm & Diderichsen, 2014; Lai, Habicht, Reinap, Chisholm & 
Baltussen, 2007) determined if a specific country mix (Australian, Danish and Estonian) of alcohol 
interventions represented an efficient use of resources. The country level analyses showed that an 
increase in taxation and advertising bans should be the highest priority of a cost-effective alcohol 
policy. Chisholm et al. (2004) confirmed that these population-wide measures imply the most cost-
effective response in populations with moderate or high alcohol use.  
 
The GCEA could also be a useful tool to compare the cost-effectiveness of alcohol policies in different 
countries, therefore the current study investigates if GCEA studies could be used in a cross-country 
comparison. An analysis of different government intervention mixes may enhance the comparison of 
alcohol policies between countries. In fact, a cross-country comparison of the cost-effectiveness of 
alcohol interventions would enable to monitor alcohol interventions with benchmarking information 
and this may potentially improve the efficiency and effectiveness of alcohol policy (Ritter, 2007).  
 
The current study investigates the possibility to conduct a cross-country comparison with GCEA 
studies. In order to identify methodological issues during a GCEA cross-country comparison, we start 
with an evaluation of the cost-effectiveness of the Belgian alcohol policy interventions and we 
illustrate a comparison across countries. Firstly, the Belgian setting is an interesting case from a public 
management point of view because the epidemiological2 and economic setting of the Belgian alcohol 
policy indicates room for improvement. The optimal intervention mix will point out if improvements of 
the Belgian alcohol policy are possible by changing the weight of interventions. This will result in 
recommendations for health policy-makers and programme managers. Secondly, this Belgian GCEA 
allows us to identify methodological issues during the execution of the GCEA and to investigate the 
feasibility of a cross-country comparison with other countries that already executed generalised cost-
effectiveness studies. The number of executed GCEA studies on alcohol is limited to three countries: 
Australia, Estonia or Denmark. This Belgian GCEA study expands the cross-country comparison with a 
country of the central-western and western European country group, by doing so, countries with 
different drinking traditions and patterns could be compared3. 
 
The paper has been organized in the following way. The first part deals with the GCEA methodology; it 
describes the approach that is used for selecting the interventions and collecting data for Belgium. The 
next section outlines the results; the cost-effectiveness of Belgian alcohol interventions is presented 
and compared across countries. Finally, the methodological issues concerning  a cross-country 
comparison with GCEA studies are discussed. 
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2. METHODS 
The GCEA, first developed by the World Health Organization CHOosing Interventions that are Cost-
Effective (WHO-CHOICE: http://www.who.int/choice) project, is a methodology that exceeds the cost-
effectiveness analysis (CEA) by overcoming a number of its limitations (e.g. the evaluation is restricted 
to a single new intervention; Murray et al., 2000). Its application provides information of multiple 
interventions at country (or regional) level by generalising results from one setting to another (Edejer 
et al., 2003), and this enables the identification of the optimal mix of interventions. Furthermore, the 
method investigates to what extent the current intervention mix is cost-effective, and if the proposed 
new intervention is appropriate4 (Hutubessy, Chisholm, Edejer & WHO-CHOICE, 2003). Therefore, it 
eliminates the effects of current alcohol policy by creating a scenario of no interventions, and the 
effects of (new or current) interventions are compared with this null situation (Edejer et al., 2003). 
These key features of the GCEA should make it a comparative measure. 
 
The current study used the WHO-CHOICE method for the Belgian GCEA, since it is a standardised data 
tool that allows cross-country comparisons in the next phase of the research. The WHO developed this 
method to simulate the cost-effectiveness of multiple interventions at the country level. Therefore it 
uses a multi-state population model (PopMod), this tool simulates the evolution in time of an 
population subject to births, deaths and a disease condition (in this case hazardous alcohol use). The 
effect of alcohol interventions on the health of the Belgian population (10 years implementation of 
the intervention) was derived via PopMod and the population-level impact was expressed in disability 
adjusted life years (DALYs 5 ). A contextualisation was conducted by collecting Belgian-specific 
demographic and epidemiological data, and Belgian-specific intervention costs. In addition, the 
effectiveness of alcohol interventions has been investigated by consulting review studies. These data 
were entered in the standard spreadsheets of the WHO-CHOICE tool and during the simulation the 
future intervention outcomes and costs were discounted at a rate of 3% (over the 10-year 
implementation period) as recommended by Edejer et al. (2003)6. Uncertainty analysis of the effects 
(with a range of plus and minus 20% of the baseline effect) have been conducted to take into account 
the uncertainty around the effectiveness of interventions (or elasticities for tax) 7.  
 
Data 
The alcohol interventions are supposed to change incidence, prevalence and mortality of alcohol-
related diseases and injuries, therefore epidemiological data were collected. The prevalence of 
hazardous alcohol use originated from the Belgian health interview survey 2008 (IPH, 2010). The 
Directorate-general Statistics and Economic information provided mortality rates from 2008 8 . 
Furthermore, the calculation of DALY requires disability weights, the measure for the decline of health 
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associated with alcohol use disorders (Rehm & Frick, 2010). The study of Stouthard et al. (1997) 
provides a comprehensive set of disease-specific disability weights in a Western European context. 
The intervention costs are assessed in Euros for the year 20089 and derived from the public 
expenditure study Drugs in Figures III (Vander Laenen et al., 2011). The missing intervention costs (e.g. 
medical expenses for a brief intervention and budget for a media awareness campaign on alcohol) 
were collected by consulting governmental administrations. The focus lies on the public expenditures 
(including social security payments) and private costs (e.g. non-refundable part of medical expenses 
and sponsoring) that are necessary to deliver each intervention; meaning that tax revenues from 
alcoholic beverages are beyond the scope of this study. Moreover, this study does not take into 
account costs for the family or intimates, time costs of the patient to participate at the interventions 
and productivity losses. These costs have neither been estimated in the previous GCEA studies on 
alcohol (Cobiac et al., 2009; Holm et al., 2014; Lai et al., 2007)10, possibly due to methodological 
problems with these cost estimates (Moller & Matic, 2010).  
 
Interventions 
The selection of interventions that reduce alcohol-attributable harm started with a comprehensive 
review of the literature (Anderson & Baumberg, 2006; Babor et al. 2010; Mulvihill, Taylor & Waller, 
2005; Ludbrook et al., 2002; Ludbrook, 2004). The literature review resulted in a global list of 37 
alcohol interventions and this list was reduced to a final selection of six interventions based upon 
three considerations: the effectiveness of alcohol policy, the cost-effectiveness of interventions and 
previous research. Firstly, Anderson & Baumberg (2006) argue that an effective alcohol policy should 
focus on the following five domains: (1) policies that regulate the alcohol market; (2) policies that 
reduce drinking and driving; (3) policies that support education, communication, training and public 
awareness; (4) policies that support the reduction of harm in drinking and surrounding environments; 
(5) policies that support advice and treatment for hazardous and harmful alcohol consumption and 
alcohol dependence. From this point of view, the optimal policy mix will only be possible if at least one 
intervention of each domain is selected11. Secondly, the study takes into account the effect of each 
intervention, this means that interventions with a high degree of effectiveness and cost-effectiveness 
are more likely to be selected. To this end, systematic reviews or meta-analyses were consulted. For 
example, the programme for drunk driving offenders by placing an interlock that prevents an impaired 
driver from operating the vehicle is excluded from this study since there is no review study available 
with evidence that alcohol locks reduce alcohol-related crashes (Marques, 2009). Thirdly, given the 
aim of a cross-country comparison, the selection process of interventions is also determined by 
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previous GCEA studies, meaning that similar cost-effective interventions were selected and the 
selection was limited to six interventions12.  
 
The selection process above resulted in six interventions for the GCEA of the Belgian alcohol policy. 
The intervention effects from the literature are presented in terms of change in alcohol consumption13 
or road traffic crashes and injuries.  
 
1. Random breath testing (RBT): i.e. programmes that randomly stop drivers to detect and prevent 
driving with a blood alcohol concentration of 0.5g/l. Different studies consider RBT as an effective 
strategy to reduce alcohol-related traffic crashes and injuries. In fact, review studies on RBT retrieved 
a 18% decline in injuries (Peek-Asa, 1999) and crashes (Shults et al., 2001). This GCEA study took into 
account a 18% reduction in fatal traffic injuries and a smaller reduction of 15% for non-fatal injuries14 
(Chisholm et al., 2004). 
 
2. Mass media “drink driving” campaign: i.e. the nationwide implementation of a mass media campaign 
to prevent drinking and driving. A well-executed mass media campaign is effective in reducing alcohol-
related crashes according to Elder et al. (2004). This systematic review of eight studies found a median 
decrease in injury-producing crashes of 10%. 
 
3. Increased taxation: i.e. an increase the alcohol price by raising the excise taxation with 25% or with 
50%. Alcohol consumption is determined by the price, therefore the effects of taxation are measured 
in terms of price elasticity15. The results of the meta analysis of Wagenaar, Salois & Komro (2009) were 
consulted: the means of reported elasticities are -0.46 for beer, -0.69 for wine and -0.80 for spirits. 
 
4. Advertising ban: i.e. a comprehensive advertising ban (e.g. via TV, radio, billboards, etc.) on alcoholic 
products. This intervention is recommended since research (e.g. Tapert et al., 2003; Anderson, de 
Bruijn, Angus, Gordon & Hastings, 2009; Winpenny et al., 2012; Bosque-Prous et al., 2014) indicated 
that alcohol advertisements influence adolescents and adults with heavy drinking patterns. Moreover 
advertising bans are recognised as a highly cost-effective measure to reduce harmful alcohol use 
(Anderson, 2009). The study of Saffer and Dave (2002),a pooled time-series analysis of data from 20 
countries over a period of 26 years, found that in the past an increase of one ban (of media or 
beverage type) reduces consumption by 5% to 8%.  
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5. Reduced hours of sale: i.e. a restriction of the purchase of alcohol by reducing hours of sale among 
retail outlets. Popova, Giesbrecht, Bekmuradov & Patra (2009) and Hahn et al. (2010) concluded that 
decreasing hours of sale (by 2 hours or more) is an effective strategy to prevent alcohol-related harm. 
Nevertheless these review studies were not able to report a mean effect. Therefore, the results of the 
study of Norström and Skog (2005) were used since it was the only study that measured the effect on 
the alcohol consumption for a European country. The authors showed that the Saturday opening of 
alcohol retail shops in Sweden increased alcohol sales and consumption with 3.7%.  
 
6. Brief intervention in primary care: i.e. counselling for at-risk drinkers by a general practitioner. An 
overload of CEA studies on brief interventions is available. The meta-analyses of Bertholet, Daeppen, 
Wietlisbach, Fleming & Burnand (2005) and Kaner et al. (2009) reported a reduction in alcohol 
consumption of -38g/week16. Moreover, Whitlock, Polen, Green, Orleans & Klein (2004) systematically 
reviewed studies on behavioural counselling interventions in primary care and revealed a 13% to 34% 
reduction in weekly drinks. In line with these results, this GCEA study took into account an effect of 
22% reduction in alcohol consumption (Moyer, Finney, Swearingen & Vergun, 2002; Chisholm et al., 
2004).  
 
3. RESULTS 
Belgian optimal intervention mix  
Table 1 presents the annual costs and effects of different interventions to reduce the hazardous 
alcohol use in Belgium. The effectiveness of the interventions (in terms of DALYs averted per year) 
ranges from 637 DALY for the mass media “drink driving” campaign to 12,274 DALY for increased 
taxation with 50% (See Table 1). There is also large variability in the yearly cost of the interventions: 
from 0.1 million euro for an advertising ban to 25.7 million for random breath testing. In terms of cost-
effectiveness, an advertising ban is the most cost-effective intervention to reduce alcohol burden, a 
volumetric taxation (+50%) and a reduction of opening hours complete the top three. The cost-
effectiveness of these three interventions ranges from 35 to 185 euros per DALY saved, this is in 
contrast with the random breath testing that costs more than 26,000 euros per DALY averted. The 
combination of the six interventions could annually save 17,990 DALYs17, this would cost 40.3 million 
euros per year. 
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Table 1: Cost-effectiveness of alcohol interventions in Belgium 
Intervention 
DALYs averted per 
year (a) 
Cost per year 
(million Euros) (b) 
ACER
18
 (Euros per 
DALY saved)(b)/(a) 
Current situation (2008)
19
 10,731 254,1 23,677 
Increased taxation (current +25%) 11,120 2,1 190 
Increased taxation (current +50%) 12,274 2,1
20
 172 
Random breath testing 974 25,7 26,400 
Mass media “drink driving” campaign 
 
637 0,5 810 
Advertising ban 2,736 0,1
21
 35 
Reduced hours of sale 666 0,1 185 
Brief intervention in primary care 2,267 13,9
22
 6,123 
Combination of interventions 17,990 40,3 2,241 
 
Figure 1 demonstrates the optimal intervention mix for a 10-year period. From a cost-effectiveness 
point of view, the best combination in case of two policy options is increased taxation and advertising 
ban; and the brief intervention in primary care should be implemented as a third policy intervention. 
The figure also illustrates the cost-effectiveness of the current situation (2008) and shows the 
potential improvements (in terms of averted DALYs) by implementing the combination of the six 
studied interventions.  
Figure 1: Cost-effectiveness of alcohol interventions in Belgium (over 10 years) 
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Furthermore, the uncertainty analysis showed that the impact of plausible variations in the 
intervention effects affected the results marginally. The interventions retain their classification of 
highly cost-effective or cost-effective after taking into account the uncertainty. In comparison with the 
baseline estimate, the cost-effectiveness ratios of the interventions decreased with 8% to 19% in the 
best case scenario and with 9% to 29% in the worse case scenario. 
 
Comparison with Australia, Estonia and Denmark 
First of all, the four countries (Belgium, Australia, Estonia and Denmark) that conducted a GCEA study 
on alcohol listed volumetric taxation and advertising ban23 as the most cost-effective strategies. 
Additionally, the cost-effectiveness of the interventions was examined more in detail by looking at the 
costs, averted DALYs and ACER. Table 2 only presents the data for Belgium and Estonia, since it is not 
possible to compare with the figures of Denmark or Australia due to conceptual and methodological 
differences24.  
Table 2: Cross-country comparison for Belgium and Estonia
25 
Intervention 
Annual intervention 
effect (DALYs per 1 
million population) 
Annual intervention cost 
(euros, per capita) 
ACER (Euros per DALY 
saved) 
Belgium Estonia Belgium Estonia Belgium Estonia 
Increased taxation (current 
+50%) 
1,151 2,260 0.20 0.11 172 47 
Random breath testing 91 1,423 2.41 0.55 26,400 387 
Advertising ban 256 756 0.01 0.07 35 93 
Reduced hours of sale 62 736 0.01 0.08 185 114 
Brief intervention in primary 
care 
213 755 1.30 0.56 6,123 747 
Firstly, the Estonian interventions accomplish more gain in health than the Belgian interventions (e.g. 
random breath testing is ten times more efficient). This could be explained by higher prevalence of 
hazardous drinking and alcohol-related traffic accidents for Estonia. Actually, the 12-month prevalence 
of alcohol use disorders was 10.2% for Estonia and 5.8% for Belgium. The alcohol-attributable 
fractions for road traffic accidents are also much higher for Estonia (44.9% for males, 44.3% for 
females) than for Belgium (19.5% for males, 7.8% for females) (WHO, 2014)26. Secondly, the 
intervention costs per capita are higher for Belgium, except for advertising ban and reduced hours of 
sale, and this may stem from economic differences between the countries. The eastern European 
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countries have a lower economic power in terms of GDP than western European countries (Shield, 
Kehoe, Gmel, Rehm & Rehm, 2012). Moreover there is an eight-year time lapse between the two 
studies, consequently it was expected that Belgium would report higher costs due to inflation.  
 
The higher effects and lower costs for Estonian alcohol interventions logically lead to better cost-
effectiveness ratios. Nevertheless, both countries have the highest cost-effective rates for the three 
legislative interventions in comparison to random breath testing and brief intervention. As for these 
other interventions, we notice that brief intervention is the more favourable cost-effective option for 
Belgium, whereas random breath testing is the most cost-effective strategy for Estonia. As mentioned 
before, the alcohol related traffic accidents are an important contributor to burden of disease in 
Estonia and thus the effect of random breath testing is much higher.  
 
 
4. DISCUSSION 
This study contributes to the discussion to what extent the GCEA approach can be applied to develop 
comparisons on the cost-effectiveness of alcohol policies between countries. Therefore, it starts with 
an evaluation of the Belgian alcohol interventions in terms of cost-effectiveness. This Belgian 
contextualisation of the GCEA is conducted in order to provide decision-makers with information on 
what could be achieved if they could start again to design the alcohol policy and reallocate all 
resources (Edejer et al., 2003).  
The results show that the Belgian policy makers should ideally adapt legislative interventions 
(advertising ban, volumetric taxation and a reduction of opening hours) in order to develop the most 
cost-effective alcohol policy. These legislative interventions are environmental prevention measures 
with a universal form, therefore these results are in line with the “prevention paradox”. The paradox 
states that interventions targeted to the whole population (universal prevention) are more likely to 
reduce population levels of alcohol-related harm than are those addressing high-risk groups (Rose, 
1981; Stockwell et al., 2004). During the recent years, the Belgian government adopted these 
legislative interventions to a limited extent. A code of conduct on advertising for alcoholic beverages 
have been developed in 2013, nevertheless this code does allow promotion be it under specific terms 
(e.g. advertising may not suggest that alcohol is needed to create a festive atmosphere). Moreover, 
the Belgian alcohol excise duties have been raised in 2013 (e.g. for still wine with 8%: 4.22 euros/HL ). 
Still the taxation rates are lower than those in other countries. For instance it would take  a 50% 
increase of Belgian excise wine duties for 2008 to make the taxation wine rates similar to the ones in 
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the Netherlands (European commission, 2008). Despite the implementation of these alcohol policy 
strategies in recent years, the examples show that there is still room for improvement for the Belgian 
alcohol policy from a public health perspective. As for the non-legislative interventions, the Belgian 
policymakers should prefer investments in brief intervention above random breath tests. The strength 
of brief intervention lies in two areas: aimed to change personal behaviour and to target the 
hazardous/harmful drinkers (instead of the general population). In the recent coalition agreement of 
the Federal government (2014), however, the focus lies on increasing the drink driving tests (target 
population of one in three drivers per year)27.  
 
In conclusion, this GCEA examines the intervention mix for alcohol control in Belgium, and reveals a 
number of factors that might improve the cost-effectiveness of the alcohol policy.  Ideally, this leads to 
an evidence-based policy, where the financial resources are assigned to the most cost-effective 
interventions (Wood et al., 2010). Despite the high number of DALYs that could be averted by 
universal prevention strategies (e.g. advertising ban, volumetric taxation and a reduction of opening 
hours), it should be stated that more targeted strategies for addressing harm related to hazardous 
alcohol users (e.g. brief intervention) are also required (Stockwell et al., 2004). In addition, policy 
makers need to keep in the mind that alcohol policy should focus on multiple domains (Anderson & 
Baumberg, 2006), therefore the roadside breath-testing may remain important for Belgium as a 
specific intervention in the policy domain to reduce drinking and driving. It is clear that the alcohol 
policy is a cross-cutting issue, meaning that the management is not limited to one single sector, it 
encompasses the central government and the other public sector agencies who are involved (Butler, 
2009). Moreover, this policy is not only driven by the public health perspective, the implementation of 
alcohol interventions is also determined by political feasibility and public acceptance. In this regard, 
interventions influencing the alcohol price or availability might not be politically popular in a society 
dominated by free markets and consumer rights (Jernigan, Monteiro, Room & Saxena, 2000). The 
alcohol industry is also involved in the alcohol policy process as a stakeholder. In the past, the 
extensive lobbying by the alcohol industry obstructed the implementation of cost-effective policies 
and initiatives in multiple countries (Caswell & Maxwell, 2005; Hope, 2006; McCambridge, Hawkins & 
Holden, 2014). In Belgium, the National Alcohol plan 2014-2018, that proposed evidence-based 
alcohol policy interventions, could not be implemented due to a lack of political consensus for the 
proposed measures related to the supply side of alcohol (Plettinckx et al., 2014).  
 
This GCEA allows us to evaluate multiple alcohol interventions for one country or region, and in doing 
so, it provides a framework for future policy directions. Moreover, a GCEA cross-country comparison 
may provide important insight into the dynamics of alcohol policy by exploring the cost-effectiveness 
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of various policy options. Country profiles providing information on alcohol policy and its impact on 
DALYs could be compiled and used as an economic evaluation tool to find the most cost-effective way 
of organizing alcohol interventions in different settings. It is unknown if this GCEA approach can be 
applied to develop comparisons between countries (Ritter, 2007). Therefore, the main goal of this 
study was to investigate if the GCEA could be used as a comparative measure. A cross-country 
comparison have been conducted for Estonia and Belgium. The results of this cross-country 
comparison are limited to an evaluation of alcohol intervention effects and their costs, no statements 
can be made about the quality of the interventions in the different countries. The main conclusion is 
that the legislative interventions are the most cost-effective strategies, furthermore we notice better 
cost-effectiveness ratios (for each intervention except advertising ban) for Estonia. This variation in 
cost-effectiveness ratios could be explained by the country specific prevalence of hazardous drinking 
and alcohol-related traffic accidents.  
 
The current study could not draw conclusions on a cross-country level with Australia and Denmark 
because the variations could be attributed to methodological differences. Moreover, the results of the 
comparison between the Belgian and Estonian GCEA should be interpreted with caution. During the 
data collection of this GCEA study, we were confronted with a couple of methodological limitations, 
and these limitations may lead to distorted figures or could endanger the cross-country comparison.  
 
Firstly, the effect of each intervention was limited to the measurement in terms of reduced hazardous 
alcohol use and reduction of road traffic accidents (for RBT and drink diving campaign) in the current 
study, as was the case in the studies of Lai et al. (2007) and Chisholm et al. (2012). Whereas Cobiac et 
al. (2009) and Holm et al. (2014) evaluated the effect on multiple alcohol-related diseases (e.g. 
ischaemic heart disease, cirrhosis, cancer, etc.) and injuries (e.g. road traffic accidents, falls, fires, etc.). 
It is clear that the latter studies have a broader scope and, consequently, the  effect of alcohol 
interventions in terms of DALYs is higher. The GCEA studies should use a common conceptual 
framework, such as the WHO cost-effectiveness modelling framework, in order to facilitate cross-
country comparisons. The WHO framework allows us to evaluate all interventions in a consistent and 
comparable manner since it provides a theoretical framework of analysis, the definition of 
interventions, the concept of the counterfactual, the intervention implementation period, etc. (Edejer 
et al., 2003). If GCEA studies opt for a broader scope than the WHO framework, it is recommendable 
to present the results for hazardous alcohol use separately from those for alcohol-related diseases 
and injuries.  
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Secondly, each intervention effect derives from scientific research, but the results of different outcome 
studies (e.g. CEA) may conflict. These studies cannot produce the absolute truth, because the 
effectiveness of a particular intervention will be determined by multiple factors. For example, in 
contrast with Saffer and Dave (2002), other studies (Nelson & Young, 2001; Nelson, 2010) state that 
advertising bans do not reduce alcohol consumption. Nelson & Young (2001) even state that 
advertising bans may lead to a consumption increase because suppliers compete for market share by 
price falls. Consequently, a GCEA is determined by the intervention effects that are derived from 
outcome studies. This problem can partially be overcome by taking into account the effectiveness of 
alcohol interventions published in systematic review or meta-analysis studies. The extrapolation of 
intervention effects may still be difficult because these review studies are also confronted with 
different sociocultural settings (e.g. regional patterns of drinking may influence the effect of an 
intervention; Chisholm et al., 2004). For example, the generalisability of the findings of Elder et al. 
(2004), Shults (2001) and Peek-Asa (1999) to other countries (such as Belgium) may be questioned, 
since these reviews mainly used data from the US and Australia. Therefore, GCEA studies conduct an 
uncertainty or sensitivity analysis in order to incorporate the sustainability of intervention health 
effects over time or to take into account the best and worst case scenario of the effectiveness of 
interventions. However, the current GCEA cross-country comparison was limited to point estimates of 
effectiveness ratios (without taking into account the ranges of intervention effects) and compares the 
average cost-effectiveness. Ideally, GCEA studies should consult meta-analysis28 that investigate the 
effectiveness of alcohol interventions by regions and they should conduct a sensitivity analysis.    
The GCEA studies are confronted with additional limitations concerning the interventions effects. The 
GCEA only takes into account the primary purpose of alcohol interventions (namely the reduction of 
alcohol consumption and road traffic accidents); other effects like productivity gain or reduced 
violence are not considered. For instance, a reduction in violence is an important effect of the 
intervention that restricts opening hours (Duailibi et al., 2007). The effect of preventive interventions 
may also be underestimated since the impact of prevention on drinking behaviour is difficult to 
measure and the effect depends on intermediary variables (Birckmayer, Holder, Yacoubin & Friend, 
2004). Furthermore, limited information about the interaction of interventions, and how this affects 
the effectiveness of intervention combinations, is available for the GCEA studies (Holm et al., 2014). It 
is clear that the effect of interventions on alcohol consumption should be interpreted carefully since 
the effectiveness of interventions are imbued with a degree of uncertainty (Hutubessy et al., 2003). 
Further research is necessary to strengthen the evidence on interventions effects, moreover the 
combined effect of multiple interventions should be investigated. 
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Thirdly, the GCEA is limited to intervention costs from a health sector perspective (resources of the 
public providers and the private sector). Costs for the family or intimates, time costs of the patient to 
participate at the interventions and productivity losses were excluded. Other potentially negative (e.g. 
loss of freedom for legislative interventions) and positive effects (e.g. productivity gain due to 
decreased alcohol consumption) have neither been estimated. Moreover, the cost calculation of 
interventions is determined by multiple factors such as the coverage rate of interventions (e.g. 
random breath testing for 40% of the drivers versus 20% of the drivers) and the data sources. For 
instance, intervention costs for health interventions have been calculated for Belgium (year 2005) in 
the study of Chisholm, Rehm, Frick & Anderson (2009)29, and a comparison with the current GCEA 
study (year 2008) shows us large differences between intervention costs: e.g. the cost for brief 
intervention (with coverage rate of 30%) was estimated to cost 43.9 million euros in the study of 
Chisholm et al. (2009) and 13.9 million euro in the current study. The differences in cost calculation 
could be attributed to the data source, since Chisholm et al. (2009) obtained cost information by 
regional costing experts (data source WHO CHOICE: Johns, Baltussen & Hutubessy, 2003) and the 
current study collected country-specific costs from the governmental administrations. Consequently, a 
cross-country comparison should take into account GCEA studies with similar data sources. The data 
from governmental administrations is recommend since these actors dispose of more complete data 
on public authorities funding. 
 
Fourthly, each GCEA study uses disability weights to calculate DALYs. However, it is not possible for the 
GCEA studies, in terms of research time, to establish an expert panel to investigate the country-related 
disability weights. Scientific research has to be consulted, for example Lai et al. (2007) use data from 
an Estonian burden of disease study (Lai et al., 2003) and Chisholm et al. (2009) refer to the Dutch 
disability weight study (Stouthard et al., 2000). Methodological differences (e.g. valuation method) 
occur between these disability weight studies, this may influence the DALYs in the GCEA studies and 
the cross-country comparison in a next phase30. Moreover, the disability weights in the Netherlands 
(Stouthard et al., 1997) and global burden of disease study (Murray & Lopez, 1996) are calculated for 
different stages of a disease. No Belgian incidence or prevalence data are available on this detailed 
level (problem drinking versus manifest alcoholism), therefore the average disability weight for alcohol 
disorders is used. This may result in less accurate figures. 
 
These limitations confirm that the GCEA must be regarded as an approximation because it is built 
mainly on various assumptions. In order to have the most realistic estimation it is important to collect 
accurate demographic and epidemiological information. In fact, the quality of the data is a crucial 
factor for a GCEA, since they determine the success of a GCEA study. Moreover, a uniform 
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methodology is necessary to compare the cost-effectiveness of different alcohol policies. In this 
respect, the initiative of the WHO to develop a guide to GCEA is a step in the good direction. During 
the contextualisation process of a GCEA study, it is still very likely that the uniformity of the 
methodology will be endangered by the input of parameters (such as target coverage rate of the 
interventions, the choice of the intervention effect, the cost calculation of the interventions, etc.), and 
this may disturb the possibility to conduct a cross-country comparison. From a methodological point 
of view, the GCEA is not the best way to compare alcohol policies between countries. Methodological 
problems have also been acknowledged in other types of studies that compared alcohol policies, 
namely public expenditure and social cost studies (Lievens et al., 2012; Ritter, 2007). In conclusion, the 
challenge continues: finding a way to overcome the methodological and conceptual problems in a 
cross-country comparison of alcohol policies. 
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6. ENDNOTE
                                                          
1
 DALY is a metric to determine the burden of disease. Therefore, it takes into account the years of potential life 
lost (YLL) due to premature mortality and the years of productive life lost (YLD) due to disability. 
2
 In a 2008 Belgian health survey 10.3% of the participants reported a problematic alcohol consumption (Gisle et 
al., 2010). Additionally, it can be noticed that 41% of the Belgian students reported heavy episodic drinking 
during the past 30 days (Hibell et al., 2009). 
3
 Denmark represents a Nordic country and Estonia belongs to the central-eastern and eastern country group. 
These geographical areas are based upon drinking traditions and patterns (WHO, 2013). 
4
 The traditional CEA is limited to evaluations of new interventions in comparison with the current mix. 
5
 DALY is the sum of years of potential life lost (YLL) due to premature mortality and the years of productive life 
lost (YLD) due to disability. 
6
 Age-weighting, which is also available in the WHO-CHOICE tool, has not been conducted for the cross-country 
comparison (the Estonian study did not use age-weighting either). Age-weighting is used in GCEA studies to take 
into account the lower value of life at young and older ages than people in middle-age (Edejer et al., 2003). 
7
 However, the cross-country comparison for Belgium and Estonia is limited to a comparison of the average cost-
effectiveness ratios. Since  the Estonian study (Lai et al., 2007) did only report the mean intervention effects and 
costs in detail. 
8
 The prevalence, mortality and remission for alcohol disorders are provided as inputs in DISMOD II. This 
software tool is used to calculate the incidence and case-fatality for alcohol disorders.  
9
 Nevertheless, a cost calculation over 10 years is conducted in order to simulate an intervention 
implementation period of 10 years. We took into account that some costs (e.g. campaign for alcohol advertising 
ban) are only made in the first year of the intervention.  
10
 Except for the study of Cobiac et al. (2009) that measured the time and travel cost for the patients. 
11
 There is no intervention selected in the fourth domain (e.g. interventions with focus on responsible beverage 
service or safer bar environment), because the effect on alcohol consumption or road traffic accidents could not 
be confirmed by a systematic review or meta-analysis. Three interventions (increased taxation, advertising ban 
and reduced hours of sale) belong to the first domain of regulating the alcohol market. 
12
 Other GCEA studies took into account five to eight interventions. The study of Estonia (Lai et al., 2007), which 
is included in the cross-country comparison, refers to five interventions: increased taxation, roadside breath-
testing, reduced access to retail outlets, advertising ban and brief advice in primary care. The current study also 
takes into account the mass media campaign in order to evaluate an intervention of the fifth policy domain that 
supports education, communication, training and public awareness. 
13
 The intervention effects in terms of alcohol consumption are used to estimate the effect on incidence or 
prevalence of hazardous alcohol use. For example, a 4% reduction in the incidence of hazardous alcohol use for 
advertising ban is simulated based upon the results of Saffer and Dave (2002) (Chisholm et al., 2004). 
14
 The 15% reduction of non-fatal injuries via RBT is retrieved from studies that analysed the alcohol-attributable 
fractions for road traffic injury (Ridolfo & Stevenson, 2001; Rehm et al., 2004). 
15
 In alignment with Chisholm et al. (2004), the effect of elasticity on consumption is taken into account for two-
thirds, because heavy drinkers are less responsive to price changes. 
16
 A decrease of 38g/week in alcohol consumption is similar to a reduction of 22% in case of a weekly alcohol 
consumption of 176g (weekly alcohol overconsumption for women from 150-180 grams and for men from 220-
264grams).  
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17
 The effect of interventions decreases if they are combined. In accordance with Chisholm et al. (2004), it is 
assumed that the combination of six interventions averts 92% of the sum of the individual interventions effects 
(DALYs). 
18
 Average cost-effectiveness ratio 
19
 The cost-effectiveness of the current situation has been measured by taking into account a current coverage 
rate of 15% for brief intervention, 20% for random breath testing, 20% for advertising ban, 10% for reduced 
hours of sale and 80% for the mass media campaign. Furthermore, the effect of the taxes in the year 2008 are 
simulated (excise tax as per cent of price, based on 100cls of each type of beverage: 23.9% for beer, 33% for 
wine and 53.5% for spirits). 
20
 The intervention cost for increased taxation does not change, since it is assumed that the cost for the taxation 
control system will not rise if the excise taxation increases. 
21
 The intervention costs for advertising ban and reduced hours of sale include the yearly costs for enforcement 
and the cost for a media awareness campaign in the first year (150.000 euros distributed over ten years). 
22
 The cost of brief intervention is based upon the assumption of four visits to the general practitioner (Chisholm 
et al. 2004), meaning an average cost of 73.56 euros per patient per year (30% of these medical expenses is non-
refundable for patients in Belgium). 
23
 The intervention reduced opening hours was listed as third cost-effective strategy in Estonia, Denmark and 
Belgium. Australia did not evaluate this intervention, however “minimum legal drink age to 21” was ranked as 
third cost-effective strategy. 
24
 The Australian and Danish study evaluated the intervention effects on multiple alcohol-related diseases and 
injuries whereas the Estonian and Belgian study measured the effect on hazardous alcohol use and the number 
of road traffic accidents. 
25
 The cost-effectiveness of mass media “drink driving” campaign is missing since Lai et al. (2007) did not 
analysed this intervention for Estonia. 
26
 The WHO modelled the prevalence of people with alcohol use disorders with a regression model. Only data for 
the year 2010 is available. 
27
 In the analysis, a duplication of the target population for brief intervention (from 15% to 30% of the hazardous 
drinkers) and for random breath testing (from 20% to 40% of the drivers) has been simulated. 
28
 The meta-analyses are preferred since these studies employ statistical methods to synthesize the effects from 
several studies into a single quantitative estimate (Petticrew & Roberts, 2006). Unfortunately, a limited number 
of meta-analyses (Moyer et al., 2002; Bertholet et al., 2005; Kaner et al., 2009; Wagenaar et al., 2009) were 
available for the analysis, therefore the current study retrieved the intervention effects mainly from systematic 
reviews. 
29
 The WHO CHOICE tool developed guidelines to estimate the costs of the interventions (Chisholm et al., 2004); 
this tool has been used to evaluate the cost-effectiveness of interventions in reducing alcohol-related harm for 
22 European countries (IAS, 2009). 
30
 There is a cross-national agreement available on disability weights, but it is only calculated for 15 diseases 
(Schwarzinger et al. 2003). This study also indicates a high level of agreement on disability weights in Western 
European countries (method: visual analogue scale (VAS) and time trade-off technique). 
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CONCLUSION 
 
In Europe, one widely accepted standard is that public resources should be used in the most efficient 
and effective way (Mandl, Dierx & Ilzkovitz, 2008), therefore governments needs to supervise the 
expenditures and evaluate the policy at the same time. This dissertation tries to guide the policy 
makers with an economic evaluation of the drug policy. It presents an economic evaluation of the 
Belgian drug policy with a public expenditure study on legal and illegal drugs and a generalised cost-
effectiveness analysis (GCEA) on alcohol. In addition, this dissertation contributes to European policy 
research with cross-country comparisons on public expenditures (on drug policy and substance abuse 
treatment in hospitals) and on cost-effectiveness.  
 
In the first part of this chapter, the main results of the two studies that evaluated the Belgian drug 
policy are examined and recommendations for Belgian drug policy are formulated. The limitations of 
the public expenditure study and GCEA are discussed, and we provide avenues for future research. In 
the second part of this chapter, the main findings of the three cross-country comparisons are 
presented. Furthermore, we discuss if these types of cross-country comparisons could be used for 
future economic evaluations of drug policy. To this end, the potential role and limitations of the cross-
country comparison are discussed, and recommendations for future research are formulated.  
 
1. EVALUATION OF THE BELGIAN DRUG POLICY 
The first paper in this dissertation provides an insight into how the drug expenditures are composed 
and what the public authorities so-called “policy mix” is. The public expenditure study allows us to 
evaluate the expenditures of the public authorities at each level of competency for the different policy 
domains. Moreover, it shows whether the government’s stated priorities for that drug policy are 
mirrored in their expenditures. Our analysis showed that there is no match between government’s 
spending and policy declarations in the Belgian case. The Belgian drug policy expenditure mix (illegal 
drugs, alcohol and psychoactive medication) consists of 76.5% treatment, 21.67% enforcement, 1.24% 
prevention, 0.24% harm reduction and 0.35% other. This contrasts with the provisions in the Federal 
Drug Policy Note (Belgian Federal Government, 2001) that states that prevention should get the 
highest priority and enforcement should be used as “ultimum remedium” towards drug users. Several 
reasons have been discussed to explain this mismatch, such as the historical resource allocation that is 
focussed on public expenditures for law enforcement and the bottom-up development of the Belgian 
drug policy. Furthermore, the study gives insight into the evolution of public expenditures on drugs 
over time. A comparison of the evolution of the public expenditures for illegal drugs between 2004 
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and 2008 showed that the expenditures for enforcement increased with 31%, while the expenditures 
for treatment remained stable and the expenditures for prevention even decreased with 8%. A higher 
percentage of recorded drug crimes led to this upward trend in enforcement expenditures, and this 
could be explained by the increased focus on public drugs nuisance (Ward, 2011) and drug tourism 
(Vander Laenen, De Ruyver, Christiaens & Lievens, 2011).  
 
The third paper focuses on the generalised cost-effectiveness of alcohol interventions. This GCEA 
exceeds other economic evaluation tools, such as the cost-effectiveness and cost-benefit analysis, by 
evaluating multiple interventions on a country level.The current GCEA study examines the alcohol 
intervention mix for Belgium and reveals a number of factors that might improve the cost-
effectiveness of the alcohol policy. The combination of six alcohol interventions (random breath 
testing, mass media “drink driving” campaign, increased taxation, advertising ban, reduced hours of 
sale and brief intervention in primary care) could annually save up to 18,000 DALYs, and would cost 
approximately 40.3 million euros per year. In terms of cost-effectiveness, an advertising ban appear to 
be the most cost-effective intervention to reduce alcohol burden, a volumetric taxation (+50%) and a 
reduction of opening hours complete the top three.  
 
Policy recommendations 
The public expenditure study and GCEA allow us to formulate recommendations for drug 
policymakers. Based upon these studies, decision makers might monitor the balance of resource 
allocation. Some people argue that the government need to strive for equality in the quantum of 
funds allocated to the various drugs and implementation sectors, others prefer budget allocation in 
accordance with the relative burden of the different types of drugs (McDonald, 2011). Another 
approach, more consistent with WHO principles, is that resource allocation should be based upon 
existing evidence for cost-effectiveness. The public expenditure study and GCEA might be useful for 
the resource allocation, nevertheless a full policy evaluation can only be completed by combining 
information about public expenditures with a range of other types of information/studies (e.g. 
epidemiological data about new trends in drug use and groups of (problem) drug users, data about 
target groups in prevention, early intervention and treatment, evaluation and cost-effectiveness 
studies, etc.)  
 
It is recommended to invest more in alcohol prevention from a cost-effectiveness point of view as well 
as from a social cost point of view. In fact, the high social costs due to harmful use of alcohol (Degreef, 
Pacolet & Bouten, 2003) could be diminished, the implementation of cost-effective alcohol 
interventions could avoid the high number of treatment admissions in hospitals, and decrease the 
CONCLUSION 
99 
 
public treatment expenditures. The results of the GCEA show that the Belgian policy makers should 
ideally adapt legislative interventions (advertising ban, volumetric taxation and a reduction of opening 
hours)1. Furthermore, the mass media “drink driving” campaign have also proved to be a cost-
effective measure. Doran et al. (2008) argue that these campaigns are most likely to be effective when 
combined with the (more expensive) intervention random breath testing (Doran et al., 2008). 
However, if Belgian policy would be confronted with the choice to increase public financing for 
random breath testing or brief intervention, than brief intervention should be the more favourable 
option from a cost-effective point of view. The effect of brief intervention (per year) is much higher for 
Belgium: 974 DALYs are averted by random breath testing versus 2,267 DALYs averted by brief 
intervention. Moreover, it should be stated that the effect of brief intervention may be even higher (in 
terms of DALYs) since the intervention may also positively influence the prevalence of other alcohol-
related diseases (e.g. ischaemic heart disease, cirrhosis, cancer, etc.). This GCEA was restricted to six 
interventions, we cannot make any statements about other cost-effective interventions such as 
warning labels on alcohol products, responsible beverage service, lower BAC for youth, etc.  
 
The public expenditures study regarding illegal drugs indicates that the public spending on prevention 
and harm reduction are but a fraction of the amount spent on treatment and law enforcement. The 
high amount of expenditures on illegal drug treatment is not necessarily bad since the consensus in 
many cost-effectiveness studies is that “drug treatment works” and that treatment produces social 
benefits that exceed its programmatic costs (Gerstein et al., 1994; Rajkumar & French, 1997; 
Cartwright, 2000; Harwood et al., 2002; Strang et al., 2012). The GCEA study in this dissertation was 
limited to alcohol interventions and cannot provide recommendations on the type of interventions 
that should be implemented to improve the cost-effectiveness of the illegal drug policy. However, 
screening and brief intervention programmes appear to be cost-effective for illegal drug abuse (Strang 
et al., 2012). Furthermore, we recommend to invest more in harm reduction in order to avoid costs in 
the more expensive sectors (treatment and enforcement). It has been proven that interventions such 
as needle syringe programmes, opioid substitution therapy and drug consumption rooms are cost-
effective (Strang et al., 2012; Wilson, Donald, Shattock, Wilson & Fraser-Hurt, 2015; Rhodes & 
Hedrich, 2010).  
 
Finally, a budgetary boost for the prevention of psychoactive medication could also be encouraged, 
since the prevention expenditures was negligible in the public expenditure study. This is in contrast 
with the fact that Belgium is a country with a high use of anti-anxiety and sedative drugs (Anthierens 
et al., 2007). In a 2008 Belgian health survey 10% of the respondents used sleeping tablets, 7% 
tranquilisers and 6% anti-depressants in the two weeks preceding the survey. These percentages 
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decreased in the year 2013, nevertheless 20% of the people aged 75 years and older reported the use 
of anti-anxiety and sedative drugs in the last 24hours (Drieskens & Gisle, 2015). The study of Bourgeois 
et al. (2012) confirms the high prevalence of chronic benzodiazepine use in Belgian nursing home. In 
accordance with Anthierens, Habraken, Petrovic & Christiaens (2007), general practitioners need to be 
more aware of the addictive nature of benzodiazepines, and a non-pharmacological approach should 
be promoted as the best first approach. A prevention campaign could improve the attitude of the 
general practitioners towards a decrease of psychoactive medication (by analogy with the campaign 
on antibiotics), ideally this campaign also focuses on the patients (target population of people aged 75 
years and older). However, the cost-effectiveness of this intervention is unknown, no CEA studies on 
psychoactive medication campaigns have been conducted. 
 
Limitations and suggestions for future research 
Firstly, the limitations of the public expenditure study are related to the conceptual and 
methodological framework. A public expenditure study is limited to the estimation of public 
expenditures on drug policy actions; neither private expenditures nor external expenditures are 
included. A social cost study is required to provide the total social cost of drugs in a given society, and 
then the drug budgets could be contrasted with the (economic) impact of the various types of drugs. 
Furthermore, public expenditure estimates are always associated with a degree of uncertainty 
because of data quality and cost calculation methods. For example, the proration method could lead 
to distorted figures, because this methodology assumes that in the case of law enforcement, all 
criminal activity has the same unit cost.  
 
Secondly, the GCEA in this dissertation is also confronted with limitations with regard to the scope and 
methodology. This GCEA only takes into account the primary purpose of alcohol interventions: namely 
the reduction of alcohol consumption and road traffic accidents. The effect of interventions on 
ischaemic heart disease, cirrhosis, cancer, etc. is excluded. Consequently the population health effect 
of alcohol interventions is underestimated. Furthermore, the GCEA must be regarded as an 
approximation, since the results are determined by the input of multiple parameters (such as the 
intervention effect, the cost calculation of the interventions, etc.). For example, the results are based 
upon point estimates of effectiveness ratios (without taking into account the ranges of intervention 
effects), despite the fact that the effectiveness of interventions are imbued with a degree of 
uncertainty (Hutubessy, Chisholm, Edejer, & WHO-CHOICE, 2003). Moreover, these effectiveness 
ratios of alcohol interventions are retrieved from review studies, since no information was available on 
Belgian country-specific effectiveness of interventions. There was also limited information available 
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about the interaction of interventions, and how this affects the effectiveness of intervention 
combinations (Holm, Veerman, Cobiac, Ekholm & Diderichsen, 2014).  
  
In conclusion, despite these limitations, the public expenditure study and the GCEA can provide a 
valuable basis for an assessment about the public spending and about cost-effectiveness, and 
contribute to a more evidence-based drug policy. Caution must be applied when using the results of a 
free-standing public expenditure study for policy (decision making) purposes. A public expenditure 
study identifies facts that are worth looking into more deeply, but only further research can detect a 
lack of performance (e.g. inefficient programmes or interventions with limited cost-effectiveness). The 
GCEA has proven to be a valuable evaluation tool to formulate recommendations for an evidence-
based alcohol policy, however, the results should also be interpreted with caution. The GCEA might 
favour interventions that are cheap from a budget point of view, but expensive in terms of loss of 
freedom (e.g. advertising ban). Moreover, it ignores the political reality that the alcohol industry and 
consumers are stakeholders in the alcohol policy making process. The implementation of interventions 
is also determined by political will, financial resources, expertise, and public awareness and support 
(WHO, 2004). Therefore, it seems advisable to take into account the cultural, social, political and 
economic situation of a country before formulating policy recommendations. 
 
Future research is necessary to formulate recommendations for a cost-effective policy for illegal 
drugs. The cost-effective government interventions in the GCEA studies for reducing substance-
related harm are not relevant for illegal drugs, since it cannot be controlled via mechanisms such as 
taxation or advertisement bans. More empirical evidence on various interventions is required in order 
to develop the most cost-effective repression, prevention, harm reduction and treatment strategies 
for illegal drugs (Chisholm et al., 2006). Furthermore, the economic evaluation studies also need to 
broaden the focus of substances to the abuse of psychoactive medication. This type of substance-
related harm has been neglected in evaluation studies so far.  
 
2. EVALUATION OF DRUG POLICIES WITH CROSS-COUNTRY COMPARISONS 
The first paper conducts a cross-country comparison on public expenditures for drug policy (illegal 
drugs). The results show that the Netherlands (0.36% of GDP), Germany (0.22%-0.26% of GDP) and 
Sweden (0.19% of GDP) are confronted with higher expenditures for drug policy in comparison with 
France (0.06% of GDP) and Belgium (0.09% of GDP). A possible explanation lies in the history of the 
countries’ drug policy, namely the late development of a drug policy may delay the growth in the 
financial investments in drug policy. Furthermore, the drug expenditure mixes of different countries 
are compared: harm reduction and prevention are the smallest sectors in each of the four studied 
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countries (Belgium, Sweden, the Netherlands and Australia2). Consequently, the recommendations for 
the Belgian drug policy, to invest more in drug prevention and harm reduction, does also account for 
these countries.  
 
The second paper in this dissertation concentrates on the public spending for illegal drug and alcohol 
treatment in hospitals for 21 EU member states. Firstly, total public spending for hospital-based 
treatment of illegal drug and alcohol abuse in the 21 EU member states studied is estimated to be 7.6 
billion euros. The results confirm other studies indicating that public expenditures for alcohol 
treatment exceed those for illegal drug treatment. Given these high costs on alcohol treatment, the 
EU member states should invest more in alcohol prevention and early intervention. Secondly, the 
expenditures (per capita) for treatment of illegal drug abuse are presented, ranging from 0.1 euros in 
Romania to 13 euros in Sweden. For alcohol abuse, that figure varies from 0.9 euros in Bulgaria to 24 
euros in Austria. The variation between countries is explained by factors such as the hospital cost per 
day, the organization of substance abuse treatment, cultural and social norms regarding substance 
use, etc. The prevalence of problematic (illegal or legal) drug use in a country did not correlate 
significantly with the number of hospital days and the expenditures that come with it. 
 
The third paper focuses on a cross-country comparison with GCEA on alcohol interventions. In fact, 
the cross-country comparison shows that the legislative interventions (increased taxation and 
advertising ban) are the most cost-effective strategies in Australia, Belgium, Estonia and Denmark. 
Furthermore, Estonia generates better cost-effectiveness ratios than Belgium, especially for random 
breath testing (Estonia: 387 euros per DALY saved; Belgium: 26,400 euros per DALY saved). This could 
be explained by the higher prevalence of hazardous drinking and alcohol-related traffic accidents in 
the Estonian population. In conclusion, the cost-effectiveness of an alcohol policy is determined by the 
mix of interventions and the epidemiological situation of a country. 
 
Potential role, limitations and suggestions for future research 
The public expenditure and GCEA approach are both distinguished as interesting tools to develop 
comparisons between countries (Ritter, 2007). These comparisons make it possible to view the 
different options in drug policy and would enable to monitor drug policy interventions with 
benchmarking information on public spending and cost-effectiveness. The potential role of cross-
country comparisons is discussed with the help of two examples. Firstly, the cross-country comparison 
with GCEA allows us to formulate recommendations to improve cost-effectiveness of alcohol policies. 
The legislative interventions have been acknowledged as most cost-effective strategies (increased 
taxation, advertising ban and reduced opening hours) in four GCEA studies (Belgium, Estonia, Australia 
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and Denmark). This cross-country comparison confirms the benefits (in terms of averted DALYs) of 
these legislative interventions in different settings. Ideally, this should enhance the implementation of 
legislative interventions in other countries. The second example is provided by the EU cross-country 
comparison on hospital expenditures. This study presented the impact of substance abuse treatment 
in hospitals on a country’s budget, and these data can also be used to illustrate the budgetary 
consequences of different drug policies. The results showed that Sweden had the highest 
expenditures (13 euros per capita) for illegal drug treatment in hospitals. These results could be 
explained by the high cost of hospitalisation and the organization of substance abuse treatment (high 
proportion of hospital days attributable to illegal drug treatment). Moreover, it shows that a drug 
policy which prioritises a drug free society and abstinence-driven treatment is more likely to be 
confronted with high hospital costs. However, future research is necessary to prove this correlation. 
 
Despite the advantages of the cross-country comparisons, we should take into account some 
important limitations. The first and third paper conducted a cross-country comparison with single-
country (public expenditure or GCEA) studies, consequently the quality of the comparison is 
determined by the conceptual and methodological framework that these individual studies applied. In 
the first paper we conclude that the public expenditure studies can only be of limited value for decision 
makers due to conceptual and methodological differences. Multiple countries conducted a public 
expenditures study, and they used different concepts and definitions to define the term “public 
expenditure” (Vander Laenen, Vandam, De Ruyver & Lievens, 2008). For example, the studies of 
Sweden and the Netherlands take into account a fraction of the reactive expenditures (e.g. 
expenditures for HIV/AIDS treatment to patients infected via IDU and drug related crimes). The public 
expenditure studies are also a fragile constructions from a methodological point of view, since 
variances occur due to differences in calculation method. It seems that a uniform methodology is 
necessary to compare public expenditure studies. In this respect, the initiative of the EMCDDA to 
develop a common EU-wide methodology for public expenditure studies warrants applause (EMCDDA, 
2008). In the third paper, it is stated that a uniform methodology for the GCEA, such as the WHO 
framework (Edejer et al., 2003), allows us to compare the cost-effectiveness of different alcohol 
policies. Nevertheless, the uniformity of the methodology may be endangered during the 
contextualisation process of a GCEA study, namely during the input of country-specific data (e.g. 
target coverage rate of the interventions, cost calculation of the interventions, etc) and other 
parameters (such as the choice of the intervention effect). Therefore, the GCEA might not be the best 
way to compare alcohol policies between countries. 
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This dissertation confirms that a common conceptual and methodological framework is indispensable 
for a valid cross-national comparison on public expenditures or cost-effectiveness. The cross-country 
comparison on hospital expenditures shows us that a uniform method could be applied with data of 
international databases. However, future research is necessary to improve these databases and to 
expand the cross-country comparison to public spending on other types of treatment. Therefore, the 
international databases (e.g. Eurostat) should provide systematic data of in- and outpatient activities 
(outpatient treatment sessions for substance abuse, inpatient days for substance abuse, consultations 
for substitution treatment, drug treatment counseling in prisons, etc.). Furthermore, the data 
coverage of the Eurostat database should also be improved to obtain more reliable results for the EU 
member states since the consistency of reporting is indispensable for international benchmarking of 
budget expenditures across countries. All these factors might improve the quality of cross-country 
comparisons, however, it should be stated that even an identical methodology will still make it difficult 
to compare public expenditures or cost-effectiveness ratios across countries. The countries differ in 
terms of social security systems, institutional structures, cultural traditions, etc.  
 
In conclusion, a set of generic problems have been acknowledged during the cross-country 
comparison of public expenditures and the cost-effectiveness of interventions. At this moment, a valid 
cross-country comparison could only be conducted on the public spending for illegal drug and alcohol 
treatment in hospitals. It seems that the challenge continues: finding a way to overcome the 
methodological and conceptual problems in a cross-country comparison of drug policies. 
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4. ENDNOTES 
                                                          
1
 During the recent years, the Belgian government adopted these legislative interventions only to a limited 
extent. The National Alcohol plan 2014-2018 proposed some cost-effective legislative interventions (e.g. 
restriction of the purchase of alcohol), however they could not be implemented due to a lack of political 
consensus for the proposed measures related to the supply side of alcohol. 
2
 Except for Australia: Moore (2008) measured the public spending for school-based drug prevention 
programmes, therefore Australian prevention expenditures (23%) are higher than treatment (17%). 
